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Dissecting Transcriptional Control Of Cd8 T Cell Responses 
Abstract 
Adaptive immune cells play key roles in antiviral and antitumor responses, and CD8 T cells are the central 
cell types during these processes. In different immunological conditions(e.g. vaccination) and disease 
settings, CD8 T cells perform distinct differentiation paths into effector, memory and exhausted T cells. 
Transcription factors(TF) play key roles in the cell fate decision, and dissecting transcriptional control of 
CD8 T cell responses provides the key mechanisms of how CD8 T cells differentiate toward specific cell 
fates. During my graduate school study, I have done four major questions related to CD8 T cell 
transcriptional control: 1) How does memory CD8 T cells(TMEM cells) survive? I have found that c-Myb is 
the key TF to control TMEM cell survival molecule Bcl-2/Bcl-XL, and c-Myb level is controlled by a 
microRNA, miR-150(Chen and Stelekati, et al., Cell Reports, 2017, Chapter 2); 2) What happens to 
canonical terminal effector T cells(TEFF cells) during chronic infection and cancer? I have found that 
chronic TEFF-like cells get diminished during chronic infection and restrained by master TF TCF-1(Chen 
and Ji, et al., Immunity, 2019, Chapter 3); 3) How does exhausted T cells(TEX cells) survive during chronic 
infection? I have found that TCF-1-centralled TF network, including c-Myb and Eomes as TCF-1 
downstream targets, contributes to the TEX precursor generation and survival(Chen and Ji, et al., 
Immunity, 2019,, Chapter 3); 4) How to generate robust TEFF-like response during chronic infection or 
cancer? I have established an optimized T cell in vivo CRISPR screening system. Using this system, I 
found TF Fli1 restrains T cell proliferation and TEFF differentiation during both acute and chronic 
infection, and Fli1-deficient CD8 T cells skew from TMEM or TEX toward a robust TEFF cell fate, leading to 
better anti-infection or anti-tumor responses(Chen et al.,bioRxiv/SSRN, 2020, Chapter 4). By answering 
these questions, we now have a more complete and better understanding of CD8 T cell responses during 
chronic infections and cancer, and hope these transcriptional mechanisms can help to improve T cell 
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ABSTRACT 
DISSECTING TRANSCRIPTIONAL CONTROL OF CD8 T CELL RESPONSES
Zeyu Chen; 
E. John Wherry Ph.D.
Adaptive immune cells play key roles in antiviral and antitumor responses, and CD8 T 
cells are the central cell types during these processes. In different immunological 
conditions(e.g. vaccination) and disease settings, CD8 T cells perform distinct 
differentiation paths into effector, memory and exhausted T cells. Transcription 
factors(TF) play key roles in the cell fate decision, and dissecting transcriptional control of 
CD8 T cell responses provides the key mechanisms of how CD8 T cells differentiate 
toward specific cell fates. During my graduate school study, I have done four major 
questions related to CD8 T cell transcriptional control: 1) How does memory CD8 T 
cells(TMEM cells) survive? I have found that c-Myb is the key TF to control TMEM cell 
survival molecule Bcl-2/Bcl-XL, and c-Myb level is controlled by a microRNA, 
miR-150(Chen and Stelekati, et al., Cell Reports, 2017, Chapter 2); 2) What happens to 
canonical terminal effector T cells(TEFF cells) during chronic infection and cancer? I have 
found that chronic TEFF-like cells get diminished during chronic infection and restrained by 
master TF TCF-1(Chen and Ji, et al., Immunity, 2019, Chapter 3); 3) How does 
exhausted T cells(TEX cells) survive during chronic infection? I have found that 
TCF-1-centralled TF network, including c-Myb and Eomes as TCF-1 downstream 
targets, contributes to the TEX precursor generation and survival(Chen and Ji, et al., 
Immunity, 2019,, Chapter 3); 4) How to generate robust TEFF-like response during 
chronic infection or cancer? I have established an optimized T cell in vivo CRISPR 
screening system. Using this system, I found TF Fli1 restrains T cell proliferation and 
TEFF differentiation during both acute and chronic infection, and Fli1-deficient CD8 T 
cells skew from TMEM or TEX toward a robust TEFF cell fate, leading to better anti-infection 
or anti-tumor responses(Chen et al.,bioRxiv/SSRN,  2020, Chapter 4). By answering 
these questions, we now have a more complete and better understanding of CD8 T cell 
responses during chronic infections and cancer, and hope these transcriptional 
mechanisms can help to improve T cell related immune therapies for better clinical 
outcomes. 
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Chapter 1 Background and Rationale for investigating transcriptional control of 
CD8 T cell responses 
    CD8+ T cells play a key role in adaptive immunity and contribute to host defense 
and anti-tumor responses. During acute infections or vaccinations, naïve CD8+ T 
cells become activated and differentiate into a pool of effector T cells containing 
KLRG1Hi terminal effector (TEFF) cells and KLRG1LoCD127Hi memory precursors 
(TMP)(Kaech and Cui, 2012). The KLRG1Hi TEFF population is often 5-20 times more 
numerous than the TMP subset and has robust effector functions. However, the 
KLRG1Hi population is terminal, largely disappearing over the ensuing weeks 
whereas the TMP population matures into a pool of long-term memory CD8+ T 
cells(Kaech et al., 2003). During chronic infections or in tumors, the KLRG1Hi 
population of TEFF (or the related TEMRA or CD57+ populations in humans) is less 
prominent (Angelosanto et al., 2012; Joshi et al., 2007; Omilusik et al., 2018) and 
CD8+ T cells are mainly differentiated into a dysfunctional cell state called exhausted 
T cells (TEX)(Wherry, 2011), which are often found in these settings express low 
amounts of KLRG1(Doering et al., 2012; Wherry et al., 2007). Moreover, lineage 
tracing studies demonstrated that the KLRG1Hi TEFF subset survives poorly during 
chronic infection and cannot give rise to TEX (Angelosanto et al., 2012). In contrast, 
the TMP pool has the potential to give rise to either functional memory CD8+ T cells or 
TEX during acutely resolved or chronic viral infection, respectively(Angelosanto et al., 
2012). Nevertheless, the developmental paths that seed the formation of TEX in 
chronic infections and cancer remain poorly understood. Dissecting these 
developmental relationships and the underlying transcriptional circuits could provide 
opportunities to avoid or reverse T cell exhaustion therapeutically. 
Transcriptional control mechanisms have begun to be dissected for developing TEFF 
and TMP following acute infections. The initial activation and conversion from naïve to 
early effector CD8+ T cells requires BATF and IRF4(Kurachi et al., 2014), and these 
transcription factors (TFs) may also be required later(Man et al., 2017). The KLRG1Hi 
 2 
TEFF subset also uses the TFs T-bet(Joshi et al., 2007), Blimp-1(Kallies et al., 2009; 
Rutishauser et al., 2009), Id2(Yang et al., 2011), and Zeb2(Dominguez et al., 2015; 
Guan et al., 2018) that foster the full complement of effector molecule expression 
such as IFNγ, perforin and granzymes, as well as effector-like homing and migration 
properties(Kaech and Cui, 2012). Conversely, the KLRG1-CD127+ TMP cell fate 
employs a distinct constellation of transcriptional control circuits including 
Eomes(Intlekofer et al., 2005), Bcl-6(Ichii et al., 2002), Id3(Yang et al., 2011) and 
TCF-1(Jeannet et al., 2010; Zhou et al., 2010). This TMP population eventually gives 
rise to memory CD8+ T cells (TMEM) that have the ability to self-renew, persist long-
term and provide protection upon subsequent infection(Zhou et al., 2010), with a 
higher survival molecule expression such as high Bcl-2 and Bcl-XL(Kaech et al., 
2003). However, one important piece missing in the TMEM biology is what is the 
transcriptional machinery that controls TMEM survival. In Chapter 2, I defined that the 
miR150-c-Myb axis regulates TMEM  survival through Bcl-2/Bcl-XL(Chen et al., 2017). 
In this part, I found that the genetic absence of miR-150 fostered differentiation of 
antigen-specific CD8 T cells into MP and resulted in more efficient formation of long-
lived memory CD8 T cells. These miR-150-deficient memory CD8 T cells provided 
better protection during secondary pathogen challenge. Conversely, overexpression 
of miR-150 significantly reduced memory formation and fostered terminal 
differentiation. Mechanistically, I identified c-Myb, a target of miR-150, as a key 
molecule mediating this effect in CD8 T cells. Expression of c-Myb mRNA and 
protein was negatively correlated with miR-150 expression, as were the key anti-
apoptotic c-Myb target genes Bcl-2 and Bcl-xL. Overexpression of a non-repressible 
c-Myb lacking the miR-150 targeting sequence rescued the defect in memory 
formation caused by overexpression of miR-150. These observations directly link c-
Myb to the effects of miR-150 and highlight an underappreciated role for c-Myb in 
memory CD8 T cell biology. Together, these data define a miR-150-c-Myb axis as a 
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critical regulator of CD8 T cell differentiation, long-term survival and protective 
immunity. 
In contrast to acute infections, these early fate commitment steps and regulation of 
population heterogeneity in the early establishment of CD8+ T cell exhaustion remain 
poorly understood. During chronic infection or cancer, the TEX that develop, unlike 
TMEM, have decreased function and high expression of multiple inhibitory receptors 
such as PD-1, LAG-3, TIGIT and others, but relatively low KLRG1(Wherry et al., 
2007). These cells are maintained by ongoing antigen-driven proliferation, that can 
often be observed by higher steady state Ki67 in established chronic infections and 
tumors (Huang et al., 2017; Shin et al., 2007). However, upon further stimulation with 
antigen the ability to induce new proliferation is highly compromised(Wherry and 
Kurachi, 2015). Moreover, it is now clear that TEX are a distinct “lineage” of mature 
CD8+ T cells differing from TEFF and TMEM by ~6000 open chromatin regions(Pauken 
et al., 2016; Philip et al., 2017; Sen et al., 2016). This epigenetic divergence begins 
as early as the first week, but becomes progressively more widespread and 
permanent over time(Doering et al., 2012; Pauken et al., 2016; Philip et al., 2017; 
Sen et al., 2016; Wherry et al., 2007). Indeed, TEX precursors present at 1 week after 
infection retain fate flexibility and can develop into functional TMEM whereas by day 30, 
TEX are fully committed to the TEX identity and do not develop into TMEM even when 
the infection is cleared (Angelosanto et al., 2012). Although a small subset of TEX 
may persist when chronic infection is cured, these cells appear not fully recover 
normal TMEM biology(Utzschneider et al., 2013; Wolski et al., 2017). 
Several transcriptional control mechanisms have been identified in TEX. Most notably, 
T-bet, Eomes and TCF-1 have been implicated in governing the biology of TEX 
subsets including a TEX progenitor population that is required to maintain the overall 
TEX pool (He et al., 2016; Im et al., 2016; Paley et al., 2012; Utzschneider et al., 2016; 
Wu et al., 2016). The existence of a TEX progenitor pool was originally described as a 
PD-1Int population of TEX capable of responding to PD-1 blockade whereas a more 
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numerous, terminal PD-1Hi subset could not respond to this checkpoint 
blockade(Blackburn et al., 2008). Subsequent work identified key roles for T-bet, 
Eomes and TCF-1(He et al., 2016; Im et al., 2016; Paley et al., 2012; Utzschneider et 
al., 2016; Wu et al., 2016). Although the precise relationship between these TFs and 
the TEX subpopulations they define remains incompletely understood, all are required 
to form and/or maintain TEX because genetic deficiency in any of these TFs leads to a 
failure to generate, or loss of, the TEX population(Im et al., 2016; Paley et al., 2012; 
Utzschneider et al., 2016). The Nr4a family of transcription factors that can be rapidly 
activated and/or induced following TCR signaling has also been implicated in 
regulating T cell exhaustion(Chen et al., 2019a; Liu et al., 2019), perhaps translating 
TCR signal strength into downstream exhaustion differentiation patterns. Additional 
TFs such as IRF4(Man et al., 2017) and NFAT(Martinez et al., 2015) are also 
required for TEX. On the other hand, TF such as Fosl2(Stelekati et al., 2018) can 
partially reverse exhaustion by promoting memory-like features such as IL-7R. 
Recent work has also shown that the HMG family protein Tox coordinates the 
epigenetic imprinting of T cell exhaustion during chronic infections and cancer (Alfei 
et al., 2019; Khan et al., 2019; Scott et al., 2019; Seo et al., 2019; Yao et al., 2019). 
This transcription factor was previously predicted to have a key role in T cell 
exhaustion(Doering et al., 2012) but likely binds DNA in a sequence independent 
manner suggesting perhaps structural or architectural changes or partnering factors 
that play a role in this process. However, Tox was essential to control optimal TCF-1 
expression in developing TEX (Alfei et al., 2019; Khan et al., 2019; Yao et al., 2019). 
Despite these previous studies, the precise sequence of events that leads to the 
developmental ontogeny of TEX versus TEFF and TMP and subsequent memory 
remains poorly understood. Furthermore, the mechanism about how TCF-1 shapes 
TEX development remains unclear. Thus, in Chapter 3, I address these questions 
about the ontogeny of TEX using a combination of single cell RNA-sequencing 
(scRNA-seq), computational modeling, lineage tracing and genetic perturbation to 
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define the early developmental relationships that initiate the TEX lineage. Studies 
using scRNA-seq revealed a molecular circuitry in which TCF-1 governed this early 
cell fate decision during chronic infection for the development of T-EX precursors at 
least in part by repressing an opposing cell fate of terminal TEFF. TCF-1 antagonized 
the TEFF-driving TFs, T-bet, Id-2 and Blimp-1, but positively regulated Eomes, and c-
Myb, both of which were essential downstream of TCF-1. In the latter case, TCF-1 
promoted c-Myb expression that in turn controlled a Bcl-2 dependent survival axis in 
TEX. Moreover, I show that early PD-1 expression protected this TCF-1+ precursor 
pool allowing the progenitor pool of TEX to form efficiently. Thus, these data define the 
molecular origins of the role for TCF-1 in CD8+ T cell exhaustion. In addition, these 
analyses revealed molecular circuitry downstream of TCF-1 that functioned at a key 
fate decision point between the TEX precursors and terminal TEFF branches of CD8+ T 
cell differentiation. These data fill an important gap between the Tox-induced 
initiation of the epigenetic changes needed for exhaustion and establishment of fully 
differentiated TEX several weeks later. Moreover, these data suggest that a key 
mechanism by which TCF-1 promotes the TEX developmental program is by 
antagonizing robust activation involved in the terminal TEFF differentiation program. 
These data further indicate that TEX cells and terminal TEFF cells are opposing fates 
and that TEX cells are not simply inefficient effector cells. Finally, revealing the key 
fate decisions and the underlying molecular circuitry of TEX development may provide 
opportunities to therapeutically manipulate or avoid CD8+ T cell exhaustion in cancer 
or chronic infections. 
With the model foundation of TEFF versus TEX binary cell fate decision, I want to 
further address the question about how to enhance a robust TEFF response during 
chronic infection and cancer on transcriptional control level. In addition to TF that 
foster TEFF formation, opposing mechanisms must temper complete commitment to 
effector differentiation. The two alternate cell fates, TMEM and TEX, cannot form from 
fully committed TEFF (Angelosanto et al., 2012; Chen et al., 2019b; Joshi et al., 2007), 
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suggesting that parts of the TEFF program must be antagonized to allow TMEM- and 
TEX to differentiate. The high mobility group (HMG) TF, TCF-1, for example, is 
essential for development and maintenance of both TMEM and TEX (Chen et al., 2019b; 
Im et al., 2016; Utzschneider et al., 2013; Wu et al., 2016; Zhou et al., 2010) TCF-1 
represses (directly or indirectly) TEFF-driving TF such as T-bet and Blimp-
1(Tiemessen et al., 2014), and may also have a role in enabling epigenetic 
changes(Xing et al., 2016) . Moreover, a second HMG TF, Tox, is essential for the 
development of the TEX cell fate by promoting TEX differentiation and repressing of the 
TEFF lineage differentiation(Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019; Seo 
et al., 2019; Yao et al., 2019). Tox reprograms the open chromatin landscape, 
inducing global TEX-specific epigenetic changes and repressing chromatin 
accessibility associated with TEFF differentiation, in part by recruiting epigenetic 
modifiers including the lysine acetyltransferase Kat7(Khan et al., 2019). Despite this 
work, mechanisms that safeguard against commitment to TEFF differentiation remain 
poorly understood. Such information could be of considerable utility for 
immunotherapies focused on enhancing anti-tumor or antiviral activity. However, 
whereas inactivating pathways like TCF-1 or Tox that would de-repress the entire 
program of T-EFF differentiation are of interest, such approaches result in terminal 
TEFF and may have limited therapeutic benefit because such cells cannot sustain 
durable responses. Thus, the discovery of mechanisms that selectively de-repress 
key aspects of T-EFF- differentiation, particularly those involved in control of numerical 
expansion and/or protective immunity would be of considerable interest. 
In Chapter 4, I used in vivo CRISPR-Cas9 screening in antigen-specific CD8 T cells 
responding to acute or chronic viral infection to identify key regulators of TEFF and TEX. 
In particular, I was interested in identifying genes that resulted by gain-of-function, 
improving TEFF differentiation (i.e. an “Up” screen (Kaelin, 2017)). The CRISPR-Cas9 
system has been used to interrogate the cancer-immune system through screening 
in cancer cells (Gerlach et al., 2016; Ishizuka et al., 2019; Manguso et al., 2017; Pan 
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et al., 2018), in vitro in human T cells(Shifrut et al., 2018) or in vivo in mouse T cells 
(Dong et al., 2019; LaFleur et al., 2019a; Shifrut et al., 2018; Wei et al., 2019; Ye et 
al., 2019). Genome-wide or large pooled screens have identified regulators of T cell 
responses such as Dhx37, a dead-box helicase(Dong et al., 2019) and the 
phosphatase Ptpn2(LaFleur et al., 2019a, 2019b). More focused screens for 
metabolic regulators or membrane proteins have also identified targets such as 
Zc3h12a (enconding REGNASE-1)(Wei et al., 2019) and Pdia3, Mgat5, Emp1 and 
Lag3(Ye et al., 2019). Many of these targets appear to function by modulating the 
activity state of the cell through altered signaling or RNA biology. For example, 
REGNASE-1 is a zinc finger protein that also may regulate mRNA decay(Uehata et 
al., 2013) and was implicated to function in CD8 T cells through regulation of 
BATF(Wei et al., 2019). Because Batf has a role in early transcription control of TEFF 
differentiation, these findings suggest that in vivo CRISPR screening could potentially 
reveal key regulators of differentiation and developmental fate choices. However, the 
ability to discover fundamental regulators of cellular differentiation state and/or 
cellular programming via in vivo CRISPR/Cas9 screening in CD8 T cells relevant for 
immunotherapy remains a key goal. Thus, I developed an in vivo CRISPR-Cas9 
screening platform in primary CD8 T cells focused on central regulators of T cell 
differentiation and fate decisions. This CD8 T cell CRISPR screening platform used 
Cas9+ antigen specific CD8 T cells combined with an optimized retroviral (RV) 
based-sgRNA expression strategy (named Optimized T cell In vivo CRISPR 
Screening system, OpTICS). We focused our screens on TF to identify genes with 
central regulatory roles in fate decisions and differentiation trajectories in TEFF versus 
TEX differentiation. Initially, we used the well-established LCMV infection system, in 
which the biology of TEFF and TEX can be interrogated with high precision, and then 
extended the findings to other infection and tumor models. This approach identified 
known key TFs that are essential for TEFF and TEX differentiation including Batf, Irf4 
and Myc where loss of function prevented initial T cell activation and differentiation. 
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We identified known TF that repress or restrain TEFF differentiation including Tcf7, 
Smad2 and Tox. However, this screen also revealed novel central regulators of TEFF 
differentiation including many that repress optimal differentiation, such as Irf2, Erg 
and Fli1, where CRISPR perturbation led to gain-of-function and improved TEFF 
responses. In particular, we discovered a novel central role for Fli1 in TEFF responses 
where this TF specifically antagonized the genome-wide function of ETS:RUNX 
activity and prevented Runx3-driven TEFF biology. Indeed, genetic loss of Fli1 
resulted in robustly improved TEFF responses whereas enforced Fli1 expression 
restrained differentiation. Fli1 prevented chromatin accessibility specifically at 
ETS:RUNX motifs and loss of Fli1 enabled transcriptional induction of the TEFF 
program in a Runx3-driven manner. Moreover, loss of Fli1 improved TEFF biology and 
protective immunity not only during LCMV infection, but also following infection with 
influenza virus or Listeria monocytogenes. Moreover, deletion of Fli1 potently 
improved anti-tumor immunity. Thus, Fli1 safeguards the developing activated CD8 T 
cell epigenome from excessive ETS:RUNX-driven TEFF differentiation and disruption 
of Fli1 activity can be exploited to improve TEFF activity and protective immunity to 
infections and cancer. 
 
Overall, the work I accomplished during my graduate school helps to complete the 
roadmap for CD8 T cell differentiation of effector response, memory formation and 
exhaustion process on the transcriptional mechanism level. I identified the functions 
of several TFs during T cell responses, including c-Myb, TCF-1, Eomes and Fli1. 
These transcriptional mechanisms will not only help to explain the T cell gene 
signatures and differentiation paths in the clinical immune profilings, but also support 
potential novel therapeutic strategies, such as Fli1-deficient CAR-T cell design, for 
better clinical outcomes. 
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Chapter 2 MiR-150 regulates memory CD8 T cell differentiation via c-Myb 
2.1 MiR-150 represses memory CD8 T cell differentiation 
Previous studies have reported a 
compromised initial expansion of miR-
150 KO TCR transgenic CD8 T cells 
following acute infection and these 
responding miR-150 KO effector CD8 
T cells were biased towards a memory 
phenotype(Smith et al., 2015). While 
in these studies the miR-150 KO CD8 
T cells killed less efficiently than wild-
type (WT) CD8 T cells and had a 
memory-biased transcriptional 
signature(Smith et al., 2015), the 
underlying molecular mechanisms for 
these events were not defined. To 
further explore the role of miR-150 in 
memory CD8 T cell development in 
the context of viral infections, we bred 
miR-150 KO mice with P14 mice 
(transgenic for a T cell receptor (TCR) 
specific for the immunodominant LCMV 
Dbgp33-41 epitope) and adoptively 
transferred either CD45.2 WT or miR-
150 KO P14 cells into CD45.1 naïve 
recipient mice. These P14 containing 
mice were then infected with LCMV Armstrong and formation of virus-specific effector 
and memory CD8 T cells was analyzed by flow cytometry (Figure 1A). We first 
Figure 1. Absence of miR-150 enhances memory CD8 T 
cell differentiation.  
2.5 × 103 CD45.1 miR-150 WT or KO P14 cells were 
adoptively transferred i.v. into individual CD45.2 naïve mice. 
Recipients were infected with LCMV Armstrong (LCMV) the 
next day, and splenocytes were harvested on d8, d15 and d35 
p.i.  
(A) Experimental design (B) Percentages of CD127hiKLRG1lo 
MP and CD127hiCXCR3hi of total P14 cells on d8, d15 and 
d35 p.i. (C) Mean fluorescence intensity (MFI) of markers on 
donor P14 cells on d35 p.i. (D) Percentages of donor P14 cells 
out of total CD8 T cells and absolute numbers per spleen on 
d35 p.i. (E) Percentages of Ki-67hi cells out of total P14 cells at 
d35 p.i. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 (two-tailed 
Student’s t-test). Data are representative of 3-5 independent 
experiments (mean±s.e.m.) with at least 6 mice/group for each 
experiment. 
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examined the effector to memory transition using phenotypic markers that distinguish 
subpopulations with different fate potential. At d8 p.i. the absence of miR-150 
resulted in a bias towards the MP subset defined by CD127 expression and low 
KLRG1 (CD127hiKLRG1lo; MP hereafter) as well as co-expression of CD127 and 
CXCR3. These differences became more pronounced at d15 p.i., as effector CD8 T 
cells underwent contraction and transitioned to memory. The miR-150 KO P14 
population contained ~ 2 - 3.5 -fold higher frequency of MP and CD127hiCXCR3hi 
cells at this time point (Figure 1B). This increased frequency of MP also translated 
into higher total numbers of CD127hi of miR-150 KO P14 cells at d8 p.i. compared to 
WT P14 (Figure S1A). This bias persisted at d35 p.i. (Figure 1B), and at the 
memory time point the miR-150 KO P14 cells also had higher expression of several 
key memory-associated molecules including CD122, CD27, Eomes and Bcl-6 
(Figure 1C). However, the differentiation of central memory (CD62Lhi) versus effector 
memory (CD62Llo) CD8 T cells was not affected by miR-150 deficiency (Figure 1B). 
At d35 p.i., significantly more memory miR-150 KO P14 cells were recovered 
compared to WT P14 donor cells (Figure 1D), suggesting that the absence of miR-
150 fostered memory CD8 T cell development. Together, these observations 
suggested a role for miR-150 in repressing optimal development of long-lived CD8 T 
cell memory.  To test whether the phenotypic bias towards memory in the absence of 
miR-150 corresponded to functional changes, we next examined cytokine production. 
At d35 p.i., no significant differences in the production of IFN-g, TNF, MIP-1α or 
CD107a were observed following 5 hrs ex vivo restimulation with gp33-41 peptide, but 
GrzmB expression was reduced in miR-150 KO P14 cells compared to WT P14 cells 
(Figure S1C-S1D), consistent with previous findings (Smith et al., 2015). However, at 
memory time points, a significantly higher percentage of miR-150 KO P14 cells 
expressed Ki-67, suggesting enhanced ongoing homeostatic proliferation compared 
to WT P14 cells (Figure 1E). Together, these data indicate a role for miR-150 in 
negatively regulating formation and homeostatic turnover of memory CD8 T cells. 
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2.2 MiR-150 KO memory CD8 T cells confer enhanced protective immunity 
Using a direct rechallenge model without secondary transfers, a previous study 
found that miR-150 KO memory CD8 T cells responded less efficiently to recall 
infection compared to WT CD8 T cells (Smith et al., 2015). Here, we examined 
whether the absence of miR-150 impacts the protective immune response of memory 
CD8 T cells in terms of 
pathogen clearance and host 
survival, using a secondary 
adoptive transfer model where 
the numbers of WT and miR-150 
KO memory CD8 T cells were 
normalized. P14 chimeras 
containing either CD45.2 WT or 
miR-150 KO P14 cells were 
infected with LCMV. On d35 p.i. 
memory P14 cells of each 
genotype were purified by flow 
cytometry and equal numbers of 
each genotype (5 x 103) were 
separately transferred to CD45.1 
naïve recipient mice.  One day 
later, these recipients were 
challenged with Listeria 
monocytogenes expressing the 
LCMV Dbgp33-41 epitope (LM-gp33; 
Figure 2A). Recipients of miR-150 KO memory CD8 T cells lost less weight than 
recipients of WT P14 or control mice that did not receive P14 cells (Figure 2B). 
Moreover, 60% of mice that received miR-150 KO P14 cells survived compared to 
Figure 2. MiR-150 KO memory CD8 T cells provide improved 
recall responses and protective immunity 
2.5 × 103 CD45.2 miR-150 WT or KO P14 cells were adoptively 
transferred i.v. into individual CD45.1 naïve mice. Recipients 
were infected with LCMV the next day. Splenocytes were 
harvested on d35 p.i. and donor CD45.2 P14 cells were purified 
by flow cytometry. 5 × 103 memory CD45.2 miR-150 WT or KO 
P14 cells were transferred i.v. into individual CD45.1 naïve mice. 
One day after transfer, recipients of P14 cells and a group of 
naïve CD45.1 mice without P14 transfer (NT) were challenged 
with 1 x 105 CFU Listeria monocytogenes-gp33 (LM-gp33) i.v.  
(A) Experimental design (B) Weight loss of recipient mice. (C) 
Adjusted survival of recipient mice. (D) Bacteria loads in the liver 
(CFU/g) on d4 p.i. (E) Total number of splenocytes on d4 p.i. and 
absolute number of CD8 T cells in the spleen on d4 p.i. (F) 
Percentages and absolute numbers of donor P14 cells in the 
spleen on d4 p.i. Flow plots are gated on total CD8 T cells.  
*P<0.05, **P<0.01, ***P<0.001 (two-tailed Student’s t-test for 2F 
or one-way ANOVA with Tukey’s multiple comparisons test for 
2B, 2D, 2E). Data are representative of 3 independent 
experiments (mean±s.e.m.) with at least 5 mice/group in each 
experiment. 
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only 20% survival for the control group (i.e. no transfer) or the group that received 
WT memory P14 cells (Figure 2C). At d4 p.i., we found that miR-150 KO memory 
P14 cells provided significantly better control of bacterial replication in the liver 
compared to WT P14 cells (Figure 2D). In addition, overall splenic cellularity tended 
to be better preserved in the presence of miR-150 KO memory P14 cells (Figure 2E). 
This advantage for protective immunity by the miR-150 KO memory CD8 T cells 
correlated with enhanced T cell expansion upon recall infection (Figure 2F). 
To examine recall responses using the same pathogen for priming and 
rechallenge, we also evaluated the recall capacity of LCMV-primed WT versus miR-
150 KO memory CD8 T cells upon LCMV rechallenge infection (Figure S2A). In this 
setting, although the recall expansion of WT and KO P14 cells was similar at d8 post 
challenge (Figure S2B), miR-150 KO memory CD8 T cells gave rise to a significantly 
larger population of CD127hiCXCR3hi CD8 T cells at d8 and d40 post rechallenge 
(Figure S2C). These observations suggested that enhanced memory development 
was a consistent, cell-intrinsic and stable property of miR-150 KO CD8 T cells. 
Together, these data indicate that miR-150 is an intrinsic factor that restrains 
CD8 T cell memory formation. The absence of miR-150 fosters the development of 
robust memory CD8 T cells that have improved proliferation and protective immunity 
following rechallenge.  
 
2.3 Overexpression of miR-150 impairs optimal memory CD8 T cell 
differentiation 
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To further interrogate the 
negative role of miR-150 
during memory CD8 T cell 
formation, we generated a 
miR-150 expressing retrovirus 
(RV) with a GFP reporter 
(Figure 3A). P14 cells were in 
vitro activated for 24 hrs and 
transduced with an empty-
GFP (eGFP) RV or miR-150 
overexpressing GFP (miR-150) 
RV resulting in ~50% 
transduction efficiency for 
each RV (Figure 3B). Using 
miR-150 RV we achieved 
initially ~5-fold 
overexpression of miR-150 
compared to eGFP RV, and 
this miR-150 overexpression 
declined to ~2-fold by d8 p.i. 
By d32 p.i. this RV-mediated 
miR-150 expression had 
returned to baseline (Figure 
3C). 
We next asked if miR-
150 overexpression influenced the MP to TE balance in the effector phase and 
subsequent long-term memory development. Control eGFP or miR-150 RV 
Figure 3. MiR-150 overexpression represses optimal 
memory CD8 T cell differentiation. 
CD45.2 P14 cells were transduced with an empty GFP-
expressing RV (eGFP) or a miR-150-IRES-GFP (miR-150) 
RV. Naïve CD45.1 mice were infected with LCMV, and 
received 5 × 104 eGFP- or miR-150- transduced CD45.2 
P14 cells on d1 p.i.  
(A) Vector design of eGFP-RV and miR-150-RV. MCS: 
Multiple Cloning Site; LTR: Long Terminal Repeats; IRES: 
Internal Ribosome Entry Site. (B) P14 cells were stimulated 
in vitro with anti-CD3, anti-CD28 and IL-2 and transduced 
with RV. GFP expression in P14 cells was measured after 
24 hrs of transduction in vitro. NT: Non-transduced P14 
cells. (C) QRT-PCR analysis of miR-150 expression in 
eGFP and miR-150 transduced P14 cells on d3 post 
transduction in vitro or at d8 and d32 p.i. in vivo. (D) 
Percentages of GFP+ cells of total transferred P14 cells. (E) 
Percentages of MP and CD127hiCXCR3hi out of GFP+ cells 
in spleens at d8 or d32 p.i.  
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 (two-tailed 
Student’s t-test). Data are representative of 2-3 
independent experiments (mean±s.e.m.) with at least 5 
mice/group in each experiment. 
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transduced, congenically marked P14 cells were adoptively transferred into naïve 
recipients followed by LCMV infection. MiR-150 overexpression conferred a 
disadvantage on CD8 T cell expansion during the effector phase and, despite similar 
initial transduction efficiency (Figure 3B), a lower ratio of miR-150 transduced 
compared to eGFP transduced P14 cells was recovered (Figure 3D). Furthermore, 
at d8 p.i. miR-150 RV transduction resulted in a significant decrease in the MP and 
CD127hiCXCR3hi populations (Figure 3E). By d32 p.i., these differences in memory 
phenotype between miR-150 and eGFP RV transduced P14 cells persisted in the MP 
population but not in the CD127hiCXCR3hi population (Figure 3E). This pattern was 
consistent with the early, but not sustained overexpression achieved by the miR-150 
RV system (Figure 3C), and supports the hypothesis that miR-150 negatively 
regulates the development of the MP subset of effector CD8 T cells with potential 
effects on formation of optimal long-term memory. 
 
 
2.4 MiR-150 negatively regulates c-Myb during CD8 T cell differentiation in vitro 
and in vivo. 
C-Myb is predicted to be one of the most likely targets for miR-150. Indeed, miR-150 
has been reported to negatively regulate c-Myb expression during B cell 
differentiation, NKT cell development and other biological processes(Bezman et al., 
2011; Bian et al., 2011; Lin et al., 2008), and this negative regulation is evolutionarily 
conserved(Lin et al., 2008). Moreover, c-Myb is a key regulator of hematopoiesis and 
early T cell development (Allen et al., 1999; Bender et al., 2004; Gewirtz and 
Calabretta, 1988; Lieu et al., 2004). Nevertheless, the role of c-Myb during effector 
and memory CD8 T cell differentiation is poorly understood. 
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    To investigate the role of c-
Myb as a potential mediator of 
the negative effect of miR-150 
in memory CD8 T cell 
formation, we examined c-Myb 
and miR-150 expression in 
WT MP and TE CD8 T cells 
following LCMV infection. On 
d8 and d35 p.i., we sorted WT 
TE and MP P14 cells and 
performed quantitative RT-PCR 
(qRT-PCR) for c-Myb and miR-
150. C-Myb expression was 
higher in the MP population 
compared to the TE population 
and inversely correlated with 
the expression of miR-150 
(Figure 4A). Thus, we 
hypothesize that c-Myb may 
function as a key transcription 
factor in effector and memory 
CD8 T cell differentiation, and 
that miR-150 could influence T 
cell memory through regulation 
of c-Myb. 
To investigate the connection between miR-150 and c-Myb during CD8 T cell 
differentiation, we isolated CD8 T cells from miR-150 WT, heterozygous (HET) and 
KO mice, and used an in vitro activation approach to examine c-Myb expression. 
Figure 4. C-Myb expression inversely correlates with miR-150 in 
CD8 T cells. 
(A) CD45.1 WT P14 cells were adoptively transferred i.v. into CD45.2 
naïve mice. Recipients were infected with LCMV the next day. Donor 
P14 TE or MP cells were purified from splenocytes by flow cytometry 
on d8 p.i. and d35 p.i. (n=2-4). C-Myb mRNA expression (normalized 
to mouse GAPDH) and miR-150 expression (normalized mouse 
snoRNA-429) were measured by qRT-PCR.  
(B) CD8 T cells were isolated from the spleens of naïve miR-150 WT 
(n=3), Heterozygous (n=3) and KO (n=2) mice and in vitro activated 
with anti-CD3, anti-CD28 and IL-2. C-Myb mRNA expression was 
measured by qRT-PCR at 18 and 42 hrs post stimulation. C-Myb 
protein expression was measured by Western Blot at 18 or 48 hrs post 
stimulation. Western Blot was quantified by ImageJ. Numbers 
represent the ratio of c-Myb to GAPDH. 
(C) Splenocytes were harvested from LCMV infected mice containing 
miR-150 WT or KO P14 cells at d8 and d35 p.i., and congenically 
marked donor cells were sorted by flow cytometry. C-Myb mRNA was 
measured on d8 (n=4) or d35 (n=3) p.i. by qRT-PCR (normalized to 
GAPDH). C-Myb protein expression was measured on d8 p.i (pooled 
samples from 6-8 mice/group). Numbers represent the ratio of c-Myb 
to GAPDH. Bar graph represents normalized quantification score of 3 
independent Western Blots. 
(D) Splenocytes were harvested at d8 p.i. from LCMV infected mice 
that had received either eGFP or miR-150 RV transduced P14 cells 
(as in Fig. 3), and GFP+ cells were sorted and analyzed for c-Myb 
mRNA expression (n=2, normalized to GAPDH).  
*P<0.05, **P<0.01, (two-tailed Student’s t-test). Data are 
representative of 3 independent experiments (mean±s.e.m.)  
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Indeed, c-Myb mRNA and protein expression was inversely proportional to the 
number of miR-150 alleles at both 18 and 42-48 hrs post activation (Figure 4B). 
However, despite a genetic deficiency in miR-150, initial proliferation did not differ 
substantially between WT, HET and KO (Figure S3A). 
To address whether miR-150 negatively regulates c-Myb expression in CD8 T 
cells in vivo, we adoptively transferred CD45.2 WT or miR-150 KO P14 cells into 
CD45.1 naïve recipient 
mice and infected the 
recipients with LCMV. 
On d8 and d35 p.i. P14 
cells were sorted and c-
Myb mRNA and protein 
expression were 
analyzed. Both c-Myb 
mRNA and protein were 
increased ~2-fold in 
miR-150 KO compared 
to WT cells (Figure 4C). 
To confirm this miR-150-
c-Myb connection during 
CD8 T cell memory 
development, we used the 
miR-150 overexpressing RV 
approach described above. 
Indeed, c-Myb expression 
was reduced in miR-150 RV 
transduced cells compared 
Figure 5. Non-repressible c-Myb overexpression rescues the 
altered memory CD8 T cell differentiation caused by miR-150 
overexpression. 
CD45.2 P14 cells were transduced with one of the following four 
combinations of RVs: 1) EmptyGFP (eGFP) and EmptyVEX (eVEX), 2) 
eGFP and miR-150-VEX, 3) non-repressible c-Myb-GFP and eVEX, and 
4) non-repressible c-Myb-GFP and miR-150-VEX. CD45.1 naïve mice 
were infected with LCMV and the next day received one of the four 
groups of transduced P14 cells. Donor P14 cells that were transduced 
with both RV were identified as GFP+VEX+.  
(A) Representative FACS plots on d8 p.i., gated on donor CD45.2 P14 
CD8 T cells. (B) Percentages of MP and CD127hiCXCR3hi out of 
GFP+VEX+ cells on d8, d15 and d26 p.i.  
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 (one-way ANOVA with 
Tukey’s multiple comparisons test). Data are representative of 2 
independent experiments (mean±s.e.m.) with at least 3 mice/group for 
each experiment. 
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to control eGFP RV transduced P14 cells (Figure 4D). Together, these data 
suggested a link between miR-150 and the regulation of CD8 T cell memory 
formation through c-Myb, a transcription factor with a key role in effector and memory 
CD8 T cell differentiation. 
 
2.5 C-Myb overexpression reverses miR-150 induced altered memory CD8 T 
cell differentiation 
 The connection between miR-150 and c-Myb expression was suggestive, but 
miRNAs can have multiple cellular targets. To directly test a potential causal role of 
the miR-150-c-Myb regulation axis in memory CD8 T cell differentiation, we 
generated a non-repressible c-Myb construct lacking the c-Myb 3’-UTR miR-150 
targeting sequence (Xiao et al., 2007) and expressed this version of c-Myb by RV. 
This GFP-marked non-repressible c-Myb construct was used in a dual RV 
transduction approach together with a miR-150 RV expressing a different fluorescent 
reporter (violet excited protein; VEX) to allow detection of dual transduced cells 
(Figure 5A). Using this approach we then tested whether expression of the non-
repressible c-Myb could reverse the effects of miR-150 overexpression on memory 
CD8 T cell differentiation. After in vitro transduction of P14 cells and in vivo transfer 
in LCMV infected mice, robust populations of single and dual transduced P14 cells 
were detectable at d8 p.i. Dual-transduction with the eGFP and empty-VEX (eVEX) 
RVs resulted in a typical memory differentiation pattern at d8, d15 and d26 p.i. 
(Figure 5B). Consistent with the single RV transduction shown in Figure 3E, dual 
transduction with eGFP RV and miR-150-VEX RV led to repression of MP and 
CD127hiCXCR3hi subsets (Figure 5B). In contrast, dual transduction with c-Myb-GFP 
RV and eVEX RV increased the proportion of MP at d8 p.i. and fostered more 
efficient memory development (Figure 5B), demonstrating a memory promoting 
effect of c-Myb. Expression of the non-repressible version of c-Myb by RV reversed 
the negative effect of miR-150 on memory differentiation in the dual c-Myb-GFP and 
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miR-150-VEX transduction setting (Figure 5B), demonstrating a causal link between 
miR-150 and c-Myb and also implicating c-Myb as a key transcription factor shaping 
optimal memory CD8 T cell differentiation. 
 
2.6 C-Myb-regulated anti-apoptotic pathways mediate the effect of miR-150 on 
CD8 T cell memory 
     C-Myb can influence multiple biological processes and could impact CD8 T cell 
memory differentiation in several ways. Bcl-2 and Bcl-xL are two anti-apoptotic c-Myb 
target genes with known roles in lymphocytes(Salomoni et al., 1997; Yuan et al., 
2010). Indeed, ENCODE ChIP-Seq data identified the genes encoding Bcl-2 and Bcl-
xL as strongly bound by c-Myb(ENCODE Project Consortium, 2012). We therefore 
hypothesized that the impact of miR-150 on CD8 T cell memory differentiation could 
be through c-Myb regulating Bcl-2 and/or Bcl-xL. We found substantially higher Bcl-2 
and Bcl-xL expression in miR-150 KO compared to WT P14 cells at d35 p.i. (Figure 
6A). Moreover, although the ratio of Bcl-2:Bim was not significantly different between 
WT and KO, the ratio of Bcl-xL:Bim was increased in the absence of miR-150 in total 
donor P14 cells (Figure 6B). However, the effects were not uniform between the MP 
and TE subsets. Gating on the MP and TE subsets of P14 effector CD8 T cells, we 
found that the Bcl-2:Bim ratio was higher in miR-150 KO MP compared to WT MP, 
whereas the Bcl-xL:Bim ratio was less impacted. In contrast, the Bcl-xL:Bim ratio was 
increased in the miR-150 KO TE compared to WT TE without an effect on Bcl-2:Bim 
ratio in this subset (Figure 6B). These data indicate that the miR-150-c-Myb axis 
regulates both Bcl-2 and Bcl-xL, but that this axis acts distinctly in each CD8 T cell 
subset. 
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Since Bcl-2 has a direct connection to memory cell survival, in part downstream of 
CD127(Kaech et al., 2003), we further tested Bcl-2 protein expression using the miR-
150 overexpression RV system as 
described above. MiR-150 
overexpression resulted in 
decreased Bcl-2 expression 
(Figure 6C). This miR-150 
repression of Bcl-2 was reversed 
by RV overexpression of a non-
repressible version of c-Myb 
(Figure 6D). Thus, we 
demonstrated that c-Myb is a target 
of miR-150 in CD8 T cells and that 
miR-150 targeting of c-Myb has a 
direct influence on Bcl-2 in the MP 
subset as well as an effect on Bcl-
xL in the TE subset. Together, 
Figure 6. Anti-apoptotic pathways downstream of c-Myb mediate the effect of miR-150 on CD8 T cell 
memory differentiation. 
A-B) 2.5 × 103 CD45.2 miR-150 WT or KO P14 cells were adoptively transferred into CD45.1 naïve mice, 
followed by LCMV infection the next day. Splenocytes were harvested on d35 p.i. (A) Bcl-2 and Bcl-xL MFI in 
WT and KO donor P14 CD8 T cells. As a control, endogenous naïve CD8 T cells gated on CD62LhiCD44lo 
were used (naïve). Histograms are gated on donor CD45.2 P14 cells. (B) Ratio of Bcl-2/Bim MFI and Bcl-
xL/Bim MFI in total P14 cells, MP P14 and TE P14 CD8 T cells.  
(C) Naïve CD45.1 mice were infected with LCMV and received 5 × 104 either eGFP or miR-150-GFP (miR-
150) RV transduced CD45.2 P14 cells on d1 p.i. GFP+ P14 cells from recipients of eGFP- or miR-150- 
transduced cells were sorted at d8 p.i. Bcl-2 protein was analyzed by flow cytometry. Histograms are gated on 
GFP+ P14 cells.  
(D) Naïve CD45.1 mice were infected with LCMV, and on d1 p.i. received 1 × 105 CD45.2 P14 cells that had 
been transduced with: 1) eGFP and eVEX, 2) eGFP and miR-150-VEX, 3) non-repressible c-Myb-GFP and 
eVEX, 4) non-repressible c-Myb-GFP and miR-150-VEX. On d8 and d26 p.i., GFP+VEX+ P14 cells were sorted 
by flow cytometry and Bcl-2 was analyzed by flow cytometry. Bcl-2 MFI was normalized to Bcl-2 MFI in 
eGFP+eVEX+ transduced P14 cells across independent sorting experiments. Each data point represents a 
pooled sample from 3-4 mice. Black lines refer to Bcl-2 MFI of eGFP+eVEX+ transduced P14 cells. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 (two-tailed Student’s t-test for 6A, 6B and 6C, one-way ANOVA 
with Tukey’s multiple comparisons test for 6D). Data are representative of 2-3 independent experiments 
(mean±s.e.m.). 
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these data define a miR-150-c-Myb axis that regulates CD8 T cell memory formation 
by affecting the expression of the memory survival molecules Bcl-2 and Bcl-xL. 
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Chapter 3 TCF-1-centered transcriptional network drives a binary effector 
versus exhausted CD8+ T cell fate decision 
3.1 Single cell RNA sequencing (scRNA-seq) reveals distinct subpopulations 
and transcriptional signatures of CD8+ T cells early during chronic viral 
infection 
To interrogate the early population dynamics during chronic infection, we performed 
single cell RNA sequencing (scRNA-seq) on LCMV DbGP33-41 specific P14 CD8+ T 
cells isolated from naïve mice, or from mice on Day 8 (D8) after infection with acutely 
resolving LCMV Armstrong (Arm), the chronic LCMV clone 13 (Cl13) strain or from 
mice infected with Cl13 and depleted of CD4+ T cells to induce a non-resolving 
chronic infection (Cl13△CD4) (Figure 7A). We identified 5 major clusters of 
responding LCMV-specific 
CD8+ T cells and visualized 
these clusters by tSNE 
(Figure 7B). Cluster 1 
contained the majority of 
cells from D8 Arm, 
whereas cluster 5 
contained almost 
exclusively naïve P14 cells 
(Figure 7C). D8 Cl13 and 
Cl13△CD4 P14 cells were 
distributed in clusters 2, 3 
and 4 with a slight bias of 
Cl13-derived D8 cells in 
cluster 4 and Cl13△CD4 in 
cluster 2 (Figure 7C). 
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We next examined the top 20 differentially expressed genes across the 5 clusters 
(Figure S4A) and visualized specific genes in tSNE space (Figure 7D). Cluster 5 
displayed high expression of naïve markers such as Lef1, Il7r, Sell, Ccr7, Tcf7 and 
Bcl2 (Figure S4A and Figure 7D) consistent with the biology of naïve CD8+ T cells 
(TN). Cluster 1 had high expression of Klrg1, Klrd1, Gzma, Gzmb, Id2 and Ccr2 
(Figure 7D and Figure S4A) in agreement with the preponderance of Arm-derived 
TEFF in this cluster. This cluster also expressed Ifng and Tbx21, but to a similar extent 
as Clusters 3 and 4 (Figure 7D). Clusters 2, 3 and 4 all expressed Pdcd1 (encoding 
PD-1) consistent with enrichment of the D8 Cl13 and Cl13△CD4 P14 cells in these 
clusters. However, whereas clusters 3 and 4 displayed high Gzmb, cluster 2 was 
relatively depleted of this gene. Cluster 4 was enriched for cell cycle genes such as 
Ccnb2, Cks1b, Cenpa, Cdk2 and Mki67 (Figure 7D and Figure S4A). Cluster 3 
contained genes encoding chemokines (Ccl3, Ccl4, Ccl5), Gzmb and other activation 
genes (e.g. S100a4, S100a6, Lgals1, Nkg7) and the inhibitory receptor Lag3 (Figure 
7D and Figure S4A). Cluster 2 was enriched for cells expressing Cxcr5, Tcf7 
(encoding TCF-1) and Slamf6 (encoding Ly108) and relatively depleted of cells 
expressing Havcr2 (encoding Tim3). In addition, cluster 2 displayed expression of a 
Figure 7. scRNA-seq identifies distinct subpopulations of virus specific CD8+ T cells during the 
early stages of chronic infection. 
(A) Experimental design for sorting and scRNA-seq. CD45.2+ P14 cells were adoptively transferred into 
naïve CD45.1+ recipient mice (5 mice/group) followed by infection with LCMV-Arm, Cl13, or 
Cl13△CD4. On D8 p.i., P14 cells were purified by flow cytometry and indexing was immediately 
performed using the Chromium System 10X Genomics, 3’ V2 kit. 
(B) tSNE plot showing the distinct clusters of cells from the scRNA-seq dataset. 
(C) Cell count of different treatment groups across 5 clusters from 1B. 
(D) Expression of representative genes displayed in tSNE space. 
(E) Gene ontology (GO) enrichment analysis across clusters 1-5. Bonferroni correction test performed 
and enrichment cutoff p<0.05. 
(F) Pseudotime analysis using Monocle 2 across naïve, Cl13, and Cl13△CD4 P14 cell populations from 
D8 p.i. using a 513 exhaustion specific gene list (ESGs) from (Bengsch, et al. 2018).  Predicted “TEFF-
like” and “TEX precursor” branc hes of the pseudotime trajectory. Distribution of clusters 2,3,4,5 from 
Figure 1B is shown. 
(G) Expression of Tcf7, Gzmb, Havcr2 projected onto the pseudotime trajectory. 
(H) Expression of Klrg1 projected onto the pseudotime trajectory；A KLRG1+ TEFF population-specific 
gene expression signature (Klrg1+ DiffGene) was generated using published data (Herndler-
Brandstetter et al., 2018). This expression signature was then projected onto the scRNA-seq tSNE 
space from Figure 1 and onto the pseudotime trajectory.  
(I) Expression of Entpd1 projected onto the pseudotime trajectory. Gene expression signatures of 
CD39+Tim-3+ CD8+ T cells (Entpd1+Havcr2+ DiffGene) or TCF-1+PD-1+ CD8+ T cells (Tcf7+Pdcd1+ 
DiffGene) were generated from published data (Sade-Feldman et al., 2018). These signatures were 
then projected onto the pseudotime trajectory.  
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subset of interferon-stimulated genes (ISGs) and transcriptional coordinators such as 
Batf, Id3, Tox, Nr4a1 and Pou2f2 in addition to Tcf7 (Figure 7D and Figure S4A). 
Consistent with the expression of individual genes, cluster 1 enriched in gene 
ontology (GO) terms reflecting cell trafficking and effector functions with a moderate 
enrichment of some of these GO terms in cluster 3, whereas cluster 2 showed 
preferential enrichment of “response to virus” likely reflecting ISGs (Figure 7E). 
Cluster 4 had strong enrichment for cell cycle related GO terms consistent with 
individual gene expression data and also with the notion of ongoing proliferation 
during the development of exhaustion (Doering et al., 2012; Wherry et al., 2007). 
Cluster 2 was of particular interest given the high co-expression of Pdcd1, Tcf7, 
Slamf6, Bcl2 and relative lack of Gzmb, Havcr2 and markers of cell cycle. This 
cluster is reminiscent of recently described TCF-1+ TEX progenitor cells in established 
exhaustion(Im et al., 2016; Utzschneider et al., 2016; Wu et al., 2016). 
 
3.2 Developmental relationships of antigen specific CD8+ T cell at the early 
stage of chronic infection 
We next used these scRNA-seq data to infer predicted developmental relationships 
during chronic infection. We applied a list of exhaustion specific genes (ESGs; n=495 
genes; (Bengsch et al., 2018)) and used Monocle-2(Qiu et al., 2017) to perform 
pseudotime analysis on P14 cells from naïve mice, as well as D8 Cl13 and 
Cl13 CD4 infection. These analyses revealed a trajectory originating at TN, but then 
bifurcating into two branches containing cells from early chronic infection (Figure 7F). 
We tentatively labeled the upper branch “TEX precursor” because this branch 
enriched for cells from cluster 2 above (Figure 7F) and displayed high Tcf7 
expression (Figure 7G). The lower branch was termed “TEFF-like” because cells in 
this branch enriched for cells from cluster 3 and 4 (Figure 7F) and had high 
expression of Gzmb and Havcr2 (encoding Tim3; Figure 7G). This branch also lacks 
Tcf7 (Figure 7G). 
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Although across the entire data set, Klrg1 expression was most prominent in cluster 
1 containing the cells from Arm D8 (Figure S4A), the pseudotime branch with high 
Gzmb and Havcr2 expression had higher Klrg1 expression than the TEX precursor 
branch (Figure 7H). To further interrogate whether this pattern reflected the broader 
transcriptional program of terminal TEFF cells, we generated a transcriptional 
signature of the KLRG1+ subset (Klrg+DiffGene) from previous data (Herndler-
Brandstetter et al., 2018). This signature was absent from cluster 5 (i.e. TN), but was 
strongly enriched in cluster 1 containing most of the Arm D8 cells (Figure S4B). 
Detection among the Cl13 clusters (2, 3 and 4) was generally low (Figure S4B), 
consistent with fewer KLRG1+ CD8+ T cells in early chronic infection. However, 
projecting the Klrg+DiffGene signature on the pseudotime trajectories, revealed 
higher representation of this transcriptional program in the Gzmb and Havcr2 branch 
and low expression in the Tcf7+ branch (Figure 7H). 
Recent studies defined CD39 or CD39 in combination with Tim-3 as potential 
markers of terminal differentiation of T cells during chronic infection and 
cancer(Gupta et al., 2015; Sade-Feldman et al., 2019). Thus, we next examined Tim-
3 (encoded by Havcr2) and CD39 (encoded by Entpd1) expression at the early stage 
of chronic infection. The lower TEFF-like branch in the pseudotime analysis from early 
chronic infection displayed high expression of Havcr2 (Figure 7G) and Entpd1 
(Figure 7I). Furthermore, we generated a Havcr2+Entpd1+ DiffGene signature from 
previous data(Sade-Feldman et al., 2019). This Havcr2+Entpd1+ DiffGene signature 
was also more strongly enriched in clusters 3 and 4 compared to cluster 2 (Figure 
S4C) and in the lower TEFF-like branch in the pseudotime analysis (Figure 7I). From 
the same dataset(Sade-Feldman et al., 2019), we also generated a Tcf7+Pdcd1+ 
DiffGene signature, and found that this signature was strongly enriched in the “TEX 
precursor” branch (Figure 7I). Together, these data suggested a binary 
developmental bifurcation early in the formation of TEX precursors consisting of a 
divergence of a “TEFF-like” branch and a distinct Tcf7+Pdcd1+ “TEX precursor” branch. 
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Moreover, these data are consistent with a role for TCF-1 in established T cell 
exhaustion, but also suggest a potential role for TCF-1 at an early stage of initiating 
the TEX developmental program. 
 
3.3 KLRG1+ TEFF-like cells from chronic infection display a distinct molecular 
signature compared to PD-1+ TEX cells. 
We next examined the relationship between TEFF cells and developing TEX. To 
complement the scRNA-seq approach where technical dropouts can limit the ability 
to determine how uniform an expression pattern is in a cell population, we also 
employ flow cytometric analysis. Thus, we examined protein expression of the 
canonical TEFF marker KLRG1(Joshi et al., 2007) and as well as PD-1. At D8 p.i. of 
Arm, a robust population of KLRG1+ TEFF was readily apparent as described(Joshi et 
al., 2007) (Figure 8A-8B). 
Consistent with previous 
work, this KLRG1+ 
population was substantially 
reduced at D8 p.i. of Cl13 
and Cl13△ CD4 infections 
(Figure 8A-8B and Figure 
S5A-S5B). Over the ensuing 
weeks, the KLRG1+ 
population gradually declined 
following Arm infection. In 
contrast, this population 
decreased precipitously 
during chronic infection with 
<5% of the P14 population 
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expressing KLRG1 by D16 p.i. (Figure 8B; Figure S5A-S5B). However, during 
developing chronic infection a clear population of PD-1+ cells was present at D8 p.i. 
and the vast majority of these cells were KLRG1- (Figure 8B; Figure S5A-S5B) 
suggesting at least partially mutually exclusive expression of KLRG1 and PD-1 in this 
setting. Compared to Arm infection, the KLRG1+ cells from Cl13 infection at D8 p.i. 
had substantially higher expression of CD39 and Tim-3 (Figure 8C), consistent with 
the TEFF-like branch in the pseudotime analysis above and a more activated state of 
the KLRG1+ TEFF-like cells in Cl13 compared to Arm infection. A KLRG1+CD39+ 
population of responding LCMV-specific CD8+ T cells was also present in multiple 
organs of Cl13 infected mice at D8 p.i. (Figure S5C-S5D) and a similar population 
was detectable in TIL populations from CT26 tumors at D8 post tumor inoculation 
(Figure S5E-S5F). 
We next investigated how the KLRG1+CD39+ and KLRG1-PD-1+ P14 populations 
compared during Cl13 infection. At D8 p.i. the KLRG1+CD39+ cells lacked TCF-1 
expression and TCF-1 expression was exclusively found in the KLRG1-PD-1+ 
population (Figure 8D). We next divided the PD-1+ P14 cells into TCF-1+ and TCF-1- 
Figure 8. Distinct cellular and molecular profiles of TEFF-like and TEX precursor CD8+ T cells during 
chronic infection. 
(A) Experimental design. 2.5 x 103 CD45.2+ P14 cells were adoptively transferred into naïve CD45.1+ mice 
followed by infection with LCMV Arm, Cl13 or Cl13△CD4. P14 cells from spleens of these mice were 
analyzed at the indicated time points.  
(B) KLRG1 and PD-1 expression at the indicated time points of Arm, Cl13 and Cl13△CD4 infections. Gated 
on donor P14 cells. 
(C) Representative flow cytometry plots for the expression of CD39 and Tim-3 by KLRG1+ P14 cells from 
Arm versus Cl13 at D8 p.i. 
(D) TCF-1 expression was assessed at D8 p.i. with Cl13 in P14 cells gated on KLRG1+CD39+ or KLRG1-
PD-1+ subsets. Naïve CD8+ T cells (endogenous CD62L+CD44-) are displayed as a control. 
(E) T-bet and Eomes expression was assessed at D8 p.i. with Cl13 in P14 cells gated on KLRG1+CD39+, 
KLRG1-PD-1+TCF-1- or KLRG1-PD-1+ TCF-1+ subsets. Naïve CD8+ T cells (endogenous CD62L+CD44-) 
are displayed as a control. The T-bet/Eomes ratio was calculated based on geometric MFI. 
(F) IFNγ, TNF, CD107a and Granzyme B (Gzmb) expression were assessed at D8 p.i. with Cl13 by P14 
cells gated on KLRG1+CD39+, KLRG1-PD-1+TCF-1- or KLRG1-PD-1+TCF-1+ subsets.  
(G) The percentage of Ki-67+ cells in the KLRG1+CD39+, KLRG1-PD-1+TCF-1- or KLRG1-PD-1+TCF-1+ 
subsets of P14 cells was assessed at D8 and D12 p.i. with Cl13. 
(H) Bcl-2 and Bim expression were assessed at D8 p.i. with Arm in the KLRG1+ P14 subset. Naïve CD8+ T 
cells (endogenous CD62L+CD44-) are displayed as a control. The ratio of Bcl-2/Bim was calculated 
based on geometric MFI. 
(I) Bcl-2 and Bim expression were assessed at D8 p.i. with Cl13 p.i. in the KLRG1+CD39+, KLRG1-PD-
1+Ly108- and KLRG1-PD-1+Ly108+ subsets of P14 cells. Naïve CD8+ T cells (endogenous CD62L+CD44-
) are displayed as a control. The ratio of Bcl-2/Bim was calculated based on geometric MFI. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 versus control (two-tailed Student’s t-test or One-Way ANOVA). 
Data are representative of 2-6 independent experiments with at least 3 mice/group (mean±s.e.m.). 
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subpopulations and interrogated the properties of these subpopulations in more 
detail (Figure S5G). For example, whereas the KLRG1+CD39+ TEFF-like population 
from chronic infection expressed the highest T-bet, expression of this TF was higher 
in the PD-1+TCF-1- population compared to the PD-1+TCF-1+ cells (Figure 8E). In 
contrast, Eomes was the highest in the PD-1+TCF-1+ D8 P14 population, but lower in 
both the PD-1+TCF-1- and KLRG1+CD39+ populations. Furthermore, the T-
bet/Eomes ratio was lowest in the PD-1+TCF-1+ population (Figure 8E). As predicted 
from the effector signatures, the KLRG1+CD39+ P14 cells displayed effector functions 
including the highest frequency of IFN-γ producing and IFN-γ and TNF coproducing 
cells, robust expression of granzyme B and the ability to degranulation (Figure 8F). 
Between the two PD-1+ subpopulations, the PD-1+TCF1+ cells were the least efficient 
at elaborating cytokines, expressing granzyme B or degranulating (Figure 8F). A 
similar hierarchy was observed when ongoing in vivo proliferation was examined at 
D8 or D12 p.i. with the PD-1+TCF-1+ cells displaying the lowest Ki67 expression 
(Figure 8G). 
Despite evidence of more proliferation, the KLRG1+ P14 cells generated early during 
chronic infection fail to persist long-term (Angelosanto et al., 2012). Thus, we 
examined expression of the anti- and pro-apoptotic molecules Bcl-2 and Bim in the 
different subpopulations of virus-specific CD8+ T cells at D8 p.i. The KLRG1+ P14 
population during Cl13 infection had higher expression of both Bcl-2 and Bim 
compared to the KLRG1+ TEFF cells from Arm infection (Figure 8H). However, when 
the Bcl-2:Bim ratio was compared, the KLRG1+ population from Arm infection had a 
substantially higher ratio of anti- to pro- apoptotic molecules (Figure 8H). Moreover, 
the KLRG1-PD-1+ subsets from D8 p.i. Cl13 had a considerably higher Bcl2:Bim ratio 
compared to the KLRG1+CD39+ cells (Figure 8I). Among the KLRG1-PD-1+ cells 
from Cl13 infection, the subpopulation that expressed TCF-1+ (using Ly108 as a 
surrogate of TCF-1 expression (Figure S5H)) had the highest Bcl-2:Bim ratio among 
all the D8 subsets found at D8 of Cl13 infection (Figure 8I). These patterns of 
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transcription factor expression, effector function, proliferation and pro- and anti-
apoptotic molecule expression were also observed in the Cl13 CD4 setting (Figure 
S6), consistent with similar patterns in the sc-RNA-seq data for these two infections 
at D8 p.i. 
The low Bcl-2:Bim ratio in the KLRG1+ CD8+ T cells from Cl13 infection suggested 
that these cells may be more prone to cell death and less durable over time. To 
further interrogate this possibility we examined genome integrity using microscopy for 
DAPI and γH2AX staining. Cells with stable chromatin and nuclear structure have a 
distinct DAPI+ nucleus with defined edges and low amounts of interspersed γH2AX 
staining. In contrast pre-apoptotic cells had higher γH2AX staining as well as 
evidence of nuclear envelope blebbing and nuclear lamina de-association, whereas 
apoptotic cells had complete co-staining of DAPI and nuclear lamina γH2AX (Figure 
S5I). At D8 p.i. of Cl13 KLRG1+CD39+ virus specific CD8+ T cells had the highest 
proportion of apoptotic and pre-apoptotic cells followed by the KLRG1-PD-1+Ly108- 
(i.e. TCF-1-) cells. In contrast, the KLRG1-PD-1+Ly108+ (i.e. TCF-1+) subset had the 
highest proportion of non-apoptotic nuclei (Figure S5I).  Together, these data 
suggest that KLRG1+ TEFF-like cells found at the early stage of chronic infection are 
highly susceptible to cell death, consistent with the inability of these cells to persist 
long-term in vivo. 
 
3.4 KLRG1+ TEFF-like cells persist poorly during chronic viral infection 
compared to PD-1+ TEX cells. 
To determine whether there was differential persistence of the different responding 
CD8+ T cell subpopulations and to define the developmental relationship between the 
subsets, we conducted lineage-tracing experiments of KLRG1+CD39+, KLRG1-PD-
1+Ly108- and KLRG1-PD-1+Ly108+ cells from the peak of Cl13 infection. We sorted 
these populations at D7/D8 p.i. and adoptively transferred equal numbers of each 
subset into congenically distinct, infection-matched recipient mice (Figure 9A and 
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S7D). At D8 post transfer (p.t.), progeny of KLRG1-PD-1+Ly108+ TEX precursors were 
considerably more numerous than for cells derived from KLRG1+CD39+ or KLRG1-
PD-1+Ly108- donor populations (Figure 9B), consistent with TCF-1 expression by 
this PD-1+Ly108+ subset (Utzschneider et al., 2016). However, when comparing the 
two D8 subsets that lacked TCF-1 expression, the KLRG1-PD-1+Ly108- population 
displayed significantly better persistence than the KLRG1+CD39+ TEFF-like population 
(Figure 9B). We also analyzed changes in differentiation state of the donor KLRG1-
PD-1+Ly108- and KLRG1-PD-1+Ly108+ subsets in the new recipient mice. Although 
both donor populations 
maintained high PD-1 
expression (Figure S7A-
S7B), neither of these 
KLRG1- subsets gave 
rise to appreciable 
numbers of KLRG1+ 
cells in this setting 
(Figure 9C and S7C)，
suggesting that divergent 
fate commitment to cells 
that could give rise to 
TEX versus KLRG1+ TEFF 
had occurred prior to of 
establishment of the 
KLRG1-PD-1+Ly108- and 
KLRG1-PD-1+Ly108+ 
populations or that 
Figure 9. Lineage tracing of subpopulations of TEFF-like and TEX 
precursor cells in early chronic viral infection. 
(A) Experimental design. 5 x 103 CD45.2+ P14 cells were adoptively 
transferred into naïve CD45.1+ C57BL/6 recipient mice. One day 
post transfer, these recipients were infected with Cl13. On D7 p.i. 
KLRG1+CD39+, KLRG1-PD-1+Ly108- or KLRG1-PD-1+Ly108+ P14 
CD8+ T cells were isolated from spleens by cell sorting and 3 x 105 
of each purified population was adoptively transferred into infection-
matched (i.e. D7 post Cl13 infection) CD45.1+ recipient mice. Donor 
P14 cells from each subset were analyzed on D8 post transfer (p.t.).  
(B) Representative flow cytometry plots and quantification of donor 
CD45.2+ DbGP33 tetramer+ P14 cells derived from KLRG1+CD39+, 
KLRG1-PD-1+Ly108- or KLRG1-PD-1+Ly108+ subsets. Endogenous 
CD45.2- DbGP33 tetramer+ CD8+ T cells are shown as gating 
controls.  
(C) Representative flow cytometry plots and quantification of splenic 
CD45.2+ donor P14 cells and host DbGP33 tetramer+ cells that are 
KLRG1+, Ly108-CD39+, or Ly108+CD39-. Note, KLRG1+CD39+ P14 
cells isolated at D7 p.i. did not give rise to sufficient numbers of 
cells for analysis on D8 p.i. (see part B). 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 versus control (two-tailed 
Student’s t-test or One-Way ANOVA). Data representative of at least 3 
mice/group (mean±s.e.m.). 
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development of KLRG1+ cells was antagonized by this time point of chronic infection. 
Moreover, PD-1+Ly108+ cells were able to generate PD-1+Ly108- cells, whereas the 
opposite was highly inefficient (Figure 9C and S7C). These developmental 
relationships were also observed for non-P14 endogenous polyclonal DbGP33 
tetramer+ CD8+ T cells (Figure S7D-S7F). Thus, these lineage tracing experiments 
highlighted a major difference in durability and ability of the three D8 virus-specific 
CD8 T cell populations generated during Cl13 infection and suggested that TEX 
precursor cells are distinct from KLRG1+ TEFF-like cells, at least in part because the 
latter are incapable of persisting long-term during chronic infection. Moreover, these 
data indicate a hierarchy of TEX precursors where a Ly108+ (i.e. TCF-1+) population of 
PD-1+ cells can give rise to PD-1+ Ly108- cells even at these early time points of 
establishing the TEX population. 
 
3.5 TCF-1 represses the TEFF fate in early chronic infection and fosters 
establishment of a TEX population. 
Recent studies identified a key role for TCF-1 in established exhaustion(He et al., 
2016; Im et al., 2016; Utzschneider et al., 2016; Wu et al., 2016). For example 
genetic deletion of TCF-1 resulted in loss of TEX, specifically during the post effector 
phase(Im et al., 2016; Utzschneider et al., 2016) suggesting a role for TCF-1 in the 
transition from the effector phase to exhaustion. However, how and when this TCF-1 
dependent activity occurs is unclear. To investigate this question, we first co-
transferred equal numbers of congenically distinct WT (Tcf7flox/floxxCD4WT) and 
Tcf7flox/floxxCD4CRE (TCF-1cKO) P14 cells to recipient mice of a third congenic 
background followed by Cl13 infection (Figure 10A). TCF-1 cKO P14 mounted an 
initial response, but failed to seed a durable TEX pool (Figure 10B) as expected (Im 
et al., 2016; Utzschneider et al., 2016; Wu et al., 2016). Based on the scRNA-seq 
results above, we next examined if the distribution of cells corresponding to the TEFF-
like versus TEX precursor branches identified in the pseudotime analysis was altered 
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in the absence of TCF-1. Indeed, staining for markers of these two pseudotime-
defined branches revealed a substantial shift in the absence of TCF-1, with fewer 
KLRG1-PD-1+ P14 cells and a substantially higher proportion of KLRG1+CD39+ or 
Tim-3+CD39+ P14 than observed for WT P14 cells in Cl13 infection (Figure 10C and 
10D). 
We next investigated how enforced TCF-1 expression impacted these early 
population dynamics. There are two major isoforms of TCF-1, p33 and p45. The p45 
isoform has a β-catenin binding domain compared to the p33 isoform(Ioannidis et al., 
2001) that could influence function(Anastas and Moon, 2013). Thus, we expressed 
TCF-1-p33 or TCF-1-p45 in P14 cells in vivo using retroviral (RV) expression (Figure 
10E and Figure S8A) as described(Kurachi et al., 2017). RV expression of either 
TCF-1 isoform repressed the formation of KLRG1+CD39+ or Tim-3+CD39+ P14 cells 
at D8 p.i. with Cl13. Moreover, using Ly108 as a surrogate of TCF-1+ cells (see 
Figure S8H) revealed 
an increased 
proportion of 
Ly108+CD39- P14 cells 
upon enforced 
expression of either 
TCF-1 p33 or TCF-1 
p45 (Figure 10F). As 
chronic infection 
progressed, the p33 
isoform displayed 
stronger repression of 
KLRG1 or CD39 
expression (Figure 
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S8B) whereas the p45 isoform more efficiently promoted CD127 and CXCR5 
expression (Figure 10G and Figure S8B). Both TCF-1 isoforms also promoted PD-1 
expression (Figure 10G) at D15, a time point corresponding to the developmental 
transition between the effector phase and early establishment of exhaustion 
(Angelosanto et al., 2012; Crawford et al., 2014; Doering et al., 2012; Schietinger et 
al., 2016). Moreover, the p45 isoform appeared to more efficiently foster durability of 
the TEX population in established chronic infection (Figure S8C-S8F). A similar effect 
of TCF-1 expression was observed in the DCD4 setting (Figure S8G-S8H). Together 
these data underscore the importance of TCF-1 in T cell exhaustion. However, these 
experiments also further revealed a major role for TCF-1 in repressing the more 
terminal TEFF branch early during the development of exhaustion. 
 
3.6 PD-1 supports the development of the TCF-1+ TEX precursor population 
early during chronic infection 
Figure 10. TCF-1 regulates the early fate bifurcation between TEFF-like and TEX precursors. 
(A) Experimental design. 1 x 103 CD45.2+ WT (TCF-1flox/flox without CD4CRE) littermate control P14 
and 1 x 103 CD45.1+CD45.2+ TCF-1flox/flox x CD4CRE (TCF-1 cKO) P14 CD8+ T cells were co-
transferred into CD45.1+ naïve recipient mice followed by Cl13 infection. Splenocytes were 
isolated on the indicated days p.i. for analysis. 
(B) Representative flow cytometry plots quantifying WT and TCF-1cKO P14 cells. The ratio of 
TCF-1cKO/WT cells is plotted over time p.i. 
(C) Representative flow cytometry plots and quantification of KLRG1+CD39+ and Tim-3+CD39+ 
subsets of responding P14 cells of each genotype on D8 p.i. with Cl13. 
(D) Representative flow cytometry plots and quantification of the KLRG1-PD-1+ subset of 
responding P14 cells of each genotype on D8 p.i. with Cl13. CD44- Endogenous naïve CD8+ T 
cells are used for gating controls. 
(E) Experimental design. WT P14 CD8+ T cells transduced with the indicated RVs were adoptively 
transferred to mice infected one day previously with Cl13. Donor RV reporter+ P14 cells were 
analyzed at the indicated time points.  
(F) Representative flow cytometry plots and quantification of KLRG1+CD39+, Tim-3+CD39+, and 
Ly108+CD39- subsets of P14 cells for experimental groups transduced with empty, TCF-1-p33, 
or TCF-1-p45 expressing RVs on D8 p.i. with Cl13 p.i.  All plots are gated on RV reporter+ 
(VEX+) P14 cells. VEX+ cell numbers were normalized to 1 X 104 VEX+P14 cell engraftment 
according to the transduction efficiency on D2 p.i. 
(G) Quantification of CD127 and PD-1 expression by P14 cells transduced with empty, TCF-1-p33, 
or TCF-1-p45 expressing RVs at the indicated time points of Cl13 infection. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 versus control (two-tailed Student’s t-test). Data are 
representative of 3-4 independent experiments (mean±s.e.m.) with at least 4 mice/group. 
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High expression of PD-1 is emblematic of terminal TEX, whereas intermediate PD-1 is 
expressed by the progenitor (a.k.a. “stem-like”) TEX population(Blackburn et al., 2008). 
In the established TEX pool, the expression of PD-1 is negatively correlated with TCF-
1(Im et al., 2016). Thus, it was somewhat unexpected that the scRNA-seq revealed 
high Pdcd1 expression in the Tcf7 cluster (Figure 7D and S4A). As previously 
described(Im et al., 2016), in established chronic infection the TCF-1+ TEX population 
had lower PD-1 than the TCF-1- subset (Figure 11A) though this amount of PD-1 
was still higher than that expressed by TMEM (data not shown). In contrast, in early 
chronic infection (D8 p.i.), TCF-1+ P14 cells expressed high PD-1 (Figure 11A). This 
contrasts D8 Arm where PD-1 expression is already low (Barber et al., 2006; Wherry 
et al., 2007). Thus, we 
next tested whether 
PD-1 had a role in 
these CD8+ T cell 
subsets in early chronic 
infection. Congenically 
distinct PD-1KO and 
WT P14 cells were co-
adoptively transferred 
followed by Cl13 
infection (Figure 11B) 
as described (Odorizzi 
et al., 2015). This 
approach revealed a 
substantial increase in 
KLRG1+CD39+ or 
Tim-3+CD39+ cells 
Figure 11. PD-1 maintains the TCF-1+ TEX precursor population at the 
early stage of chronic infection. 
(A) Representative flow cytometry plots of TCF-1 and PD-1 expression by 
responding P14 cells at the indicated days of Cl13 infection. PD-1 MFI of 
TCF-1- (black) and TCF-1+(red) subsets of P14 cells is shown in the flow 
cytometry plots and summary data presented below.  
(B) Experimental design. 5 x 102 CD45.2+ WT P14 and 5 x 102 
CD45.1+CD45.2+ PD-1KO P14 cells were co-adoptively transferred into 
CD45.1+ naïve recipient mice followed by Cl13 infection. Responding P14 
cells from the spleen were then analyzed on D8 p.i. with Cl13. 
(C) Representative flow cytometry plots and quantification of KLRG1+CD39+ 
or Tim-3+CD39+ subsets of responding WT or PD-1KO P14 cells on D8 p.i. 
(D) Representative flow cytometry plots and quantification of TCF-1+CD39- 
subsets of responding WT or PD-1KO P14 cells on D8 p.i. 
*P<0.05, **P<0.01 versus control (two-tailed Student’s t-test). Data are 
representative of 2-4 independent experiments (mean±s.e.m.) with at least 3 
mice/group. 
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(Figure 11C) and reduction in the TCF-1+ subset at D8 p.i. in the absence of PD-1 
(Figure 11D). Again, these effects of PD-1 deficiency on the early TEX 
subpopulations were also observed in the DCD4 setting (Figure S9A-S9B). These 
data are consistent with the observation that absence of PD-1 results in the erosion 
of the TEX population over time(Odorizzi et al., 2015). Thus, PD-1 is necessary to 
preserve the TCF-1+ subset of early TEX precursors and repress the formation of the 
terminal TEFF-like subset in early chronic infection. 
 
3.7 State Transition Inference Prediction (STIP) to identify transcriptional 
circuits downstream of TCF-1 in TEX 
To begin to understand how TCF-1 might be involved in early events in the 
establishment of CD8+ T cell exhaustion, we developed a computational approach to 
take advantage of scRNA-seq data for inferring transcriptional circuits. This approach 
uses a selected pseudotime trajectory and then anchors the analysis on a TF of 
interest, in this case Tcf7. This method then calculates the correlation in expression 
pattern for other transcriptional regulators with Tcf7 across the pseudotime trajectory. 
Thus, this approach identifies sets of TFs that are correlated and anti-correlated with 
Tcf7 as well as those key TFs that change dynamically specifically at the major 
inflection point of change in Tcf7 expression. Using scRNA-seq data, this latter 
feature may reveal transcriptional circuits working coordinately or in opposition 
specifically at transitions between cell states. One advantage of this approach, 
termed, State Transition Inference Predictor (STIP) from scRNA-seq data is that it 
overcomes some limitations of lowly expressed genes by using correlation 
coefficients rather than absolute gene expression (see Methods). Thus, we applied 
STIP to the pseudotime trajectory of CD8+ T cells from D8 of chronic infection 
(Figure 12A). Across this pseudotime trajectory, Tcf7 expression undergoes a 
monotone increase allowing anchoring on expression of this gene for analysis. Thus, 
several TF genes including Tox, Id3, Eomes, Myb and Nr4a1 displayed a strong 
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positive correlation with Tcf7, though the latter three displayed slightly delayed 
kinetics in pseudotime space 
(Figure 12B). In contrast, Id2 
was strongly anti-correlated 
with Tcf7 with both TFs 
displaying a similar inflection 
point in the pseudotime 
trajectory. We then examined 
an extended list of TFs to 
interrogate correlation 
patterns to Tcf7 along this 
trajectory (Figure 12C). Two 
major clusters of TFs 
emerged including one 
containing Id3, Eomes, Myb, 
Batf, Irf4, Tox Nr4a1 and 
Hif1α that was positively 
correlated with Tcf7 over the 
pseudotime trajectory and a 
second cluster containing 
Id2, Runx1, Prdm1, Tbx21, 
Irf1 and Irf8 that was 
negatively correlated with 
Tcf7. In addition to these 
two major clusters, several 
TF genes including Smad7, 
Gata3, Runx2 and Zeb2 
Figure 12. State Transition Inference Prediction (STIP) to identify 
transcriptional circuits downstream of TCF-1. 
(A) Pseudotime trajectory across naïve P14 cells and P14 cells from 
D8 of Cl13 and Cl13△CD4 infections. PCA space was created 
using the same ESGs from Figure 1. The line from point 1 to 
point 2 represents the longest lineage trajectory predicted by 
TSCAN (pseudo-Time reconstruction in Single-Cell RNA-seq 
Analysis as described (Z. Ji and H. Ji, 2016)). 
(B) Tcf7 expression monotonically increases through the pseudotime 
trajectory. Expression of Tcf7 and other indicated TFs is plotted 
over pseudotime.  
(C) A heatmap is shown displaying TF expression across the 
pseudotime trajectory. 
(D) Genes encoding TFs from part C were interrogated for open 
chromatin regions in naïve CD8+ T cells or LCMV-specific CD8+ T 
cells from D8 Cl13 using published ATAC-seq data (Sen et al. 
2016). These open chromatin regions were examined for TCF-1 
binding motifs in cis-regulatory regions. This information was then 
integrated into a network model with transcriptional data and 
visualized as a Tcf7 centered network. Border color for each gene 
represents the mRNA-expression relationship for each TF and 
Tcf7 (e.g. positively or negatively correlated with Tcf7 in orange 
and blue respectively). A subset of TFs has an intermediate 
expression pattern that is neither strongly correlated nor anti-
correlated with Tcf7. These are indicated as in transition (purple 
outline). Fill color indicates the presence of Tcf7 binding motif(s) 
in the open chromatin of the indicated TFs in naïve only (cyan), 
naïve and Cl13 (dark blue) or Cl13 only (red). 
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occupied an intermediate location in the pseudotime trajectory around the location of 
greatest change for Tcf7 and Id2 perhaps reflecting a metastable state along this 
trajectory or additional (perhaps transient) population heterogeneity (Figure 12C).  
To further interrogate how TCF-1 might regulate the TFs identified by STIPs in TEX 
we constructed a transcriptional network (Figure 12D). Thus, we used existing Assay 
for Transposase Accessible Chromatin using sequencing (ATAC-seq) data for TN and 
virus-specific CD8+ T cells from D8 Cl13 infection (Sen et al., 2016) and identified TF 
encoding genes containing a predicted TCF-1 motif in open chromatin regions. 
Combining this analysis and the STIP data, we identified TFs predicted to be 
regulated by TCF-1 in TN only (e.g. Ikzf1, Gata3), in TN and early TEX populations (e.g. 
Myb, Hif1a, Eomes, Id3, Prdm1) or only in early TEX populations (e.g.Id2, Tox, Zeb2, 
Smad7, Batf, Nfatc1) (Figure 12D). Notably, TCF-1 was predicted to repress genes 
including Id2, Prdm1, and Runx1 that are involved in TEFF differentiation and to 
promote expression of genes such as Eomes, Batf, and Nfatc1 that have been 
implicated in fostering exhaustion (Figure 12D). TCF-1 may also have a dose-
dependent or more complex regulatory connection to Smad7 and Zeb2, because the 
greatest change in expression of these genes occurred at the transition of greatest 
change in Tcf7 (Figure 12C-12D). Thus, these data suggested a key role for TCF-1 
in coordinating transcriptional circuitry at time points corresponding to the formation 
of precursors of TEX. 
 
3.8  TCF-1 mediates a T-bet and Eomes transition during chronic infection. 
Previous studies identified roles for the TFs T-bet and Eomes in progenitor and 
terminal TEX subsets(Paley et al., 2012), and TCF-1, T-bet and Eomes are all 
important for TEX because genetic deletion of any of these TFs results in a collapse of 
the TEX population(Im et al., 2016; Paley et al., 2012; Utzschneider et al., 2016). 
However, the relationship between these three TF programs remains to be defined. 
Based on the data above and a known connection between TCF-1 and Eomes in 
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TMEM (Zhou et al., 2010), we hypothesized that TCF-1 might regulate T-bet and/or Eomes in 
developing TEX precursors. At D8 of chronic infection, a clear subpopulation of TCF-
1+ virus-specific CD8+ T cells was identifiable that also expressed Eomes (Figure 
13A). Moreover, these TCF-1+ TEX precursor cells expressed slightly lower T-bet than 
























tumor infiltrating CD8+ T cells at D8 in mouse CT26 tumors (Figure 13B). To test 
whether these correlative relationships were causal, we examined Eomes and T-bet 
expression in the absence of TCF-1. Genetic deletion of TCF-1 reduced Eomes 
expression at D8 of Cl13 infection (Figure 13C). In contrast, although the percentage 
of T-bet+ cells decreased, the amount of T-bet per cell (MFI) was moderately 
increased in the absence of TCF-1 (Figure 13C). These data suggested that TCF-1 
was upstream of Eomes, but have only minimal effect on T-bet at this time point. To 
directly test the effect of TCF-1 on Eomes gene expression, we employed the TCF-1 
p33 and TCF-1 p45 RV approach and EomesGFP P14 cells (Figure 13D and Figure 
S10A). Enforced TCF-1 expression, and in particular TCF-1 p45, promoted 
enhanced EomesGFP reporter activity with increasing EomesGFP expression over time 
and also fostered increased Eomes mRNA expression (Figure 13E-13F). 
Figure 13. TCF-1 regulates distinct molecular modules during TEX development. 
(A) Representative flow cytometry plots of TCF-1 and Eomes or TCF-1 and T-bet co-expression in 
P14 CD8+ T cells on the indicated days of Cl13 infection. Quadrant gates were set using CD44- 
naïve T cells (T-bet-Eomes-TCF-1+) for each time point. 
(B) Representative flow cytometry plots of TCF-1 and Eomes or TCF-1 and T-bet co-expression in 
tumor infiltrating CD44+CD8+ T cells (TILs) at D8 post CT26 tumor inoculation. Quadrant gates 
were set based on CD62L+CD44- naïve T cells (T-bet-Eomes-TCF-1+) from spleen. 
Quantification of T-bet and Eomes MFI of TCF-1+ or TCF-1- TILs show on the right. 
(C) Representative flow cytometry plots and quantification of Eomes and T-bet expression in WT or 
TCF-1cKO P14 cells at D8 p.i. with Cl13. 
(D) Representative flow cytometry plots of GFP expression from EomesGFP reporter P14 cells 
transduced with in empty, TCF-1-p33 or TCF-1-p45 RVs on D8 p.i. with Cl13. Plots gated on 
VEX+ P14 cells (see Figure S7A for gating). 
(E) Quantification of Eomes-GFP+ cells in the RV transduced (VEX+) P14 donor population for the 
indicated RV constructs on the indicated days p.i. Both percent and numbers are shown. Cell 
numbers are normalized to 1 X 104 VEX+ P14 cell engraftment according to VEX+ transduction 
efficiency on D2 p.i. (Figure S7A). 
(F) Eomes mRNA expression is shown for P14 cells transduced with empty, TCF-1-p33 or TCF-1-
p45 RVs. VEX+ (i.e. transduced) P14 cells were sorted by flow cytometry on D8 Cl13 p.i. and 
Eomes mRNA measured by qRT-PCR. 
(G) Myb mRNA and c-Myb protein expression were examined by qRT-PCR and Western blot in 
purified WT and TCF-1 cKO P14 cells isolated from spleens of co-transferred mice on D8 p.i. 
with Cl13.  
(H) Representative flow cytometry plots and quantification of Bcl-2 expression in WT versus TCF-1 
cKO P14 cells on D8 p.i. with Cl13. Gated on donor P14 cells of each genotype. Naïve control 
is gated on endogenous CD44-CD8+ T cells. 
(I) Myb mRNA expression in sorted WT P14 cells transduced with empty, TCF-1-p33 or TCF-1-
p45 RVs D8 p.i. with Cl13. Transduced cells were sorted based on VEX expression. 
(J) Representative flow cytometry plots and quantification of Ly108+CD39- and Tim-3+CD39+ 
subsets of responding P14 cells transduced with empty versus c-Myb RVs. Plots are gated on 
transduced (VEX+) donor P14 cells on D8 p.i. with Cl13. VEX+ cell numbers were normalized to 
1 X 104 VEX+P14 cell engraftment according to the transduction efficiency on D2 p.i. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-test and One-Way 
Anova analysis). Data are representative of 2 independent experiments (mean±s.e.m.) with at least 
3 mice/group. 
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To further interrogate the role of Eomes in TEX, we crossed EomesWT or Eomesflox/flox 
mice to CREERT2 P14 mice on a Rosa26LSL-YFP reporter background (i.e. to monitor 
CRE activity).  We used EomesWTxCREERT2xRosa26LSL-YFP (Eomes WT) and 
Eomesflox/floxxCREERT2xRosa26LSL-YFP inducible conditional KO (Eomes icKO) on 
different congenic backgrounds in a co-adoptive transfer experimental design. We 
then induced Eomes deletion in Eomes icKO P14 cells using tamoxifen treatment 
between D9-D13 p.i. (Figure S10B). Prior to tamoxifen treatment, Eomes WT and 
Eomes icKO P14 cells were present at a 1:1 ratio (Figure S10C). After tamoxifen 
delivery there was efficient CRE activity as indicated by the Rosa locus YFP reporter 
(Figure S10D). However, when these YFP+ cells were examined, 98%+ were from 
the WT donor cells with almost no Eomes icKO cells surviving after tamoxifen 
induced deletion of Eomes during the early phase of chronic infection (Figure S10E). 
These data are consistent with our previous studies demonstrating that constitutive 
deletion of Eomes compromises the development of TEX (Paley et al., 2012), but 
extend this earlier work to indicate that even after establishment of TEX precursors, 
Eomes has a critical role in the durability of this cell type. Moreover, these data 
indicate that a likely essential function of TCF-1 in the setting of TEX development is 
to mediate effective regulation of Eomes expression.We next examined the role of T-
bet. RV-mediated T-bet expression fostered development of KLRG1+CD39+ TEFF-like 
cells at D8 of Cl13 infection, though the Ly108+CD39- TEX precursor population was 
unchanged (Figure S10F). However, RV enforced expression of T-bet decreased 
expression of PD-1, Lag-3, and CD127 at this time point, but promoted expression of 
Tim-3 (Figure S10G) consistent with the role of T-bet in fostering Tim-3 expression 
early in infection, but repressing PD-1, Lag-3 and CD127(Kao et al., 2011). These 
data suggested that during the early phases of establishing TEX T-bet may promote 
TEFF differentiation consistent with the role of this TF in acute infection(Joshi et al., 
2007). However, the ability of T-bet to repress expression (though not fully) of 
inhibitory receptors also suggest a role in restraining terminal exhaustion. Thus, a 
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strong influence of TCF-1 on Eomes expression may be necessary to help form all 
TEX and Eomes (or perhaps TCF-1 itself) may help blunt the effector-promoting 
activity of T-bet in these TEX precursor cells. 
 
3.9  TCF-1 enhanced Bcl-2 expression via c-Myb in TEX during chronic infection 
The TF c-Myb was also of considerable interest in the network analysis of early TEX 
precursors. In memory CD8+ T cells c-Myb regulates Bcl-2 expression and promotes 
TMEM survival following acute infection(Chen et al., 2017). To test whether c-Myb 
might also have a role in TEX and interrogate whether this TF was regulated by TCF-1, 
we used the TCF-1 cKO versus WT co-transfer model. In this setting c-Myb mRNA 
and protein was reduced in the absence of TCF-1 at D8 of Cl13 infection (Figure 
13G). This reduced c-Myb expression corresponded to decreased Bcl-2 expression 
in the TCF-1 cKO (Figure 13H). Conversely Myb mRNA expression was induced by 
enforced expression of the p45, but not the p33 isoform of TCF-1 (Figure 13I). 
Furthermore, RV expression of c-Myb significantly increased the proportion of the TEX 
precursor (Ly108+CD39-) population and reduced expression of CD39 and Tim-3 
(Figure 13J), suggesting that c-Myb antagonized the TEFF-branch of differentiation 
and participated in fostering the establishment of TEX precursor population. Although 
overall cell numbers were not changed with enforced c-Myb expression (Figure 
S10H-S10I), there was a bias to fostering the Ly108+CD39- subset at the expense of 
the Tim-3+CD39+ subset (Figure S10I). Thus, these data identify an early fate 
bifurcation in the establishment of the TEX population and point to a TCF-1-related 
transcriptional network that implicates TCF-1 as a key regulator necessary to 
antagonize an early TEFF-like population during chronic infection and support the TEX 
developmental path.  
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Chapter 4 In vivo CRISPR screening identifies Fli1 as a transcriptional 
safeguard that restrains effector CD8 T cell differentiation during infection and 
cancer 
 
4.1  Optimized CRISPR-Cas9 for gene editing in murine primary T in vivo 
Recently, several CRISPR-Cas9-based genetic perturbation approaches have been 
developed for unbiased genetic screen to reveal novel regulatory pathways in murine 
primary T cells in vivo (Dong et al., 2019; LaFleur et al., 2019a; Wei et al., 2019; Ye 
et al., 2019). The current methods either adoptive transferring the Cas9-edited bone 
marrow progenitors into recipient mice which could lead to unexpected 
developmental effects (LaFleur et al., 2019a) or using genome-wide screening 
approaches that require large, non-physiological numbers of CD8 T cells in vivo 
(Dong et al., 2019; Ye et al., 2019) which could skew responses to chronic infections 
and tumors with aberrant effects on disease control and T cell 
differentiation(Badovinac et al., 2004, 2007; Blackburn et al., 2008; Blattman et al., 
2009; Marzo et al., 2005; Wherry et al., 2005). To address these limitations, we set 
out to develop a system that can 1) perform genetic manipulation in mature CD8 T 
cells and 2) use a physiological number of cells that mimicking normal T cell 
development in the setting of viral infections and cancer. To enable gene editing in 
antigen specific primary CD8 T cells, we crossed LSL-Cas9+ mice(Platt et al., 2014) 
to CD4CRE+P14+ mice bearing CD8 T cells specific for the LCMV DbGP33-41 epitope 
(termed Cas9+P14, or C9P14). We expressed the backbone-optimized Cas9 single 
guide RNA (sgRNA, Grevet et al., 2018) together with a fluorescence-tracking marker 
in a retroviral (RV) vector (Figure S11A). To evaluate gene editing efficiency in vivo, 
we retrovirally transduced C9P14 cells ex vivo with either negative control sgRNA 
(sgCtrl) or sgRNA targeting Pdcd1 (Encoding PD-1, sgPdcd1) following an optimized 
murine T cell RV transduction protocol(Kurachi et al., 2017) (Figure S11B). The 
double-positive populations of sgRNA (mCherry+) and Cas9 (GFP+) CD8 T cells 
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(Figure S11C) were adoptively transferred into congenic recipient mice infected with 
the chronic strain of LCMV (clone13; LCMV-Cl13) (Figure S11B). 9 days post 
infection (p.i.), sgRNA+C9P14 cells were isolated for phenotypic and gene editing 
evaluation. As expected, sgPdcd1 induced antigen specific CD8 T cells expansion 5 
fold greater than the control sgRNA (Figure S11D), consistent with the genetic 
knockout of Pdcd1(Odorizzi et al., 2015). We found that the sgPdcd1 resulted in both 
a robust decrease of PD-1 protein level using flow cytometry (Figure S11E) and indel 
mutations in the corresponded genomic locus of Pdcd1 using sanger-sequencing 
(Figure S11F). Furthermore, we confirmed the high gene editing efficiency of our 
system by designing sgRNAs targeting Klrg1 and Cxcr3 loci (Figure S11G). 
Collectively, this in vitro sgRNA RV transduction in C9P14 followed by in vivo 
adoptive transfer system provides a robust platform to investigate genetic regulatory 
network of murine CD8 T cells in vivo. 
  
4.2 OpTICS enables pooled genetic screening in CD8 T cells in vivo 
To enable in vivo pooled genetic screening in LCMV infection system, we decided to 
further optimize the parameters of the C9P14 and retroviral sgRNA platform (Figure 
14A). First, we determined a physiologically relevant number of adoptively 
transferred CD8 T cells for pooled genetic screening, as the T cell numbers can 
influence the outcome of infection or tumor models. For example, in the case of 
LCMV-Cl13 infection model, high numbers of adoptively transferred P14 CD8 T cells 
can cause lethal immunopathology or convert a chronic infection to an acutely 
resolved infection(Blattman et al., 2009) preventing the study of TEX cells. We, 
therefore, limited the maximal number of adoptive transferred CD8 T cells to 1x105 
per mouse (approximately 1x104 after take) that was previously shown not to trigger 
immunopathology or clearance of chronic infection(Chen et al., 2019b; Kao et al., 
2011). Next, to evaluate the performance of our system, we performed pooled 
genetic screening against a focused set of 29 TFs in CD8 T cells in vivo using LCMV 
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models. Previously, we found that sgRNA targeting functional important protein 
domains can substantially improve genetic screening efficiency, as both inframe and 
frameshift mutations contribute to generating loss-of-function alleles(Shi et al., 2015). 
We designed and cloned a sgRNA library targeting the DNA-binding domains of 29 
TFs and other control genes (e.g. non-selected control sgRNAs and Pdcd1) with 4-5 
sgRNAs per target. We found that increasing the average input coverage of more 
than 400 cells per sgRNA after CD8 T cells engraftment could increase the signal to 
noise ratio, and successfully identify hits, in comparison to 100 cells per sgRNA 
(Figure S12A-S12B). Third, we assessed the performance of our in vivo screen 
using P14 cells expressing heterogeneous versus homogeneous alleles of the LSL-
Cas9 transgene. We observed that Cas9 heterozygous P14 cells outperformed Cas9 
homozygous ones in terms of signal-to-noise ratio in different tissues and 
consistency between independent screens (Figure S12A-S12C). We speculated that 
this is presumably due to reduced off-target DNA damage in the heterozygous setting 
as we have recently noted for CRE recombinase(Kurachi et al., 2019). From these 
preliminary optimization screens, we identified Batf, Irf4, and Myc as essential for 
early T cell activation because genetic targeting of these genes potently inhibited T 
cell activation in vivo (Figure S12A-S12B), consistent with known roles for Batf and 
Irf4 (Grusdat et al., 2014; Kurachi et al., 2014; Man et al., 2013, 2017; Quigley et al., 
2010), and Myc (Lindsten et al., 1988; Wang et al., 2011) in TEFF biology. Of note, 
this system was highly efficient with up to ~100-fold enrichment for genes essential 
for CD8 T cell responses (Figure S12A-S12B) and nearly 20-fold enrichment for 
genes that suppress T cell activation and differentiation (Figure S12D). Thus, this 
platform, termed the Optimized T cell In vivo CRISPR Screening system (OpTICS), 
provides a robust method for focused in vivo CRISPR screening in CD8 T cells 
4.3 OpTICS identifies novel TF involved in TEFF and TEX cell differentiation 
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To identify new TFs governing TEFF and TEX cell differentiation, we constructed 
another domain-focused sgRNA library against 120 TFs. This library has 675 
sgRNAs total, including 4-5 sgRNAs per DNA-binding domain, positive selection 
controls (sgPdcd1), and non-selection controls (e.g. sgAno9, sgRosa26, etc.) (Figure 
14A). With this 120-TF targeting sgRNA library, we next interrogated in vivo selection 
and sgRNA enrichment at 1 or 2 weeks p.i. with acutely resolving LCMV Arm (LCMV-
Arm) or chronic LCMV-Cl13 (Figure 14A). We examined C9P14 cells from 4 different 
anatomical locations (PBMC, spleen, liver and lung) to identify TFs that were broadly 
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important for CD8 T cell responses to infection. In general, groups clustered by time 
point and infection, rather than anatomical location (Figure S12E). At 2 weeks p.i. 
the data for LCMV-Arm and LCMV-Cl13 diverged (Figure S12E), consistent with 
different trajectories of T cell differentiation during acutely resolved versus chronic 
infections(Wherry et al., 2007). Focusing on the spleen, Batf, Irf4 and Myc emerged 
as some of the strongest negative selected hits at both time points in both infections, 
consistent with the importance of these TFs for initial CD8 T cell activation and TEFF 
differentiation (Figure 14B-14C). We also confirmed several other known effector-
driving TFs including Tbx21 (encoding T-bet), Id2, Stat5a, Stat5b, and components of 
the NF-kB complex (Figure 14B-14C). In addition, several TFs with potential novel 
roles in T cell activation and differentiation were revealed including Smad4, Smad7 
and Mybl2 (Figure 14B-14C).  
Many screens are designed to identify loss of function targets such as the TF noted 
above. In addition to identifying genes necessary for initial CD8 T cell activation and 
Figure 14. Dissecting transcriptional programs during CD8 T cell response using OpTICS system. 
(A) Experimental design for Optimized T cell In vivo CRISPR Screening (OpTICS). On Day 0(D0), CD8 T 
cells were isolated from CD45.2+ C9P14 donor mice and activated in vitro; CD45.1+ WT recipient mice 
were infected with LCMV. On D1 p.i., activated C9P14 cells were transduced with the retroviral (RV) 
sgRNA library for 6 hours. On D2 p.i., Cas9+sgRNA+ P14 cells were sort purified; 5-10% of the sorted 
cells were directly frozen for D2 baseline (T0 time point), and the rest were adoptively transferred into 
LCMV-infected recipient mice. Cas9+sgRNA+ P14 cells were then isolated from different organs of 
recipient mice on the indicated days by MACS and FACS sorting (T1 time point). Genomes were isolated 
from the Cas9+sgRNA+ P14 cells isolated at the indicated time points and conditions. Targeted PCR with 
sequencing adaptors for the sgRNA cassettes was performed and PCR products were sequenced. The 
CRISPR Score (CS) was calculated according to the formula shown. 
(B) The CS comparing T1 time point to T0 time point (D2 baseline) for different target genes from 
Cas9+sgRNA+ cells from spleen on D8 p.i. of Arm, D15 p.i. of Arm, D9 p.i. of Cl13 and D14 p.i. of Cl13. X-
axis shows targeted genes; y-axis shows the CS of each targeted gene (calculated using 4-5 sgRNAs).  
(C) Heatmap of CS for targeted genes. Heatmap ranks the geometric means of CS for each targeted 
gene. Normalization details in Star Methods. 
(D) Distribution of Ctrl, Pdcd1 and Fli1 sgRNAs. Axis represents log2 fold change (FC). Histogram shows 
distribution of all sgRNAs. Red bars represent targeted sgRNAs, grey bars represent all other sgRNAs. 
(E) Western blot for Fli1 protein from sorted Cas9+sgFli1+ P14 cells and paired Cas9+sgFli1- P14 cells 
from spleen. Two Fli1-sgRNAs (sgFli1_290 and sgFli1_360) were used. Pooled mice were used in these 
experiments (3-5 mice for Arm, 10-15 mice for Cl13). Bar graph represents the normalized band intensity 
of Fli1. The normalized band intensity of Fli1 was first normalized to GAPDH, then a ratio between 
Cas9+sgFli1+ versus Cas9+sgFli1- was calculated and presented in the bar graph. 
(F) Normalized Cas9+sgRNA (VEX)+ cell numbers from spleen for Ctrl-sgRNA(sgCtrl) and 2 Fli1-sgRNA 
(sgFli1_290 and sgFli1_360) groups on D8 p.i. of Arm, D15 p.i. of Arm, D9 p.i. of Cl13 and D14 p.i. of 
Cl13. Cell numbers normalized to the sgCtrl group based on D2 in vitro transduction efficiency (see 
Figure S3B and S3D). 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (One-Way Anova analysis). Data are 
representative of 4 independent experiments (mean±s.e.m.) with at least 4 mice/group for F. 
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differentiation, we also used the OpTICS system as an “UP” screen(Kaelin, 2017) to 
identify genes that repressed optimal T cell activation and TEFF cell differentiation. 
Such genes, like Pdcd1, represent potential immunotherapy targets for improving 
efficacy of T cell responses in cancer or infections. PD-1 served as a prototypical 
positive control where, as expected, Pdcd1-sgRNAs were strongly positively selected 
across infections, time points and in all tissues (Figure 14B-14D). This screen also 
identified TFs that scored as antagonizing robust CD8 T cell responses (Figure 14B-
14C). Among these, Tcf7 (encoding TCF-1), Tox and Smad2 have been implicated in 
limiting robust TEFF cell differentiation, activation and/or expansion. In particular, TCF-
1 promotes stem cell-like memory T cells in acutely resolved infections(Zhou et al., 
2010) or TEX precursors and progenitors during chronic infections(Chen et al., 2019b; 
Im et al., 2016; Utzschneider et al., 2013; Wu et al., 2016); suppressing TCF-1 has 
also been shown to augment TEFF cell differentiation(Chen et al., 2019b; Lin et al., 
2016). Tox is an essential driver of TEX cell fate and represses terminal TEFF 
differentiation (Alfei et al., 2019; Khan et al., 2019; Seo et al., 2019; Yao et al., 2019).. 
Smad2 has been shown to limit TEFF cell responses during both acute and chronic 
infection(Tinoco et al., 2009). We also identified Nfatc2 and Nr4a2 (Figure 14C), 
both of which have been implicated in fostering T cell exhaustion and thus limiting 
TEFF responses(Chen et al., 2019a; Martinez et al., 2015). In addition, Gata3 
identified here has been implicated in driving T cell dysfunction and inhibiting TEFF 
cell response(Singer et al., 2017). Thus, this screen identified key TFs known to 
restrain TEFF differentiation and, in some cases, promote exhaustion. 
This OpTICS screen also identified novel TFs that restrained optimal TEFF 
differentiation. This set of genes included Atf6, Irf2, Erg and Fli1, with Fli1 among the 
strongest hits in repressing TEFF cell differentiation. The identification of Fli1 as a 
repressor of TEFF differentiation occurred similarly in LCMV-Arm and LCMV-Cl13 
infections indicating a common role for this TF in restraining TEFF biology in settings 
of acutely resolving or chronic infection. In both infections, Fli1-sgRNAs were the top 
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ranking positively selected sgRNAs across different conditions (Figure 14B-14D). 
We therefore focused additional efforts on interrogating the biology of Fli1 in CD8 T 
cell differentiation.   
Fli1 is an ETS family TF with roles in hematopoiesis and other developmental 
pathways in non-immune cell types(Kruse et al., 2009; Pimanda et al., 2007; Tijssen 
et al., 2011). In hematopoiesis, Fli1 has been implicated in regulating stem cell 
maintenance and differentiation(Cai et al., 2015). The role of Fli1 in TEFF, TMEM or TEX 
cells, however, is unknown. To interrogate this question, we selected 2 Fli1-sgRNAs 
(sgFli1_290 and sgFli1_360) and confirmed that these sgRNAs effectively edited the 
Fli1 gene (70%-80% editing; Figure S13A) leading to reduced protein expression 
(Figure 14E). Targeting Fli1 using these individual Fli1-sgRNAs in C9P14 cells in 
vivo resulted in 5-20 fold greater expansion at 1 and 2 weeks p.i. with either LCMV-
Arm or LCMV-Cl13 (Figure 14F and S13B-S13E). These data indicate repression of 
robust CD8 T cell expansion by Fli1 in acutely resolving or developing chronic 
infection. 
  
4.4 Genetic deletion of Fli1 promotes robust TEFF-differentiation during acutely 
resolved infection 
We next interrogated the differentiation state of Fli1-sgRNA (sgFli1) or Ctrl-sgRNA 
(sgCtrl) transduced C9P14 cells during acutely resolved infection. On Day 8 p.i., Fli1 
deletion reduced the proportion of the CD127Hi memory precursors (TMP), whereas 
the frequency KLRG1Hi terminal effector (TEFF) population remained unchanged at 
this time point consistent with a slight increase in the CD127LoKLRG1Lo population 
(Figure 15A). These effects were more dramatic at Day 15 p.i. resulting in a 
reduction in the CD127Hi TMP population and, at this time point, an increase in the 
proportion of KLRG1Hi TEFF cells (Figure 15A). However, at both time points the 
absolute number of both TMP and TEFF was increased due to the proliferative 
expansion of Fli1-deficient CD8 T cells (Figure 15A). This skewing of T cell 
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differentiation towards TEFF-like populations was also observed when CX3CR1 and 
CXCR3 were used to identify TMEM- and TEFF-like cells(Gerlach et al., 2016), with 
sgFli1 significantly enriching for the CX3CR1+CXCR3- TEFF population compared to 
the CX3CR1-CXCR3+ early TMEM subset (Figure 15B). To further interrogate the 
causality of Fli1 in these effects on CD8 T cell differentiation, we next enforced Fli1 
expression in WT LCMV-specific P14 cells using a retroviral (RV) based 
overexpression (OE) system(Kurachi et al., 2017). A ~5-fold reduction in responding 
Fli1-OE-RV transduced P14 cells was observed Day 8 and Day 16 p.i. compared to 
the empty vector control (Figure 15C). Furthermore, enforced Fli1 expression also 
skewed responding 
P14 cells towards TMP 









15E). Together, these 
data reveal a role for 








4.5  Fli1 antagonizes TEFF-like differentiation during chronic infection 
During chronic viral infection, there is an early fate bifurcation for CD8 T cell 
responses where antiviral CD8 T cells develop into either TEFF-like cells or form TEX- 
precursors that ultimately seed the mature TEX population(Chen et al., 2019b; Khan 
et al., 2019). We therefore investigated the role of Fli1 in this cell fate decision during 
the first 1-2 weeks of chronic infection. As in acutely resolving infection, genetic 
perturbation of Fli1 resulted in a skewing of the virus-specific CD8 T cell response 
towards the TEFF pathway, as defined by TCF-1-GrzmB+ or Ly108-CD39+ (Figure 16A 
and (Chen et al., 2019b)). Due to the 5-10-fold increase in total Fli1-deficient cells, 
the cell numbers of both the TEFF-like and TEX precursor populations were increased 
(Figure S14A-S14B). In contrast, enforced Fli1 expression not only resulted in lower 
cell numbers (Figure S14C), but also fostered formation of Ly108+CD39- or TCF-
1+GrzmB- TEX precursors (Figure S14D-S14E). Moreover, genetic perturbation of Fli1 
resulted in an increased proportion of T-EFF-like cells marked by high CX3CR1 or 
Tim3 expression (Figure 16B and (Chen et al., 2019b; Zander et al., 2019)). These 
Figure 15. Fli1 inhibits TEFF cell proliferation and differentiation during acute infection. 
(A) Flow cytometry plots and statistical analysis of KLRG1HiCD127Lo Terminal Effectors (TEs) and 
KLRG1LoCD127Hi Memory Precursors (MPs). Frequencies (left) and numbers (right) from spleen for 
sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Arm. Gated on Cas9(GFP)+ sgRNA(VEX)+ P14 
cells. 
(B) Flow cytometry plots and statistical analysis of CX3CR1+CXCR3- TEFF cells and CX3CR1-
CXCR3+ early TMEM cells frequencies (left) and numbers (right) from spleen for sgCtrl and 2 sgFli1 
groups on D8 and D15 p.i. of Arm. Gated on Cas9+sgRNA+ P14 cells.  
(C-E) Experimental design. On D0, CD45.1+ P14 cells were activated and recipient mice were 
infected with Arm; On D1 p.i., activated P14 cells were transduced with Empty-RV or Fli1-over 
expression(OE)-RV for 6 hours. On D2 p.i., VEX+ P14 cells were purified by sorting from Empty-RV 
or Fli1-OE-RV groups, and 5 x 104 cells were adoptively transferred into the infected recipient mice. 
(C) Flow cytometry plots of CD45.2+VEX+ cell frequency and statistical analysis of CD45.2+VEX+ cell 
number for Empty-RV and Fli1-OE-RV conditions.  
(D) Flow cytometry plots and statistical analysis of KLRG1HiCD127Lo TE and KLRG1LoCD127Hi MP 
frequencies from spleen for Empty-RV and Fli1-OE-RV groups on D8 and D15 p.i. of Arm. Gated on 
VEX+ P14 cells. 
(E) Flow cytometry plots and statistical analysis of CX3CR1+CXCR3- TEFF cell and CX3CR1-CXCR3+ 
early TMEM cell frequencies from spleen for Empty-RV and Fli1-OE-RV groups on D8 and D15 p.i. of 
Arm. Gated on VEX+ P14 cells. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-test and One-Way 
Anova analysis). Data are representative of 2-4 independent experiments (mean±s.e.m.) with at 
least 3 mice/group. 
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data were confirmed by enforced Fli1 expression during LCMV-Cl13 infection that 











To dissect the 
underlying 
mechanism by 
which Fli1 regulates 
CD8 T cell 
differentiation, we 
performed RNA-
seq on sorted 
sgCtrl+ or sgFli1+ 
C9P14 cells on 
Day 9 of LCMV-
Cl13 infection. Both 
sgRNAs targeting 
Fli1 resulted in a 
similar transcription 
Figure 16. Fli1 antagonizes TEFF-like cell differentiation during chronic 
infection. 
(A) Flow cytometry plots and statistical analysis of Ly108-CD39+ or TCF-1-Gzmb+ 
TEFF-like cells and Ly108+CD39- or TCF-1+Gzmb- TEX precursor frequencies from 
spleen for sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Cl13. Gated on the 
Cas9(GFP)+sgRNA(VEX)+ P14 cells. 
(B) Statistical analysis of CX3CR1+ and Tim-3+ frequencies, and KLRG1 and PD-1 
MFIs from spleen for sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Cl13. Gated 
on the Cas9+sgRNA+ P14 cells. 
(C) Heatmap showing differentially expressed genes between sgCtrl and 2 sgFli1 
groups. 
(D) Gene Ontology (GO) enrichment analysis for the sgFli1 groups. 
(E) GO enrichment analysis for the sgCtrl groups. 
(F) Gene Set Enrichment Analysis (GSEA) of TEX precursor signature (adapted 
from Chen et al. 2019) between sgCtrl and sgFli1 groups. 
(G)GSEA of TEFF-like signature (adapted from Bengsch et al. 2018) between sgCtrl 
and sgFli1 groups. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-
test and One-Way Anova analysis). Data are representative of 4 independent 
experiments (mean±s.e.m.) with at least 4 mice/group for A and B. 
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effect (Figure 16C, S14G). In contrast, the sgFli1+ C9P14 cells were transcriptionally 
distinct from the sgCtrl+ C9P14 cells with over 1400 genes differentially expressed 
between the two conditions (Figure 16C, S14G). Among the major changes were a 
robust increase in effector-associated genes such as Prf1, Gzmb, Cd28, Ccl3 and 
Prdm1 in the sgFli1+ C9P14 cells, whereas the sgCtrl+ C9P14s were enriched in TEX 
precursor genes such as Tcf7, Cxcr5, Slamf6 and Id3 (Figure 16C). Gene Ontology 
enrichment analysis also identified cell division-associated and T cell activation-
associated pathways in sgFli1+ C9P14 cells (Figure 16D), whereas sgCtrl+ C9P14s 
enriched in multiple metabolic pathways, in particular nucleotide, nucleoside and 
purine biosynthesis (Figure 16E). We next used gene set enrichment analysis 
(GSEA) to examine skewing between signatures of subpopulations during the early 
phase of chronic infection, when a divergence of differentiation into either TEFF-like or 
TEX precursor cell fates occurs. Indeed, the TEX precursor signature(Chen et al., 
2019b) was strongly enriched in sgCtrl+ C9P14 cells compared to the sgFli1+ C9P14 
population whereas a TEFF gene signature(Bengsch et al., 2018) was strongly 
enriched in the sgFli1+ C9P14 population (Figure 16F-16G). Thus, Fli1 repressed 
optimal TEFF differentiation in both acutely resolving and chronic infection and loss of 
Fli1 antagonized the development of TEX cells. However, although genetic 
perturbation of Fli1 drove an increase in expression of effector-associated genes at 
Day 9 of chronic infection, Tox, Tox2 and Cd28 were also increased. This effect may 
suggest that although loss of Fli1 might enhance TEFF-like biology and might not be at 
the expense of genes necessary to sustain responses in chronic infection of cancer. 
4.6 Fli1 remodels the epigenetic landscape of CD8 T cells and antagonizes TEFF-
associated gene expression 
In acute myeloid leukemia, FLI1 co-localizes with the chromatin remodeler 
BRD4(Roe et al., 2015). Moreover, the oncogenic EWS-FLI1 fusion protein can bind 
genomic microsatellites(Gangwal et al., 2008), trigger de novo enhancer formation 
via chromatin remodeling and inactivate existing enhancers by displacing ETS family 
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members(Riggi et al., 2014). Though EWS-FLI1 and FLI1 have similar GGAA-binding 
motifs(Riggi et al., 2014; Roe et al., 2015), the prion-like domain from EWS changes 
the overall function of the EWS-FLI1 fusion likely leading to distinct mechanisms of 
action(Boulay et al., 2017). Thus, it is unclear how Fli1 affects epigenetic landscape 
changes in general, especially in developing TEFF, TMEM or TEX cells. 
To examine the role of Fli1 in supporting the epigenetic landscape of CD8 T cells, we 
performed ATAC-seq on sgFli1+ and sgCtrl+ C9P14 cells on Day 9 p.i. with LCMV-
Cl13. Compared to sgCtrl+ C9P14 cells, the sgFli1+ group had considerable changes 
in chromatin accessibility (Figure 17A). Over 5000 open chromatin regions (OCRs) 
differed between the control and Fli1-perturbed groups with approximately equal 
numbers of peaks gained or lost (Figure 17B-17D). Most of these changes were 







To define how 
these changes in 
OCRs could impact 
the differentiation 
of TEFF or TEX cells, 
we next assigned 
each OCR to the 
nearest gene to 
estimate genes 
 53 
that could be regulated by these cis-regulatory elements. TEFF-associated genes, 
such as Ccl3, Ccl5, Cd28, Cx3cr1 and Prdm1, gained chromatin accessibility in the 
sgFli1+ group (Figure 17D), consistent with the RNA-seq data. In contrast, there was 
decreased chromatin accessibility near genes involved in T cell progenitor biology 
such as Tcf7, Slamf6, Id3 and Cxcr5 (Figure 17D) in the sgFli1+ group. Moreover, 
the sgFli1+C9P14 cells had altered accessibility in the Tox (and Tox2) locus, but 
these changes included both increased and decreased accessibility across different 
peaks (Figure 17D), consistent with the complex transcriptional and epigenetic 
control of Tox expression(Khan et al., 2019). These changes in chromatin 
accessibility corresponded to changes in gene expression with ~1/3 of the genes that 
changed transcriptionally associated with a differentially accessible chromatin region 
(402 out of 1467) (Figure 17E). In general, increased accessibility correlated with 
increased transcription though there was a clear subset of regions where decreased 
accessibility corresponded to increased transcription suggesting potential negative 
regulatory elements controlled by Fli1 (Figure 17F). 
To define the mechanisms by which these Fli1-mediated chromatin accessibility 
changes regulated T cell differentiation, we next defined the TF motifs present in the 
Figure 17. Fli1 reshapes the epigenetic profile of CD8 T cells and inhibits TEFF-associated gene 
expression. 
(A) PCA plot of ATAC-seq data for sgCtrl, sgFli1_290 and sgFli1_360 groups on D9 p.i. of Cl13. 
(B) Overall open chromatin region (OCR) peak changes for sgFli1 groups compared to sgCtrl group. 
(C) Categories of Cis-element OCR peaks that changed between sgCtrl and sgFli1 groups. Left plot 
represents all changes; right plot represents changes for increased or decreased accessibility. 
(D) Heatmap shows differentially accessible peaks between sgCtrl group and 2 sgFli1 groups (adjusted 
p-value<0.05, Log10 Fold Change>0.6). Some of the nearest genes assigned to the peaks are listed. 
(E) Overlapping Venn plot of the genes with differentially accessible (DA) peaks and differentially 
expressed genes from Figure 3C. 
(F) Pearson correlation of the peak accessibility of the nearest genes versus the differential expression of 
the genes.  
(G) Transcription factor (TF) motif gain or loss associated with loss of Fli1. X-axis represents the logP-
value of the motif enrichment. Y-axis represents the fold change of the motif enrichment. Targeted motifs 
in the changed OCR between the sgCtrl and sgFli1 groups were compared to the whole genome 
background to calculate p-value and fold change. 
(H) IgG or Fli1 binding signals from CUT&RUN on P14 cells on D8 p.i. of Cl13 and OCR signals detected 
by ATAC-seq for sgCtrl-sgRNA, sgFli1_290 and sgFli1_360 groups at the Cd28, Cx3cr1, and Havcr2 loci. 
(I) Histogram of CD28 staining and statistical analysis for sgCtrl, sgFli1_290 and sgFli1_360 groups on 
D8 Cl13 p.i. Grey shows CD28 staining of CD44- naïve T cell. 
(J) Heatmap shown differentially accessible (DA) peaks overlapped with the Fli1 CUT&RUN binding 
peaks between sgCtrl group and 2 sgFli1 groups. Some of the nearest genes assigned to the peaks are 
listed. 
(K)Top 4 enriched TF motifs in the Fli1 CUT&RUN peaks are listed.  
*P<0.05, **P<0.01 versus control (One-Way Anova analysis). Data are representative of 2 independent 
experiments (mean±s.e.m.) with at least 5 mice/group for I. 
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OCRs that were dependent on Fli1 for altered accessibility. Among the OCRs that 
decreased in accessibility in the absence of Fli1, the most enriched TF motifs were 
for IRF1 and IRF2 (Figure 17G), potentially linking Fli1 activity to the role of IRF1 
and IRF2 downstream of IFN signaling or to the regulation of cell cycle by these 
TFs(Choo et al., 2006). In the group of OCRs that increased in accessibility in the 
absence of Fli1, ETS and RUNX motifs were highly enriched (Figure 17G). In 
particular, the composite ETS:RUNX motif was by far the most changed with 18-fold 
enrichment (Figure 17G). These observations suggested that Fli1 may limit the 
activity of other ETS family members (e.g. ETS1, ETV1 or ELK1) or alter accessibility 
at ETS:RUNX binding sites (Figure 17G). Runx3 is a central driver of TEFF 
differentiation and functions by directly regulating effector gene expression, 
coordinating and enabling the effector gene regulation via T-bet and Eomes and 
antagonizing TCF-1 expression(Cruz-Guilloty et al., 2009; Shan et al., 2017; Wang et 
al., 2018). Thus, a potential role for Fli1 in Runx3 biology would provide a 
mechanistic link between loss of Fli1 and improved TEFF differentiation. 
We next tested how Fli1 genomic binding was related to changes in chromatin 
accessibility and TEFF biology, using Fli1 CUT&RUN(Skene and Henikoff, 2017). At 
Day 9 p.i. with LCMV-Cl13 >90% of the identified Fli1 binding sites were contained in 
OCRs detected by ATAC-Seq (Figure S14H-S14I). Specifically, Fli1 bound to OCRs 
of TEFF-like genes such as Cx3cr1, Cd28 and Havcr2. Chromatin accessibility 
increased at these locations upon Fli1 deletion (Figure 17H), resulting in increased 
transcription (Figure 17C) and protein expression (Figure 17B and 17I). In contrast, 
for genes involved in progenitor biology that were decreased in expression in the 
absence of Fli1 such as Tcf7 and Id3, direct binding of Fli1 was not observed (Figure 
S14H), likely indicating that the major role of Fli1 is to safeguard against an overly 
robust TEFF program rather directly enabling memory/progenitor biology. Furthermore, 
78% of the sites where Fli1 was defined to bind by CUT&RUN increased in chromatin 
accessibility in the absence of Fli1; in contrast, 22% decreased in accessibility 
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(Figure 17J), suggesting that Fli1 mainly functions to repress chromatin accessibility. 
Analyzing the DNA binding motifs in the Fli1 CUT&RUN data revealed the expected 
FLI1 motif. However, SP2, NFY1 and RUNX1 motifs were also significantly enriched 
where Fli1 bound (Figure 17K). Together with the increase in ETS:RUNX motifs in 
the Fli1-deficient ATAC-seq data above, these data support a model where Fli1 
coordinates with RUNX family members to control TEFF differentiation.  
 
4.7 Enforced Runx3 expression synergizes with Fli1-deletion to enhance TEFF 
responses 
RUNX family TFs are key 
regulators of CD8 T cell biology. 
In particularly, Runx3 is central to 
the transcriptional cascade that 
coordinates TEFF 
differentiation(Cruz-Guilloty et al., 
2009; Wang et al., 2018). Runx3 
also antagonizes a follicular-like 
CD8 T cell fate by inhibiting TCF-
1 expression(Shan et al., 2017) 
and fosters the development of 
tissue and tumor resident CD8 T 
cells(Milner et al., 2018). Runx1, 
in contrast, is antagonized by 
Runx3 during TEFF 
differentiation(Cruz-Guilloty et al., 
2009). The roles of Runx1 and 
Runx3 in TEX development in the 
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early phase of chronic infection are less clear. Because TEFF and TEX are opposing 
fates in chronic infection(Chen et al., 2019b; Khan et al., 2019; Yao et al., 2019; 
Zander et al., 2019) and ETS:RUNX motifs become more accessible in the absence 
of Fli1, we hypothesized that a RUNX-Fli1 axis might influence TEFF versus TEX 
differentiation. We tested whether Runx1 or Runx3 expression in Fli1-deficient CD8 T 
cells would impact TEFF differentiation in early chronic infection. 
Enforced expression of Runx1 in WT P14 cells reduced cell numbers at Day 7 p.i. 
with LCMV-Cl13 infection (Figure S15A) suggesting that Runx1 antagonized CD8 T 
cell activation and differentiation. Moreover, Runx1-OE fostered formation of 
Ly108+CD39- TEX precursors at the expense of the more TEFF-like Ly108-CD39+ 
population at this early time point (Figure S15A). Next, to interrogate the impact of 
enforced Runx1 expression in the absence of Fli1, we used a dual RV transduction 
approach and combined control or Fli1 sgRNA RV transduction with either empty or 
Runx1 expressing RVs. Singly versus dually transduced cells were distinguished 
using VEX (for sgRNA) and mCherry. C9P14 cells were transduced and adoptively 
transferred into LCMV-Cl13-infected mice and the double transduced (i.e. 
GFP+VEX+mCherry+) C9P14 cells were analyzed at Day 8 p.i. (Figure 18A). Dual-
transduction was efficient and allowed robust detection of GFP+VEX+mCherry+ 
C9P14 cells (Figure S15B). In the sgFli1+Runx1-OE group the number of 
GFP+VEX+mCherry+ C9P14 cells was reduced and there were fewer Ly108-CD39+ 
Figure 18. Overexpression of Runx1 inhibits the phenotypes of Fli1-deficiency while 
overexpression of Runx3 enhances Fli1-deficient effects. 
(A) Experimental design. On D0, CD8 T cells were isolated from CD45.2+ C9P14 donor mice and 
activated; CD45.1+ WT recipient mice were infected with LCMV Cl13. On D1 p.i., activated C9P14 
cells were transduced with sgRNA-RV or OE-RV for 12 hours, and 1 x 105 transduced cells were 
adoptively transferred into infected recipient mice. 
(B-D) Flow cytometry plots (B) and statistical analysis (C-D) of VEX+mCherry+ C9P14 cells and 
Ly108-CD39+/Ly108+CD39- C9P14 cells from spleen for sgCtrl-VEX + Empty-mCherry, sgCtrl-VEX + 
Runx1-mCherry, sgFli1_290-VEX + Empty-mCherry and sgFli1_290-VEX + Runx1-mCherry on D8 
p.i. of Cl13. Gated on Cas9(GFP)+CD45.2+ P14 cells. 
(E-G) Flow cytometry plots (E) and statistical analysis (F-G) of VEX+mCherry+ C9P14 cells and 
Ly108-CD39+/Ly108+CD39- C9P14 cells from spleen for sgCtrl-mCherry + Empty-VEX, sgCtrl-
mCherry + Runx3-VEX, sgFli1_290-mCherry + Empty-VEX and sgFli1_290-mCherry + Runx3-VEX 
at D8 p.i. of Cl13. Gated on Cas9+CD45.2+ P14 cells. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (One-Way Anova analysis). Data are 
representative of 2 independent experiments (mean±s.e.m.) with at least 5 mice/group. 
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cells. In contrast the sgFli1+Empty-RV group had an increase in the 
GFP+VEX+mCherry+ C9P14 cell population and these cells were skewed towards the 
Ly108-CD39+ TEFF-like fate (Figure 18B-18D, S15C) as above. However, in the Fli1-
deficient setting where there is enhanced CD8 T cell expansion, Runx1 
overexpression reduced the magnitude of the response and partially reversed the 
skewing towards the Ly108-CD39+ TEFF-like fate caused by loss of Fli1 (Figure 18B-
18D). 
We next investigated the impact of enforced expression of Runx3 in the absence of 
Fli1 using the same dual transduction approach (Figure 18A, 18E-18G, S15D-S15E). 
Enforced expression of Runx3 alone (in the sgCtrl+ group), modestly increased the 
magnitude of the CD8 T cell response but robustly skewed the GFP+VEX+mCherry+ 
C9P14 population towards a CD39+Ly108- TEFF-like population (Figure 18E-18G). 
These effects were more dramatic in the absence of Fli1 with greater numerical 
amplification and even further skewing towards CD39+Ly108- TEFF-like cells in the 
sgFli1+Runx3-OE enforced expression group in both proportion and cell number 
(Figure 18E-18G). While the sgFli1+Runx3-OE group shows reducing the frequency 
of the TEX precursor population, this group did not show a cell number reduction of 
this population (Figure 18E and 18G; S15E). Taken together, these data support a 
model where loss of Fli1 reveals ETS:RUNX motifs that can be used by Runx1 
and/or Runx3. However, whereas Runx3 drives a more TEFF-like population, an effect 
amplified in the absence of Fli1, Runx1 appears to antagonize TEFF generation, in 
agreement with the opposing functions of Runx1 and Runx3(Cruz-Guilloty et al., 
2009). Thus, Fli1 restrains the TEFF promoting activity of Runx3 function by restricting 
genome access and protecting ETS:RUNX binding sites. These data reveal Fli1, 
Runx3 and perhaps Runx1 (as a modest Runx3 antagonist) as key regulators of the 
fate choice between TEFF and TEX early after initial activation. 
  
 58 
4.8  Augmented TEFF cell responses in the absence of Fli1 improve protective 
immunity against pathogens 
The data above provoke the question of whether loss of Fli1 would improve control of 
infections due to the augmented TEFF differentiation. To test this idea, we used 
LCMV-Cl13 to investigate protective immunity during chronic infection and two 
models of acute infection with influenza virus (PR8) or Listeria monocytogenes (LM) 
each expressing the LCMV GP33-41 epitope (PR8GP33 and LMGP33) recognized by P14 
cells (Figure 19A). 
During LCMV-Cl13 infection, adoptive transfer of sgCtrl+ C9P14 cells conferred a 
moderate degree of viral control compared to the no transfer condition (NT, Figure 
19B) as expected(Blattman et al., 2009). However, when we compared the two 
transferred groups, sgFli1+ C9P14 provided substantially improved control of viral 
replication at ~2 weeks p.i. (Figure 19B), demonstrating a phenotypic benefit due to 
loss of Fli1 even in chronic viral infection where induction of exhaustion is a major 
barrier to effective protective immunity. 
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We next evaluated the impact of loss of Fli1 during acutely resolving infections. 
During influenza-PR8GP33 infection, mice receiving sgFli1+ C9P14 cells lost less 
weight than control non-transferred mice or mice receiving sgCtrl+ C9P14 cells 
(Figure 19C). This decreased weight loss was associated with better control of viral 
replication in the lungs of mice receiving sgFli1+ but not sgCtrl+ C9P14 cells (Figure 
19D). In this setting, there was variation in the magnitude of the sgFli1+ C9P14 
expansion in the lungs following PR8GP33 infection (Figure S16A-S16C). This 
heterogeneity in the T cell responses was associated with differences in viral control, 
with some mice nearly eliminating viral RNA by this time point (Figure 19D) and 
recovering from infection-associated weight loss. Therefore, we tested whether there 
was a relationship between recovery from infection and/or control of viral replication 
and the magnitude of the C9P14 response. Indeed, the overall magnitude of the 
C9P14 response was lower in mice that had recovered, consistent with prolonged 
viral replication and higher antigen load driving increased T cell expansion in mice 
that had not yet controlled the infection (Figure S16A-S16B). Notably, 6 out of 12 of 
the mice receiving sgFli1+ C9P14 cells had controlled disease by this time point, as 
compared to only 1 out of 11 mice receiving sgCtrl+ C9P14 (Figure 19D, S16B). In 
Figure 19. Fli1-deficiency in CD8 T cells leads to better protective immunity against infections. 
(A) Experimental design. On D0, CD8 T cells were isolated from CD45.2+ C9P14 donor mice and activated; 
CD45.1+ WT recipient mice were infected with LCMV Cl13, lnfluenza virus PR8-GP33 or Listeria 
Monocytogenes-GP33 (LM-GP33). On D1 p.i., activated C9P14 cells were transduced with sgCtrl or sgFli1 RV 
for 6 hours. On D2 p.i., Cas9+sgRNA(VEX)+ P14 cells were purified by flow cytometry for sgCtrl or sgFli1 
groups, and adoptively transferred into the infected recipient mice. For LCMV-Cl13, 1.5 x 105 VEX+ C9P14 
cells were adoptively transferred per mouse; for PR8-GP33 and LM-GP33, 1.0 x 105 VEX+ C9P14 cells were 
adoptively transferred per mouse. 
(B) LCMV-Cl13 viral load was measured by plaque assay on D15 p.i. with Cl13 in liver, kidney and serum of 
non-transferred (NT) mice or mice receiving sgCtrl+ or sgFli1+ adoptively transferred C9P14 cells. Data pooled 
from 2 independent experiments. 
(C) Weight curve for PR8-GP33 infected mice from NT, sgCtrl+ cell-transferred, or sgFli1+ cell-transferred 
groups. Dashed line represents the time of C9P14 adoptive transfer. 
(D) PR8-GP33 viral RNA load in the lung of NT, sgCtrl+ or sgFli1+ C9P14 recipient mice. Dashed line indicates 
the limit of detection. Lung samples from naïve mice and spleen samples from PR8-GP33 infected mice were 
used as negative controls. 
(E) Adjusted survival curve of LM-GP33 infected mice for NT, sgCtrl+ or sgFli1+ C9P14 recipient mice. Dashed 
line represents the time of C9P14 adoptive transfer. 
(F) LM-GP33 bacteria load in spleen and liver of the surviving NT, sgCtrl+ or sgFli1+ C9P14 recipient mice on 
D7 p.i.  
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (One-Way Anova analysis). Data are 
representative of 2 independent experiments (mean±s.e.m.) with at least 3 mice/group. 
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the group of mice still harboring viral RNA in the lungs, sgFli1+ C9P14 cells had 
expanded to substantially higher numbers than sgCtrl+ C9P14 cells (Figure S16B). A 
similar difference in TEFF cell expansion was also observed in spleen where sgFli1+ 
C9P14 cells were ~3 times more numerous than the sgCtrl+ group (Figure S16C). 
Loss of Fli1 conferred a similar advantage following LMGP33 infection. Although both 
sgCtrl+ and sgFli1+ C9P14 cells improved survival following a high dose LMGP33 
challenge (Figure 19E), sgFli1+ C9P14 cells resulted in substantially better control of 
bacterial replication in the spleen and liver compared to the sgCtrl+ C9P14 cells at D7 
p.i. (Figure 19F). Consistent with the influenza virus setting, this improved protective 
immunity was associated with greater numerical expansion of sgFli1+ C9P14 cells 
compared to the sgCtrl+ group (Figure S16D). Thus, deficiency in Fli1 confers a 
substantial benefit on TEFF cell expansion and protective immunity during chronic 
LCMV-Cl13 infection, respiratory influenza virus infection, and systemic infection with 
an intracellular bacterium. 
  
4.9  Loss of Fli1 in CD8 T cells enhances immunity to tumors 
We next asked whether the Fli1 deficiency could also mediate increased protective 
immunity in a cancer setting. Thus, we next employed a subcutaneous B16GP33 tumor 
model. Tumor-bearing mice received equal numbers of sgCtrl+ or sgFli1+ C9P14 cells 
on day 5 post tumor inoculation (p.t.) (Figure 20A). We used Rag2-/- recipient mice to 
isolate the effects of sgCtrl+ versus sgFli1+ C9P14 cells (Figure 20A). In this setting 
sgFli1+ C9P14 cells robustly controlled tumor progression compared to non-
transferred mice or the sgCtrl+ C9P14 group (Figure 20B). Furthermore, tumor 
weight was significantly lower in the sgFli1+ C9P14 group compared to either control 
group at endpoint (Figure 20C). Although there was not a clear difference in the 
number of C9P14 cells/g of tumor, this tumor control was associated with a 
significant increase in Ly108-CD39+ donor C9P14 in the sgFli1+ group, consistent 
with a shift towards the more TEFF-like population (Figure 20D-20E). In the spleen, 
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however, there was a significant increase in sgFli1+ C9P14 cell numbers, as well as 
the proportion of Ly108-CD39+ cells compared to the sgCtrl+ group (Figure 20F-20G). 
We next extended these findings into immune competent mice using B16GP33 tumors. 
We used Cas9+ C57BL/6 recipient mice to prevent rejection of the C9P14 donor cells 
to allow responses to be analyzed for an extended period of time (Figure S17A). In 
this setting, sgFli1+ C9P14 cells again conferred substantial benefit on tumor control 
(Figure S17B-S17C) compared to sgCtrl+ C9P14 cells. Furthermore, this improved 
tumor control was associated with an increase in the Ly108-CD39+ TEFF-like 
population in the tumor, draining lymph node (dLN) and spleen, as well as the 
increased C9P14 cell numbers in the dLN and spleen (Figure S17D-S17G). Thus, 
genetic deletion of Fli1 conferred a substantial benefit on tumor control indicating a 
central role for Fli1 in coordinating and restraining protective TEFF responses during 
tumor invasion and progression. Together, these data show that loss of Fli1 results in 
improved protective immunity, in the setting of systemic and local, acutely resolving 
and chronic infections, as well as tumor progression. In these settings enhanced CD8 
T cell expansion and a shift in differentiation highlight the role of Fli1 as a key 
regulator of CD8 T cell differentiation. These data suggest that manipulating Fli1-






Figure 20. Loss of Fli1 in CD8 T cells results in more potent anti-tumor immunity. 
(A) Experimental design. On D0, CD45.2+Rag2-/- mice were inoculated with 1 x 105 B16-Dbgp33 
cells. On D3 post tumor inoculation (p.t.), CD8 T cells were isolated from CD45.1+ C9P14 mice and 
activated. On D4 p.t., activated C9P14 cells were transduced with sgCtrl or sgFli1 RVs for 6-8 hours. 
On D5 p.t., sgRNA (VEX)+Cas9 (GFP)+P14 cells were purified by flow cytometry from sgCtrl or 
sgFli1 groups, and 1 x 106 purified VEX+ C9P14 cells were adoptively transferred into the tumor-
bearing mice.  
(B) Tumor volume curve for mice receiving NT, sgCtrl+ or sgFli1+ C9P14 cells. 
(C) Tumor weight on D23 p.t. for mice receiving NT, sgCtrl+ or sgFli1+ C9P14 cells. 
(D-E) Flow cytometry plots (D) and statistical analysis (E) of CD45.1+ sgRNA(VEX)+Cas9+P14 cells 
and Ly108-CD39+/Ly108+CD39- C9P14 cells from tumor for sgCtrl or sgFli1 groups on D23 p.t.  
(F-G) Flow cytometry plots (F) and statistical analysis (G) of CD45.1+ sgRNA+Cas9+ P14 cells and 
Ly108-CD39+/Ly108+CD39- C9P14 cells from spleen for sgCtrl or sgFli1 groups at D23 p.t.  
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-test and One-Way 
Anova analysis). Data are representative of 2 independent experiments (mean±s.e.m.) with at least 
5 mice/group. 
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Chapter 5 Perspectives of transcriptional control of CD8 T cell responses 
My graduate study and research at Penn are mainly focused on dissecting 
transcriptional control of CD8 T cell responses during acute and chronic infection as 
well as cancer progression.  
In my first study(Chapter 2, Chen and Stelekati et al.,Cell Reports, 2017), I have 
identified a key role for miR-150-c-Myb axis in promoting terminal effector(TE) CD8 T 
cell differentiation while antagonizing memory precursor(MP) and subsequent 
memory formation. I have defined a molecular circuit by which miR-150 directly 
repressed c-Myb. C-Myb in turn, is a positive regulator of the pro-survival molecules 
Bcl-2 and Bcl-xL, and we identified a key role for c-Myb in optimal memory CD8 T 
cell development through tuning the balance of anti- to pro- apoptotic proteins. Thus, 
higher miR-150 reduced c-Myb leading to less Bcl-2 and Bcl-xL, and lower ratios of 
these anti-apoptotic molecules to the pro-apoptotic molecule Bim. MiR-150 itself was 
dynamically regulated and expression rapidly declined upon initial activation, though 
remaining higher in TE compared to MP.  While the precise mechanisms controlling 
expression of miR-150 remain to be fully defined, this difference in expression 
between TE and MP was consistent with better formation of memory in the absence 
of miR-150.  Overall, this study identifies a key molecular pathway that tunes the 
balance between MP and TE through a miR-150 to c-Myb to Bcl-2 and Bcl-xL axis. 
In my second study(Chapter 3, Chen and Ji et al., Immunity, 2019), I addressed 
the early events involved in establishing the population of precursors that form TEX 
and the relationship of these TEX precursors to other effector phase populations, and 
identified an early fate bifurcation that distinguished early TEX precursors from TEFF-
like cells that are generated during chronic infection. Moreover, I demonstrated that 
the TEFF-like population in early chronic infection is more activated than the 
corresponding TEFF population during acute infection and survives poorly in the 
presence of excessive antigen stimulation. These studies also define a series of 
transcriptional circuits centered on TCF-1 that repress the TEFF-like developmental 
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path and foster the formation of TEX precursors. These data are analogous to roles of 
TCF-1 in repressing terminally differentiated cells in other settings(Lin et al., 2016). 
However, our new data extend this role for TCF-1 to the setting of early chronic 
infection and initiation of T cell exhaustion. PD-1 plays a critical role at this stage of 
TEX development by protecting the TCF-1+ TEX precursors and ensuring these cells 
can seed the long-term TEX pool. Moreover, I identify novel circuits through which 
TCF-1 acts in this early development of TEX precursors. For example, TCF-1 
enhanced Bcl-2 expression through c-Myb to support the survival of TEX precursors 
and TCF-1 also promoted a T-bet and Eomes transition to foster formation of a 
durable Eomes+ TEX population. 
In my third study(Chapter 4, Chen et al.,preprint bioRxiv/SSRN, 2020), I used a 
focused in vivo CRISPR screening approach to specifically interrogate the 
mechanisms governing TEX versus TEFF differentiation. Among our screening hits, I 
identified Fli1 as a key TF that safeguards the transcriptional and epigenetic 
commitment to full TEFF differentiation. Fli1 also negatively regulated CD8 T cell 
expansion and genetic loss of Fli1 resulted in considerable improvement in antigen-
specific CD8 T cell expansion generating more TEFF without numerical loss of 
progenitor or memory precursor populations. Mechanistically, Fli1 limited epigenetic 
accessibility to ETS:RUNX sites, preventing Runx3 from fully enabling an effector 
program. As a result, deleting Fli1 robustly improved protective immunity in multiple 
models of acute infection, chronic infection and cancer, thus identifying Fli1 as a 
novel regulator of the TEFF versus TEX differentiation programs and a target for future 
immunotherapy strategies. 
All these studies have helped the field to establish a transcriptional roadmap of TEFF, 
TMEM and TEX differentiation, and could potentially benefit T cell related therapies in 
clinics. For example, the enhancement of Myb expression could serve as a potential 
CAR-T design strategy to enhance CAR-T cell persistence during cancer progression, 
while genetic deletion of Fli1 level in CAR-T cells can enhance TEFF cell response for 
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potential better clinical outcome. However, when I put my graduate work as well as 
the recent published work together, one unsolved question that puzzles me is 
whether we want more effective T cells with better killing capacity or more persistent 
T cells with long-term life span and self-renew potential. The molecular modules 
involved in T cell persistence during chronic infection and cancer are mainly involved 
in TCF-1-centralized transcriptional networks, which on the other hand may eliminate 
TEFF cell differentiation and trigger less cytotoxicity killing for viral infected or cancer 
cells. However, driving hyper activated TEFF cell response may lead to immune 
pathology, and at the same time burst out antigen specific T cell pool to keep 
equilibrium stage between virus/cancer and immune system. These issues make 
manipulating CD8 T cell response in clinics very critical and could be the main 
reasons for failure of clinical tumor remission of immune therapies. Thus, how to 
control the balance of TEFF, TMEM and TEX differentiation of antigen specific T cells is 
the central question in T cell immune therapies, and my perspective is that a robust T 
cell immunotherapy in the setting of chronic diseases, should have both efficient 
cytotoxic TEFF/TEX cells to control the current viral load or tumor burden, and enough 
TMEM/TEX progenitor cells to maintain antigen specific T cell pool.  
To achieve this goal, the key thing is to build up a complete cell fate roadmap of T 
cell differentiation in distinct antigen stimulation intensity levels, and involve major 
transcriptional circuits at different stages. Thus, three key perspectives could be 
further pursued to answer this question: 1) For given key transcription factors, 
investigating the distinct transcriptional mechanisms of controlling cell fate decisions 
in different settings. For examples, TCF-1 may play different very roles during 
memory formation(Lin et al., 2016; Zhou et al., 2010) and exhaustion(Chen et al., 
2019b; Im et al., 2016; Utzschneider et al., 2016; Wu et al., 2016), with potential 
shared downstreams(Chen et al., 2019b; Zhou et al., 2010) and content-specific 
downstreams(Chen et al., 2019b; Wu et al., 2016); 2) To dissect the TCR intensity 
dependence, TCR transgenic mice models for other LCMV antigen specific T cells 
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should be established and profiled in details. For example, NP396+ CD8 T cells have 
the most terminal TEFF differentiation while GP276+ CD8 T cells have the most TEX 
precursor population(data not shown). These two tetramer+ T cell populations are 
thought to have a distinct TCR affinity to LCMV compared to canonical P14 cells. 
Thus, using transcriptional profiling to compare the key TF control changes of 
multiple TCR transgenic cells would start to address how TCR signaling affects the 
transcriptional programs of CD8 T cells; 3) Studying the synthetic effect of different 
TFs during CD8 T cell response. I have found that Fli1 and Runx1 potentially 
synergize to restrain TEFF cell response and antagonize Runx3 function. It would be 
interesting and important to build up a complete transcriptional landscape of CD8 T 
cell responses using single cell CRISPR-sequencing technology(see Chapter 6 
discussion).  
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Chapter 6 Perspectives of high-throughput profiling and screening in T cell-
related studies 
High-throughput methods, including high dimensional proteomic and genomic 
profilings and high-throughput genetic perturbations, have fundamentally changed 
the ways of how we think of immunology, both in basic mechanistic studies as well as 
in clinical research. Currently researchers are not only thinking of immune dynamics 
and immune cell heterogeneities in a “marked-cell” base level but further zoom in 
multiple features to in detail describe cell state and cell fate changes in systemic 
features. Furthermore, with the development of CRISPR-Cas9 technology, scientists 
now can perform multiple genetic perturbations in immune cells at the same time, 
which further not only reduce the time and labor to find novel biologies but also have 
the ability to process potential synergistic studies across different candidates. 
In my first story(Chapter 2, Chen and Stelekati et al.,Cell Reports, 2017), we were 
using miRNA+mRNA network analysis to identify miRNA-mRNA pairs that could 
potentially contribute to T cell differentiation in vivo. We have miRNA microarray data 
across different infection stages of LCMV, both in Arm or Cl13 strains(Stelekati and 
Zhang, et al. in preparation), and we are able to perform this paired network using 
this miRNA microarray data and the published mRNA data(Doering et al., 2012). 
MiR-150-c-Myb pair is one key axis for TMEM cell survival, and we also found a couple 
of the other pairs including miR-155-Fosl2(Stelekati et al., 2018), miR-29-
TET2(Stelekati and Zhang, et al. in preparation) and miR-21-Smad7(unpublished). 
This method can be extended to study mouse T cells in tumor models or human T 
cells across multiple sampling time points. Moreover, since miRNAs are small and 
can be easily linked to transduction constructs, using miRNAs to manipulate 
transcriptional machinery in CAR-T cells could be a promising therapeutic strategy to 
enhance CAR-T responses in vivo. 
In my second story(Chapter 3, Chen and Ji et al., Immunity, 2019), I was using 
scRNA-Seq pseudotime analysis to define cell fate decision at early stage of chronic 
 68 
infection, and we further developed State Transition Inference Predictor (STIP) to 
predict the TCF-1 downstream TFs, combined with motif analysis from ATAC-Seq. 
This pipeline can be further adapted to anchor any TF as a central point to study its 
potential downstreams, and it also has the potential to process up and downstream 
analysis between different TFs(Chen and Ji, et al. Unpublished). Furthermore, single 
cell  transcriptional profiling and pseudotime analysis have been broadly used to 
study T cell biology in clinics, especially in different tumor microenvironments. 
Combined lineage tracing methods of mRNA and TCR data also help to define the 
road map of T cell differentiation in clinical samples(Zhang et al., 2018). Thus, it 
would be interesting to address T cell differentiation paths in a Pan-cancer setting 
and subtyping different cancers by its immune profiling. 
In my third story(Chapter 4, Chen et al.,preprint bioRxiv/SSRN, 2020), I developed 
OpTICS, an in vivo screening system that does not disrupt T cell maturation or the 
very early signals of T cell activation, to better understand the fate commitment of 
TEFF and TEX cells. This screen revealed known targets essential for positive 
regulation of the primary steps in T cell activation and differentiation including Batf, 
Irf4 (Kurachi et al., 2014; Man et al., 2013)and Myc(Lindsten et al., 1988; Wang et al., 
2011) as well as TFs that have key roles in developing and controlling the effector 
program such as members of the NF-kB family and the T-box TF, T-bet. A key goal 
of this screen was to identify TFs that restrain full TEFF differentiation and prevent 
optimal protective CD8 T cell responses during chronic infection and cancer. Genes 
known to promote T cell exhaustion, like Tox, Nr4a1 and Nr4a2 (Alfei et al., 2019; 
Chen et al., 2019a; Khan et al., 2019; Liu et al., 2019; Scott et al., 2019; Seo et al., 
2019; Yao et al., 2019) were revealed, as was Tcf7 due to its the ability to antagonize 
T cell activation and TEFF differentiation(Chen et al., 2019b). We also, however, 
identified several novel negative regulators of TEFF differentiation, including Smad2, 
Erg and Fli1. We focused on Fli1 and defined its functions during both acute and 
chronic infection, as restraining TEFF cell responses. Thus, the OpTICS platform 
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provides a highly robust in vivo platform to screen genes involved in regulating CD8 
T cell differentiation as it relates to tumor immunotherapy. This highly focused and 
optimized platform allows for a 20-100-fold enrichment of sgRNA detection and 
considerable resolution for gain-of-function screening.  
One of the key further directions is to combine scRNA-Seq with CRISPR screening 
together, and to profile the phenotypic changes of multiple different genetic 
perturbations at the same time in the same microenvironments. In that case, we can 
not only compare how different candidates impact T cell responses at the same time 
but also study the synergistic effect of different targeted genes. The central tool to 
accomplish this goal is to build up a retroviral sgRNA-sequencing index stable 
expressing construct, and isolate the tag fragments from the single cell cDNA library. 
This technology, called Perturb-seq(Dixit et al., 2016) or CROP-Seq(Datlinger et al., 
2017), has not been adapted to retroviral vectors for T cell studies and I hope to 
achieve this in the near future. 
Another interesting idea is to find “co-target” genes of different cells in the same 
microenvironments, using scRNA-Seq or CRISPR screening. On a pharmaceutical 
point, a target specific molecule should mainly affect one cell type in a tumor 
microenvironment. However, it may also have side effects on the other cell types. 
One interesting idea is that if we can find the common targets across different cell 
types towards the same anti-tumor effect. For example, target A may induce tumor 
cell death while at the same time drives TEFF cell burst. To achieve this, I am planning 
to design a “waterfall screening strategy”--1) build up a tumor in vivo screening first; 2) 
take out the negative selected candidates from the tumor screening and perform a T 
cell in vivo screening in the tumor model; 3) find out the T cell positive selected 
candidates and perform a bone marrow chimera screening on the other immune cell 
types. In that case, we can possibly find the co-targets to reactivate the whole tumor 
microenvironment.  
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Chapter 7 Methods and protocols for experimental processes 
Mice 
PD-1KO(Odorizzi et al., 2015), EomesGFP (Paley et al., 2013), TCF-1flox/flox (Weber et al., 
2011) and Eomesflox/flox (Intlekofer et al., 2005) mice have been described. MiR-150 KO, LSL-
Cas9-GFP, Constitutive-Cas9-GFP, CD4CRE and Rosa26-CREERT2 mice were 
purchased from Jackson Laboratory. LSL-Cas9-GFP mice were bred to CD4CRE mice 
and TCR transgenic P14 C57BL/6 mice (TCR specific for LCMV DbGP33–41) and back 
crossed for more than 6 generations before use. MiR-150 KO or Constitutive-Cas9-
GFP mice were bred to TCR transgenic P14 C57BL/6 mice. TCF-1flox/flox mice were 
bred to CD4CRE mice and TCR transgenic P14 C57BL/6 mice (TCR specific for LCMV 
DbGP33–41). Eomesflox/flox mice were bred to Rosa26-CREERT2 mice and TCR 
transgenic P14 C57BL/6 mice. PD-1KO and EomesGFP mice were bred to TCR 
transgenic P14 C57BL/6 mice. 6-8 week-old C57BL/6 Ly5.2CR (CD45.1) or C57BL/6 
(CD45.2) mice were purchased from NCI. Both male and female mice were used. All 
mice were used in accordance with Institutional Animal Care and Use Committee 
guidelines for the University of Pennsylvania. 
Virus/Bacteria infection and tumor challenge experiments 
LCMV Infection: Mice were infected intraperitoneally (i.p.) with 2 × 105 plaque-
forming units (PFU) LCMV Armstrong or intravenously (i.v.) with 4 × 106 PFU LCMV 
Cl13. Plaque assay for LCMV-Cl13 to detect viral load was processed as previously 
described(Pauken et al., 2016).The mice of Cl13 CD4 group received 200µg 
GK1.5/mouse i.p. treatment on day -1 and day 1 post Cl13 infection. The mice of 
inducible genetic deletion group received 2mg tamoxifen/mouse i.p. everyday on 
day9 to day13 post Cl13 infection.  
Listeria Monocytogenes (LM) infection: LM expressing DbGP33(LM-gp33) 
concentration was measured by optical density (OD) after overnight culture in brain 
heart infusion (BHI) media (1 OD refers to 8 × 108 LM-gp33). Each recipient mouse 
was infected intravenously (i.v.) with 1 × 105 CFU LM-gp33. Adjusted survival was 
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based on mice remaining above the mandatory Institutional Animal Care and Use 
Committee (IACUC) euthanasia cut off of 30% weight loss.  
Influenza PR8 infection: Mice were infected intranasally (i.n.) with PR8 strain 
expressing DbGP33 (PR8-gp33) at a dose of 3.0 LD50. Mice were anesthetized 
before i.n. infection. PR8 viral qPCR detection for viral RNA amount was calculated 
as previously described(Laidlaw et al., 2013). 
Tumor transfer: B16F10 melanoma cells expressing DbGP33 (B16F10-gp33, 
(Prévost-Blondel et al., 1998)) were maintained at 37 °C in DMEM medium 
supplemented with 10% FBS, penicillin, streptomycin and L-glutamine. Tumor cells 
were injected subcutaneously into the flanks of Rag2-/-mice at 1 x 105 cells/recipient 
and of Cas9+ B6 mice at 2 x 105 cells/recipient. Activated sgRNA+ C9P14 cells are 
sorted and transferred into recipient mice at a dose of 1 x 106 cells/recipient (for 
Rag2-/-) or 3 x 106 cells/recipient (for Cas9+). Tumor size was measured using digital 
calipers every 2-3 days after inoculation. 
For CT26 tumor cell line, 2 x 105 CT26 cells were subcutaneously injected into 
BALB/C mice. Established CT26 tumors (D8 post transfer) were excised and 
processed for flow cytometry as described(Knight et al., 2013). In brief, tumors were 
digested with 1 mg/ml collagenase D and 0.02 mg/ml DNaseI at 37 . 
Cell culture and in vitro stimulation 
CD8+ T cells were purified from spleens by negative selection using EasySep Mouse 
CD8+ T Cell Isolation Kit (STEMCELL Technologies) according to manufacturer’s 
instructions. Cells were stimulated with 100 U/mL recombinant human IL-2, 1 µg/mL 
anti-mouse CD3ε , and 5 µg/mL anti-mouse CD28  in RPMI-1640 medium with 10% 
fetal bovine serum (FBS), 10 mM HEPES , 100 µM non-essential amino acids 
(NEAA), 50 U/mL penicillin, 50 µg/mL streptomycin, and 50 µM β-mercaptoethanol. 
 
Retroviral vector (RV) experiments 
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MiR-150 cDNA was cloned from miRNASelectTM pEP-hsa-mir-150 Expression Vector 
(Cell Biolabs, Inc.) and c-Myb cDNA was cloned from MSCV-PIG-Myb vector 
(Addgene), as described(Roe et al., 2015). MiR-150 or c-Myb cDNA was cloned into 
the MSCV-IRES-GFP or MSCV-IRES-VEX plasmid. The TCF-1 p33 (MR226713) 
cDNA clone was obtained from OriGene and the TCF-1 p45 cDNA clone was 
extended from the TCF-1 p33 cDNA using PCR. TCF-1 p33 or TCF-1 p45 cDNA 
were cloned into the MSCV-IRES-VEX plasmid. The T-bet RV was constructed as 
described(Kao et al., 2011). RVs were produced in 293T cells with MSCV and pCL-
Eco plasmids using Lipofectamine 3000. RV transduction was performed as 
described(Kurachi et al., 2017). Briefly, CD8+ T cells were purified from spleens of 
P14 mice using EasySepTM Mouse CD8+ T Cell Isolation Kit. After 18-24 hrs of in 
vitro stimulation, P14 cells were transduced with RV in the presence of polybrene 
(0.5 µg/ml) during spin infection (2,000 g for 60 min at 32 ) following incubation at 37  
for 6 hrs for single RV and sgRNA library, or 12 hrs for double RV. RV-transduced 
P14 cells were adoptively transferred into recipient mice that were infected 24-48 hrs 
prior to transfer. 
Flow cytometry and sorting 
For mouse experiments, tissues were processed, single cell suspensions obtained, 
and cells were stained as described(Wherry et al., 2003). Mouse cells were stained 
with LIVE/DEAD cell stain (Invitrogen) and with antibodies targeting surface or 
intracellular proteins. Intracellular cytokine staining was performed after 5 hrs ex vivo 
stimulation with GP33-41 peptide in the presence of GolgiPlug, GolgiStop and anti-
CD107a. After stimulation, cells were stained with surface antibodies, followed by 
fixation with Fixation/Permeabilization Buffer and then stained with intracellular 
antibodies for TNF, IFN-γ  and GrzmB using Permeabilization Wash Buffer according 
to manufacturer’s instructions. Flow cytometry was performed with an LSRII. Cell 
sorting experiments were performed with a BD-Aria sorter, with 70 micron nozzle and 
a 4°C circulating cool-down system. 
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For sorting RV+ cells optimized sorting in the transfer experiments, the BD Aria Sorter 
was set at 37°C and 100-micron nozzle, with a flow rate lower than 3.0. 3 X 106 Cells 
are concentrated in 300ul 10% complete RPMI with 100 U/mL recombinant human 
IL-2 during sorting. 37°C pre-warmed collection tubes with 10% complete RPMI (100 
U/ml IL-2) are used. Sorted cells are washed by 37°C warm pure RPMI before 
transferring into recipients.、 
Single cell RNA sequencing(For Chapter 3) 
P14 cells from spleens of naïve or infected mice were isolated using EasySepTM 
Mouse CD8+ T Cell Isolation Kit. Cells were double-sorted for the CD8+CD45.2+(P14+) 
population into 1.5 ml Lo-Bind Eppendorf tubes with complete RPMI (10% FBS). 2 x 
104 P14s were collected and washed with PBS twice before loading to a Chromium 
single cell sorting system (10X Genomics). Library construction was performed 
following the protocol of Chromium Single Cell 3’ Library system, with a standard 
loading targeting 5 x 103 cells recovered. The final pooled library with 4 samples 
(Naïve, Arm, Cl13 and Cl13△CD4) was sequenced on a NextSeq 500 using 1 pair-
end high throughput FlowCell. 
RNA isolation and qPCR 
Total RNA was isolated using RNeasy micro kit from QIAGEN. QRT-PCR was 
performed using iTaqTM Universal SybrGreen Supermix from BioRad on the ViiA™ 7 
Real-Time PCR System according to manufacturer’s instructions. 
Western blot 
2 x 105 T cells were sorted using FACS machine and the pellets were frozen down. 
Protein from these samples was extracted and denatured by boiling at 95°C in 2X 
working loading sample buffer (1M Tris-HCl, 10% SDS, Glycerol, 10% Bromophenol 
blue). Lysate was run on a 10% SDS-PAGE gel and then transferred to a 
nitrocellulose membrane.  Blots were stained for c-Myb (1:200 for antibody staining 
for 1 hr at room temperature) and actin (1:5000 for secondary staining for 1hr at room 
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temperature). Primary Fli1 (1:200) and GAPDH (1:1000) antibodies were stained 
overnight, followed by 1:5000 secondary antibody staining on the next day. Western 
blots were quantified by ImageJ. 
TIDE Assay(For Chapter 4) 
At least 1 x 104 Cas9+sgRNA+ T cell pellets were frozen down. Genomic DNA was 
isolated from these samples using QIAmp DNA Mini Kit. A TIDE PCR, using 2x 
Phusion Flash High-Fidelity PCR Master Mix and primers designed around the 
genome region of the sgRNA target part was run for each sample to extract the guide 
region from the genome DNA; the resulting products were then gel verified, PCR 
purified, and sent for Sanger sequencing.  
Immunofluorescence(For Chapter 3) 
Cells were fixed in 4% paraformaldehyde in PBS for 30min at room temperature. 
After two PBS washes, cells were permeabilized with 0.5% Triton X-100 in PBS for 
10min, followed by two additional PBS washes. Cells were then blocked in 10% BSA 
in PBS for 1h at room temperature, and were incubated with γH2AX antibodies 
(Abcam, ab2893, 1:200 or Millipore, 05-636, 1:100) in 5% BSA in PBS supplemented 
with 0.1% Tween 20 (PBST) overnight at 4 . The next day, cells were washed 4X 
10min with PBST, and then incubated with Alexa Fluor 647-conjugated secondary 
antibody in 5% BSA/PBST for 1h at room temperature, followed by 4X 10min washes 
with PBST. Cells were then stained with 1µg/ml DAPI for 5min and washed twice with 
PBS. The coverslip were mounted with ProLong Gold, and imaged with Leica TCS 
SP8 fluorescent confocal microscope (63X). 
Computational analysis of single cell RNA sequencing data(For Chapter 3) 
Data processing: Raw sequencing files were aligned to the mouse mm10 genome 
using Cell Ranger software (10x Genomics). Mitochondrial genes were removed and 
cells that had positive read counts of at least 1000 genes were retained. Scran (Lun 
et al., 2016) was used to normalize the raw gene expression counts and normalized 
expression values were used throughout the analysis. 
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ScRNA-Seq analysis: MAST(Finak et al., 2015) was used to perform differential 
analysis comparing gene expression of two cell clusters. GAM (in R package 
VGAM(Yee et al., 2015) ) was used to fit the gene expression along a pseudotime 
trajectory. A Tobit family (lower threshold=0.1) was used to account for potential 
dropout events. To determine whether expression of a gene changed significantly 
along the pseudotime trajectory, a likelihood ratio test was performed comparing the 
full model with an intersect-only null model. FDRs were calculated for p-values of the 
likelihood ratio tests. A gene with FDR < 0.05 was determined to have differential 
expression along the pseudotime axis. Packages for pseudotime analysis include 
Monocle-2(Qiu et al., 2017), TSCAN(Ji and Ji, 2016) and STIP 
(http://github.com/zji90/STIP). Briefly STIP functions as follows: Given a pseudotime 
trajectory and gene expression profiles, STIP first extracts the TFs for which 
expression changes significantly along the pseudotime trajectory. Expression of each 
gene is then standardized to have a mean of zero and variance of one across all 
cells. For each gene STIP then calculates the pseudotime point at which the 
standardized expression is zero (zero point). Only genes that have 1 or 2 zero points 
are retained. Finally it reorders genes based on expression patterns (monotone 
increasing, single peak, monotone decreasing) and the occurrence of the zero point 
within each pattern. One can then compare the correlations between different genes 
with a selected anchor gene (Tcf7 in this study). 
ATAC-Seq and Network Analysis: Open chromatin regions for each sample (Naïve 
and D8 Cl13 samples as described(Sen et al., 2016)) were determined by peak 
calling using macs2v2.1.1 “callpeak” function at a q value of 0.01. For each peak 
identified, TF binding sites were scanned using the FIMO algorithm in the 100 bp 
centered around the summit of the peak, the TF motifs were obtained for MOUSE 
transcription factors (core) from HOCOMOCO V11 mouse. TF binding sites in these 
enhancers were linked to corresponding promoters/genes that were defined in a 
manner similar to the GREAT software, where each gene is assigned a basal 
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regulatory domain that is defined as the promoter region and extended in both 
directions to the nearest gene basal domain but no more than 1000kb each direction. 
Network analysis was visualized using Cytoscape software(3.7.1 ). 
Gene Ontology Analysis: For each cluster, a GO analysis was conducted 
comparing the top 100 genes that were highly differentially expressed and all the 
other genes in the dataset. GO analysis was performed using DAVID with default 
parameters. 
Gene index generation: The Klrg1+DiffGene index was generated using bulk RNA-
seq data(Herndler-Brandstetter et al., 2018). The comparison was between 
KLRG1+exKLRG1+ versus KLRG1-exKLRG1- groups. We selected the entire set of 
differentially expressed coding genes with the FDR<0.05. The Havcr2+Entpd1+ 
DiffGene index was generated using scRNA-seq(Sade-Feldman et al., 2019). The 
comparison was between the Havcr2+Entpd1+ and the Havcr2-Entpd1- groups. We 
selected the top 100 differentially expressed coding genes that were higher in the 
Havcr2+Entpd1+ group with an FDR<0.05. The Tcf7+Pdcd1+ DiffGene index was 
generated using scRNA-seq(Sade-Feldman et al., 2019). The comparison was 
between the Tcf7+Pdcd1+ and the Tcf7-Pdcd1- groups. We selected the top 100 
differentially expressed coding genes that were higher in the Tcf7+Pdcd1+ group with 
an FDR<0.05. 
OpTICS screening(For Chapter 4) 
sgRNA candidate selection: 271 TFs that met the following criteria were selected 1) 
Among the top 50 differentially expressed across(Doering et al., 2012) and(Philip et 
al., 2017) , 2) Among the top 10 differentially open TF motifs across Naïve, D8 Arm 
and D8 Cl13 in the previous described(Sen et al., 2016), 3) Involved in the top 
immune-regulatory families, such as IRF and STAT proteins. 120 TFs were manually 
chosen to be included in the TF library. 
Library construction: 4-5 sgRNA were designed against individual DNA binding 
domains or other functional domains of each TF based on the domain sequence 
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information retrieved from NCBI Conserved Domains Database. All of the sgRNA 
oligos, including positive and negative control sgRNAs, were synthesized by 
Integrated DNA Technologies (IDT) and pooled in equal molarity. The pooled sgRNA 
oligos were then amplified by PCR and cloned into BsmBI-digested SL21 vector 
using Gibson Assembly Kit. To verify the identity and relative representation of 
sgRNAs in the pooled plasmids, a deep-sequencing analysis was performed on a 
MiSeq instrument. We confirmed that 100% of the designed sgRNAs were cloned in 
the SL21 vector and the abundance of >95% of individual sgRNA constructs was 
within 5-fold of the mean (data not shown). 
Mouse Experimental Workflow: On day 0, C9P14 cells were isolated from the 
spleens and lymph nodes of CD45.2+ C9P14 mice and processed to standard T cell 
activation protocol using anti-CD3/CD28 and IL-2; on the same day, naïve CD45.1+ 
recipient mice were infected by LCMV. On D1 p.i., activated C9P14 cells were 
transduced by RV-sgRNA library and incubated for 6 hours before washing out the 
RV supernatant. 18-24 hours later, the transduced sgRNA+Cas9+ cells were sorted. 
Then, 10% of the sgRNA+Cas9+ T cells were frozen down as a D2 baseline (T0 time 
point) control prior to any selection, while 90% of the cells are transferred to the 
infected recipients (maximum 1X105 cells/recipient). On the T1 time point (D8 in the 
graph), sgRNA+Cas9+ CD45.2+ T cells were sorted out from multiple organs of the 
recipients. 
Isolated library construction and MiSeq processing: To quantify the sgRNA 
abundance of reference and end time points, the sgRNA cassette was PCR amplified 
from genomic DNA using high-fidelity polymerase. The PCR product was end-
repaired by T4 DNA polymerase, DNA Polymerase I, Large (Klenow) Fragment, and 
T4 polynucleotide kinase. Next, a 3’ A-overhang was then added to the ends of 
blunted DNA fragments with Klenow Fragment (3'-5' exo-). The DNA fragments were 
ligated to diversity-increased custom barcodes with Quick ligation kit. Illumina paired-
end sequencing adaptors were attached to the barcoded ligated products through 
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PCR reaction with high-fidelity polymerase. The final product was quantified by 
Bioanalyzer Agilent DNA 1000 and pooled together in equal molar ratio and pair-end 
sequenced by using MiSeq (Illumina) with MiSeq Reagent Kit V3 150-cycle (Illumina). 
Data processing: The sequencing data was de-multiplexed and trimmed to contain 
only the sgRNA sequence cassettes. The read count of each individual sgRNA was 
calculated with no mismatches and compared to the sequence of reference sgRNA 
as described previously(Shi et al., 2015). Data of each sample were normalized to 
the same read account. Waterfall plots (Figure 11B): For each gene, mean of the 
log2 fold changes from multiple sgRNA was computed. Heatmap (Figure 11C): For 
each gene, mean of the log10 fold changes from multiple sgRNA was computed. In 
the matrix of genes by conditions, quantile normalization was performed across 
conditions such that each condition has the same distribution of values. Genes were 
ordered by the mean value of each row. Histogram (Figure 11D): For each condition, 
the background (grey bars and the histogram) was plotted for sgRNAs of all the 
genes. The 5% and 95% intervals were extracted by using the 5th percentile and 
95th percentile of background values. The red bars show the log folds change for 
sgRNAs for one gene (or the control) 
 
RNA-Sequencing(For Chapter 4) 
Experiment workflow: At D8 p.i. with Cl13, CD8 T cells were isolated from spleens 
of infected recipients. VEX+GFP+ cells are sorted using FACS with >95% purity. RNA 
were isolated using the QIAGEN RNeasy Micro Kit with 2 x 104 cell per sample. 
cDNA libraries were generated using SMARTSeq V4 Ultra Low kit. Libraries were 
quantified by qPCR using a KAPA Library Quant Kit (KAPA Biosystems). Normalized 
libraries were pooled, diluted to 1.8pg/ml loaded onto a TG NextSeq 500/550 Mid 
Output Kit v2 (150 cycles, 130M reads, Illumina) and paired-end sequencing was 
performed on a NextSeq 550 (Illumina). The estimated read depth per sample is 15M 
reads. 
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Data processing: Raw FASTQ files from RNAseq paired-end sequencing were 
aligned to the GRCm38/mm10 reference genome using Kallisto 
(https://pachterlab.github.io/kallisto/). Sequencing reads were read in for 19357 
genes and 8 samples. Genes with zero read count in more than three conditions 
were filtered out. 13628 genes remained after this step. Then, differential expression 
analysis was run using the DESeq 2 package. The expression of 1440 genes were 
found to significantly differ between the two conditions at a BH corrected P-value < 
0.05. GO enrichment analysis was performed using ClusterProfiler. The top 20 most 
enriched pathways are shown in the plot. GSEA was performed using the Broad 
Institute software (https://www.broadinstitute.org/gsea/index.jsp). Enrichment scores 
were calculated by comparing sgCtrl to sgFli1 groups. TEX precursor gene signature 
was from(Chen et al., 2019b),Chapter 3). TEFF gene signature was from(Bengsch et 
al., 2018). 
ATAC-Sequencing(For Chapter 4) 
Experimental Workflow: ATACseq sample preparation was performed as described 
with minor modifications(Buenrostro et al., 2013). VEX+GFP+ cells were sorted using 
FACS with >95% purity. Sorted cells (2.5 x 104) were washed twice in cold PBS and 
resuspended in 50ml of cold lysis buffer (10nM Tris-HCl, pH 7.4, 10mM NaCl, 3mM 
MgCl2, 0.1% Tween). Lysates were centrifuge (750xg, 10min, 4oC) and nuclei were 
resuspended in 50ml of transposition reaction mix (TD buffer [25ml], Tn5 
Transposase [2.5ml], nuclease-free water [22.5ml]; (Illumina)) and incubated for 
30min at 37oC. Transposed DNA fragments were purified using a Qiagen Reaction 
MiniElute Kit, barcoded with NEXTERA dual indexes (Illumina) and amplified by PCR 
for 11 cycles using NEBNext High Fidelity 2x PCR Master Mix (New England 
Biolabs). PCR products were purified using a PCR Purification Kit (Qiagen) and 
amplified fragment sizes were verified on a 2200 TapeStation (Agilent Technologies) 
using High Sensitivity D1000 ScreenTapes (Agilent Technologies). Libraries were 
quantified by qPCR using a KAPA Library Quant Kit (KAPA Biosystems). Normalized 
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libraries were pooled, diluted to 1.8pg/ml loaded onto a TG NextSeq 500/550 Mid 
Output Kit v2 (150 cycles, 130M reads, Illumina) and paired-end sequencing was 
performed on a NextSeq 550 (Illumina). Estimation read depth per sample is 10M 
reads. 
Data processing: Raw ATACseq FASTQ files from paired-end sequencing were 
processed using the script available at (https://github.com/wherrylab/jogiles_ATAC). 
Samples were aligned to the GRCm38/mm10 reference genome using Bowtie2. We 
used samtools to remove unmapped, unpaired, mitochondrial reads. ENCODE 
blacklist regions were also removed 
(https://sites.google.com/site/anshulkundaje/projects/blacklists). PCR duplicates were 
removed using Picard. Peak calling was performed using MACS v2 (FDR q-value 
0.01). For each experiment, we combined peaks of all samples to create a union 
peak list and merged overlapping peaks with BedTools merge. The number of reads 
in each peak was determined using BedTools coverage. Differentially accessible 
regions were identified following DESeq2 normalization using an FDR cut-off  0.05 
unless otherwise indicated. Motif enrichment was calculated using HOMER (default 
parameters) on peaks differentially accessible across sgCtrl group and sgFli1 group. 
Transcription binding site prediction analysis was performed using known motif 
discovery strategy. 
CUT&RUN 
Experimental Workflow: CUT&RUN experiments were performed as previously 
described(Skene et al., 2018) with modifications. Briefly, 2x105 sorted cells were 
washed twice with 1 ml of cold wash buffer (20 mM HEPES-NaOH pH 7.5, 150 mM 
NaCl, 0.5 mM Spermidine, and protease inhibitor cocktails from Sigma) in 1.5ml 
tubes. Cells were then resuspended in 1 ml of cold wash buffer and incubated with 
10 ml of BioMagPlus Concanavalin A (Bangs laboratories) by rotating at 4°C for 25 
min to allow the cells to bind. Tubes were placed on a magnetic stand and liquid was 
removed after the solution turned clear. Primary antibody in 250 ml of cold antibody 
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buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 2 mM 
EDTA, 0.1% digitonin, and protease inhibitor cocktails from Sigma) was added to the 
tubes and rotated at 4°C overnight. The next day, after washing cells once with 1 ml 
of cold wash buffer, protein A-MNase (pA-MN) in 250 ml of cold digitonin buffer (20 
mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 0.1% digitonin, and 
protease inhibitor cocktails from Sigma) was added to the tube and rotate at 4°C for 1 
h. To wash away unbound pA-MN, cells were washed twice with 1 ml of cold 
digitonin buffer, and then resuspended in 150 ml of cold digitonin buffer. The tubes 
were placed on a pre-cooled metal block. To initiate pA-MN digestion, 3 ml of 0.1 M 
CaCl2 was mixed with cells in a 150 ml cold digitonin buffer by gently flicking the 
tubes 10 times. Tubes were immediately placed back in the metal block. After 30 min 
incubation, the digestion was stopped by adding 150 ml of 2x stop buffer (340 mM 
NaCl, 20 mM EDTA, 4 mM EGTA, 0.02% Digitonin, 50 mg/ml RNase A, 50 mg/ml 
Glycogen, and 4 pg/ml yeast heterologous spike-in DNA). Target chromatin was 
released by incubating the tubes on a heat block at 37°C for 10 min. Supernatant 
was spun at 16,000 g for 5 min at 4°C and transferred to a new tube. Chromatin was 
incubated with 3 ml of 10% SDS and 2.5 ml of 20 mg/ml proteinase K at 70°C for 10 
min, followed by phenol:chloroform:isoamyl alcohol extraction. Upper phase 
containing DNA was mixed with 20 mg of glycogen and incubated with 750 ml of cold 
100% ethanol at -20°C overnight. DNA was precipitated by centrifugation at 20,000 g 
for 30 min at 4°C. DNA pellets was washed once by cold 100% ethanol, air-dried, 
and stored at -20°C for library preparation. Protein A-MNase (batch 6, use at 1:200) 
and yeast heterologous spike-in DNA were kindly provided by Dr. Steve Henikoff. 
The antibodies used were: Fli1, ab15289, used at 1:50 (abcam) and guinea pig anti-
rabbit IgG, used at 1:100, ABIN101961 (antibodies-online). 
CUT&RUN DNA library was prepared as previously described(Liu et al., 2018) with 
slight modifications. Briefly, all DNA precipitated from pA-MN digestion was used for 
library preparation using NEBNext Ultra II DNA Library Prep Kit (NEB). The adaptor 
 82 
was diluted to 1:25 for adaptor ligation. DNA was barcoded and amplified for 14 PCR 
cycle, and DNA library was cleaned up by AMPure XP beads(Liu et al., 2018). The 
library quality was checked with Qubit and bioanalyzer, and the quantity of the library 
was determined by qPCR using NEBNext Library Quant Kit for Illumina (NEB) 
according to manufacture’s instruction. Eighteen barcoded libraries were pooled at 
equal molarity and sequenced in the NextSeq 550 platform with NextSeq 500/550 
High Output Kit (75 cycles) v2.5 kit. Paired-end sequencing was carried out 
(42:6:0:42). 
Data processing: Paired-end reads were aligned to mm10 reference genome using 
Bowtie2 v2.3.4.1 with options suggested by Henikoff(Skene et al., 2018). Picard tools 
v1.96 was used to remove presumed PCR duplicates using the MarkDuplicates 
command. Bam files containing uniquely mapped reads were created using Samtools 
v1.1. For downstream analysis, biological replicates (3 per condition) were merged at 
this step. Bedtools v2.28.0 was used to generate fragment BED files with size 40bp-
500bp. Blacklist regions, random chromosomes, and mitochondria were removed. 
Filtered BED files were used for downstream analysis. Read per million (RPM) 
normalized bigwig files were created using bedGraphToBigWig (UCSC) and were 
used to visualize binding signals. Peaks were called using MACS v2.1 using the 
broadPeak setting with p-value cutoff of 1e-8, -f BEDPE and IgG as controls. Genes 
proximal to peaks were annotated against the mm10 genome using 
annotatePeaks.pl from HOMER v4. Fli1 binding motifs were identified using 
findMotifsGenome.pl from HOMER v4. Venn diagram of comparison with ATAC-Seq 
peaks was plotted using Bioconductor package ChIPpeakAnno. Heatmap was 




Statistical significance was calculated with unpaired two-tailed student’s t-test or one-
way ANOVA with Tukey’s multiple comparisons test by Prism 7 (GraphPad Software). 
P values are reported in the figure legends.  
 84 
Chapter 8 New generated available data and resource  
Vectors, Constructs and sgRNA libraries 
MiR-150 overexpression vector on pMSCV-GFP or VEX, C-Myb overexpression 
vector on pMSCV-GFP or VEX, TCF-1 p33/p45 overexpression vector on pMSCV-
VEX, Runx3 vector on pMSCV-VEX are available upon email requirement to 
wherry@pennmedicine.upenn.edu; all sgRNA vectors, Fli1 overexpression vector on 
SL21-PGK-VEX or GFP and sgRNA libraries are available upon email requirement to 
jushi@mail.med.upenn.edu.  
New Generated Sequencing Data 
Single cell RNA sequencing data of P14 cells from Naive, D8 Arm, D8 Cl13, D8 
Cl13+GK1.5 groups is available on GSE131535；sgCtrl vs sgFli1 RNA sequencing 
at D8 Cl13 p.i. is available on GSE149838; sgCtrl vs sgFli1 ATAC sequencing at D9 
Cl13 p.i. is available on GSE149836; IgG vs Fli1-ab(ab15289) CUT&RUN 






Figure S1 Absence of miR-150 does not affect the percentage of central memory or 
cytokine producing memory CD8 T cells.  
2.5×103 CD45.1 miR-150 WT or KO P14 cells were adoptively transferred into CD45.2 naïve 
mice, followed by LCMV-Armstrong（LCMV） infection the next day. Splenocytes were 
harvested on d8, d15 and d35 p.i.  
(A) CD127hi P14 cell numbers per spleen on d8 p.i. 
(B) Percentage of central memory cells (CD62Lhi) out of P14 on d8, d15 and d35 p.i.  
Splenocytes from miR-150 WT or KO P14 cell recipients were isolated on d35 p.i., and then 
stimulated with gp33-41 peptide in the presence of CD107a antibody for 5 hrs. Intracellular stain 
for IFN-γ，TNF-α，MIP-1α and GrzmB was performed.  
(C) Percentage of IFN-γ+TNF-α+ cells out of P14 cells. 
(D) MFI of IFN-γ，TNF-α，MIP-1α, CD107a and GrzmB. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 (two-tailed Student’s t-test). Data are 







Figure S2 MiR-150 KO memory cells retain 
an enhanced memory phenotype during 
secondary LCMV challenge. 
2.5×103 CD45.2 miR-150 WT or KO P14 cells 
were adoptively transferred into individual 
CD45.1 naïve mice, followed by LCMV 
infection. Splenocytes were harvested on d35 
p.i. and sorted for CD45.2 P14 cells. 5×103 
sorted CD45.2 miR-150 WT or KO P14 cells 
were transferred into naïve CD45.1 mice, and 
the recipients were infected with LCMV one 
day later.  
(A) Experimental design. (B) Percentage of 
donor P14 cells out of CD8 T cells and total 
number of donor P14 cells per spleen. (C) 
Percentages of MP and CD127hiCXCR3hi of 
total P14 cells on d8 and d40 p.i.  
*P<0.05, **P<0.01, ***P<0.001. ****P<0.0001 
versus control (two-tailed Student’s t-test). 
Data are representative of 3 independent 
experiments (mean±s.e.m.) with at least 5 
mice/group for each experiment. 
Figure S3 MiR-150 expression does not influence proliferation 
in vitro. 
CD8 T cells were isolated from the spleens of miR-150 WT (n=3), 
Heterozygous (Het, n=3) and KO (n=2) mice, 1×106 cells were 
plated per well in 24-well culture plates and activated with anti-
CD3, anti-CD28 and IL-2. Cell numbers were determined at 
multiple time points. Data are representative of 2 independent 




Figure S4. Significant differentially expressed genes across 5 scRNA-seq clusters. 
(A) Heatmap showing top 20 differentially expressed coding genes for the 5 clusters in Figure 7B. 
(B) Klrg1+ DiffGene signature in different clusters. 






Figure S5. Population dynamics and molecular signatures of TEFF-like and TEX precursor cells. 
(A) Population dynamics of KLRG1+ P14 cells following LCMV Arm infection and KLRG1+PD-1- or 
KLRG1-PD-1+ subsets of responding P14 cells during LCMV Cl13 infection. 
(B) Similar data as in part (A) for Cl13△CD4 infection. Note, the same LCMV Arm data from part (A) 
is plotted here for comparison.  
(C) KLRG1+CD39+ and KLRG1-PD-1+ P14 cells in spleens on D8 p.i. with Arm or Cl13. Gating 
strategies are based on staining of endogenous naïve cells. Plots are gated on donor P14 cells. 
(D) KLRG1 versus PD-1 as well as CD39 expression in KLRG1+ responding P14 cells in the indicated 
tissues on D8 p.i. with Cl13. KLRG1+ gate was based on staining of P14 cells in Arm infection and 
CD39- gate was based on staining of endogenous naïve cells. 
(E) Gating for KLRG1+PD-1- and KLRG1-PD-1+ populations in the tumor infiltrating CD8+ T cells 
(TILs) of CT26 tumor. Splenic CD8+ T cells are shown as the gating control. 
(F) Phenotypic analysis of KLRG1+PD-1- (red) and KLRG1-PD-1+ (black) TILs versus spleen CD8+ T 
cells (green) on D8 post CT26 tumor inoculation. Representative KLRG1 versus PD-1 expression 
on TIL is shown in S5E.  
(G) Gating for KLRG1+CD39+TCF-1-, KLRG1-PD-1+TCF-1- and KLRG1-PD-1+TCF-1+ responding P14 
cells at D8 p.i. with Cl13. The PD-1 versus KLRG1 gate was based on staining of endogenous 
CD44- naïve CD8+ T cells.  
(H) Representative flow cytometry plots for co-expression of TCF-1 and Ly108 during Cl13 infection. 
The Ly108 versus TCF-1 gate was based on staining of endogenous CD8+ T cells at each time 
point. Plots are gated on donor P14 cells.  
(I) Imaging of nuclear γH2AX staining. KLRG1+CD39+, KLRG1-PD-1+Ly108- and KLRG1-PD-
1+Ly108+ P14 CD8+ T cells were sorted at D8 p.i. with Cl13 and stained with DAPI and for γH2AX.  
Data are representative of 2-3 independent experiments with at least 3 mice/group. 
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Figure S6. Identification of KLRG1+CD39+ TEFF-like and PD-1+TCF-1+ TEX progenitor cells in the 
absence of CD4 help. 
(A) TCF-1 expression in KLRG1+CD39+ and KLRG1-PD-1+ P14 cells at D8 of Cl13△CD4 infection. TCF-1
expression in endogenous naïve CD62L+CD44-CD8+ T cells is shown as a control.
(B) T-bet and Eomes expression in KLRG1+CD39+ and KLRG1-PD-1+ P14 cells at D8 of Cl13△CD4
infection. Naïve CD62L+CD44-CD8+ T cells were again used as a control. T-bet/Eomes ratio was
calculated based on geometric MFI.
(C) Gating for KLRG1+CD39+TCF-1-, KLRG1-PD-1+TCF-1- and KLRG1-PD-1+TCF-1+ responding P14
cells at D8 of Cl13△CD4 infection. The PD-1 versus KLRG1 gate was based on staining of
endogenous CD44- naïve CD8+ T cells.
(D) IFNγ, TNF, CD107a and Granzyme B (Gzmb) expression by KLRG1+CD39+ TCF-1-, KLRG1-PD-
1+TCF-1- and KLRG1-PD-1+TCF-1+ subsets of responding P14 cells at D8 of Cl13△CD4 infection.
(E) The percentage of Ki-67+ cells in the KLRG1+CD39+, KLRG1-PD-1+TCF-1- or KLRG1-PD-1+TCF-1+
subsets of P14 cells was assessed at D8 and D12 of Cl13△CD4 infection.
(F) Bcl-2 and Bim expression were assessed at D8 p.i. of Cl13△CD4 infection in the KLRG1+CD39+,
KLRG1-PD-1+Ly108- and KLRG1-PD-1+Ly108+ subsets of P14 cells. Bcl-2 and Bim expression in
naïve CD62L+CD44-CD8+ T cells is shown as a control. The ratio of Bcl-2/Bim was calculated based
on geometric MFI.
*P<0.05, **P<0.01, ***P<0.001 versus control (two-tailed Student’s t-test and one-way Anova). Data are
representative of 2 independent experiments with at least 4 mice/group (mean±s.e.m.).
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 Figure S7. Lineage tracing for KLRG1+CD39+ chronic TEFF-like cells, KLRG1-PD-1+Ly108- TEX 
cells and KLRG1-PD-1+Ly108+ TEX precursors. 
(A) Expression of PD-1 by CD45.2+ donor KLRG1-PD-1+Ly108- or KLRG1-PD-1+Ly108+ P14 cells in
the spleen following adoptive transfer into infection-matched recipient mice.  Host DbGP33
tetramer+ cells are shown as a control. Note, KLRG1+CD39+ P14 cells isolated at D7 p.i. did not
give rise to sufficient numbers of cells for analysis on D8 p.t. (see Figure 9B).
(B) Expression of PD-1 by CD45.2+ donor KLRG1-PD-1+Ly108- or KLRG1-PD-1+Ly108+ P14 cells in
the liver following adoptive transfer into infection-matched recipient mice similar to part A. Note,
KLRG1+CD39+ P14 cells isolated at D7 p.i. did not give rise to sufficient numbers of cells for
analysis on D8 p.t. (see Figure 9B).
(C) Representative flow cytometry plots and quantification of CD45.2+ donor P14 cells and host
DbGP33 tetramer+ cells that are KLRG1+, Ly108-CD39+, or Ly108+CD39- in the liver. Generation
of each cell type is quantified for donor KLRG1-PD-1+Ly108- and KLRG1-PD-1+Ly108+ subsets.
Note, KLRG1+CD39+ P14 cells isolated at D7 p.i. did not give rise to sufficient numbers of cells
for analysis on D8 p.t. (see Figure 9B).
(D) Experimental design. CD45.1+ mice were infected with Cl13. On D8 p.i. DbGP33 tetramer+ CD8
T cells were sorted for KLRG1+CD39+, KLRG1-PD-1+Ly108- or KLRG1-PD-1+Ly108+ subsets
from the spleen. Equal numbers of each subset (1.7 x 105 of each) were then adoptively
transferred into infection matched (D8 p.i. Cl13) CD45.2+ recipient mice. Donor cells were
analyzed on D8 p.t.
(E) Representative flow cytometry plots and quantification of donor CD45.1+CD8+ T cells for the
KLRG1+CD39+, KLRG1-PD-1+Ly108- and KLRG1-PD-1+Ly108+ donor groups. Gated on
DbGP33+ CD8+ T cells.
(F) Representative flow cytometry plots and quantification of KLRG1+CD39+, Ly108-CD39+ and
Ly108+CD39- subsets of CD45.1+CD8+ T cells for the KLRG1-PD-1+Ly108+ donor cell group.
Endogenous CD45.2+ DbGP33+ CD8+ T cells are used as gating controls.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 versus control (two-tailed Student’s t-test or One-Way
ANOVA). The experiment has at least 2 mice/group (mean±s.e.m.).
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Figure S8. TCF-1 contributes to the 
development of TEX cells that persist. 
(A) Representative flow cytometry plots of P14
cells transduced with empty, TCF-1-p33 or
TCF-1-p45 expressing RVs on D8 p.i. with
Cl13. Gated on P14 cells.
(B) CD39, KLRG1, CD122, CXCR5
expression on VEX+ P14 cells transduced
with Empty, TCF-1-p33 or TCF-1-p45
expressing RVs on D22 p.i. with Cl13.
(C) Experimental design. WT P14 cells
transduced with the indicated RVs were
adoptively transferred to mice infected one
day previously with Cl13. Donor RV
transduced VEX+ P14 cells were analyzed
at the indicated time points.
(D) VEX transduction efficiency on D2 p.i. for
Empty-VEX, TCF-1-p33-VEX or TCF-1-
p45-VEX RVs.





(F) VEX+ P14 cell numbers were normalized
to 1 X 104 VEX+ P14 cell engraftment
according to the transduction efficiency on
D2 p.i. and analyzed at D8, D12, D16,
D22, D30 Cl13 p.i.
(G) Representative flow cytometry plots and
quantification of KLRG1+CD39+ and Tim-
3+CD39+ subsets of WT and TCF-1cKO
responding P14 cells on D8 p.i. with Cl13.
(H) Representative flow cytometry plots and
quantification of the KLRG1-PD-1+ subset
of WT and TCF-1cKO responding P14
CD8+ T cells on D8 p.i. with Cl13. The PD-
1 versus KLRG1 gate was based on
staining of CD44- naïve CD8+ T cells.
*P<0.05, **P<0.01, ***P<0.001 versus control
(One-way Anova or two-tailed Student’s t-test).
Data are representative of 2 independent
experiments with at least 4 mice/group
(mean±s.e.m.).
Figure S9. PD-1 sustains the TCF-1+ precursor pool during chronic infection. 
(A) Experimental Design. 5 x 102 CD45.2+ WT P14 or 5 x 102 CD45.2+ PD-1KO P14 CD8+ T cells
were
   adoptively transferred into separate CD45.1+ naïve recipient mice and these recipients were 
treated with GK1.5 followed by infection with Cl13.  
(B) Representative flow cytometry plots to detect TCF-1+CD39- P14 cells on D8 p.i. Summary
analysis for the percent of donor TCF-1+CD39- P14 cells present in the spleen on D8, D17, D22,
D34 p.i. with Cl13 is shown.
*P<0.05, **P<0.01, ***P<0.01 versus control (two-tailed Student’s t-test). Data represents 2
independent experiments (mean±s.e.m.) with at least 3 mice/group.
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Figure S10. Effect of TCF-1-related TFs during TEX development. 
(A) Transduction of EomesGFP P14 cells with empty, TCF-1-p33, or TCF-1-p45 expressing RVs.
Representative flow cytometry plots of P14 cells indicating transduction efficiency on D2 following
transduction and on D8 p.i. with Cl13.
(B) Experimental design. 2 x 103 CD45.2+ x RosaLSL-YFP x Eomesflox/flox x Rosa-CREERT2 P14 cells and 2 x
103 CD45.1+CD45.2+ x  RosaLSL-YFP x EomesWT x Rosa-CREERT2 control P14 cells were co-transferred
into naive CD45.1+ recipients and these recipient mice infected with Cl13. These recipient mice were
then treated with tamoxifen from D9 p.i. to D13 p.i. At D18 p.i. donor YFP+ (i.e. indicating CRE activity)
P14 cells were analyzed.
(C) Representative flow cytometry plots and quantification of pre-transfer P14 cell mix and D8 p.i. before
tamoxifen treatment. Samples at D8 p.i. were collected from spleen.
(D) Representative flow cytometry plots of pre (D8 p.i.) and post (D18 p.i.) tamoxifen treatment. Gated on
CD8+ T cells.
(E) Representative flow cytometry plots and quantification of YFP+ P14 cells after tamoxifen treatment
(D18 p.i.).
(F) Representative flow cytometry plots and quantification of KLRG1+CD39+ and Ly108+CD39- subsets of
responding P14 cells transduced with empty versus T-bet expressing RVs. Plots are gated on
transduced (VEX+) donor P14 cells on D8 p.i. with Cl13. Note: Empty controls are the same controls as
Figure 7J.
(G) Expression of PD-1, Lag-3, Tim-3, CD160, 2B4 and CD127 in the P14 cells transduced with empty
versus T-bet RVs on D8 p.i. with Cl13.
(H) Number of donor P14 cells transduced with empty versus c-Myb expressing RV at the indicated time
points. VEX+ cell numbers were normalized to 1 x 104 VEX+P14 cell engraftment according to the
transduction efficiency on D2 p.i. and analyzed at D8, D15 and D23 Cl13 p.i.
(I) Quantification of Ly108+CD39- and Tim-3+CD39+ subsets of responding P14 cells transduced with
empty versus c-Myb RVs. Plots are gated on transduced (VEX+) donor P14 cells on D15 and D23 p.i.
with Cl13. VEX+ cell numbers were normalized to 1 x 104 VEX+ P14 cell engraftment according to the
transduction efficiency on D2 p.i.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-test and One-Way Anova
analysis). Data are representative of 2 independent experiments (mean±s.e.m.) with at least 3 mice/group.
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Figure S11 High-efficiency gene editing using retroviral-transduced sgRNA in Cas9+ antigen 
specific CD8 T cells. 
(A) Optimizing sgRNA backbone compared to the original sgRNA.
(B) Experimental design for in vivo gene editing test. At Day 0 (D0), CD8 T cells were isolated from
CD45.1+ LSL-Cas9+CD4CRE+P14 (C9P14) donor mice and activated with anti-CD3, anti-CD28 and IL-
2; CD45.2+ WT recipient mice were infected with LCMV-Cl13. At D1 p.i., activated C9P14 cells were
transduced with either Ctrl-sgRNA(sgCtrl) or Pdcd1-sgRNA (sgPdcd1). 6 hours after transduction, 5
X 104 activated donor cells were adoptively transferred into infected recipient mice. C9P14 cells
were then isolated, at the indicated times, from different organs of recipient mice for analysis.
(C) D2 in vitro transduction efficiency of activated C9P14 cells with sgRNA vector (mCherry). Gates
are set based on the non-transduced control.
(D) Flow cytometry plots of Cas9(GFP)+sgRNA(mCherry)+ population in the spleen at D9 p.i. of
sgCtrl group and sgPdcd1 group.
(E) Histogram of PD-1 expression and statistical analysis of PD-1+ population from the
Cas9+sgRNA+ P14 cells in the PBMC (D7 p.i.), spleen (D9 p.i.) or liver (D9 p.i.).
(F) Sanger sequencing results for the Pdcd1 locus from FACS sorted Cas9+sgRNA+ P14 cells from
the sgCtrl group (pooled 5 mice) or the sgPdcd1 group (pooled 2 mice).
(G) Histogram of KLRG1 or CXCR3 expression and statistical analysis of KLRG1+ or CXCR3+
populations from Cas9+sgRNA+ P14 cells from the spleen (D8 p.i. of LCMV-Arm) between targeted-
sgRNA and sgCtrl group.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-test). Data are
representative of 2 independent experiments (mean±s.e.m.) with at least 3 mice/group.
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Figure S12 Technical optimization of OpTICS system. 
(A-B) Log2 fold change (L2FC) of D8 p.i.(T1) to D2 baseline(T0) across different sgRNAs from 
spleen (A) or liver (B) under 3 conditions during LCMV-Arm infection. X axis represents different 
sgRNAs, y axis represents L2FC of D8 p.i.(T1) to D2 baseline(T0). Condition 1: No optimized 
sorting, average input coverage -- 100 cells/sgRNA, Cas9+/+ P14 donor. Condition 2: Optimized 
sorting (in Star Methods), average input coverage -- 400 cells/sgRNA, Cas9+/+ P14 donor. Condition 
3: Optimized sorting, average input coverage -- 400 cells/sgRNA, Cas9+/- P14 donor. Example target 
genes are highlighted with the indicated color. 
(C) Rank correlation of targeted genes between 2 independent screenings of Cas9+/+ or Cas9+/-
donor P14 groups. The mean values of sgRNA L2FC from each targeted gene were calculated and
ranked from the independent screenings. Pearson correlation of the rankings was calculated.
(D) Fold change enrichment of sgPdcd1 at D14 p.i. of LCMV-Cl13 in the spleen. Data from the
screening performed in Figure 14A-14C.
(E) Pearson correlation of different samples from the screening performed in Figure 14A-14C.
Sample collection time (days p.i.), LCMV infection and organ of sorted Cas9+sgRNA+ cells are
presented.
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Figure S13 Genetic deletion of Fli1 leads to a greater T cell expansion. 
(A) TIDE assay results showing genome disruption efficiency of Fli1 locus on the Cas9+Fli1-sgRNA
(sgFli1)+ cells. Genome disruption was detected by sanger sequencing.
(B) Flow cytometry plots (gated on donor P14 cells) of Cas9 (GFP)+sgRNA(VEX)+ population on D2
after in vitro transduction; D8 and D15 p.i. of Arm from splenocytes from sgCtrl or 2 Fli1-
sgRNA(sgFli1_290 and sgFli1_360) groups. 5 X 104 activated donor cells were adoptively
transferred into infected recipient mice on D1 p.i.
(C) Normalized Cas9+sgRNA+ cell numbers from PBMC, liver and lung from sgCtrl and the two
sgFli1 groups at D8 and D15 p.i. of Arm. Cell numbers normalized to the sgCtrl group based on D2
in vitro transduction efficiency.
(D) Flow cytometry plots (gated on donor P14 cells) of Cas9+sgRNA+ P14 cells on D2 post in vitro
transduction, D9 and D15 p.i. with Cl13 (speen) for sgCtrl and the two sgFli1 groups. 5 X 104
activated donor P14 cells were adoptively transferred into the infected recipient mice on D1 p.i.
(E) Normalized Cas9+sgRNA+ cell numbers from PBMC, liver and lung from sgCtrl and the two
sgFli1 groups at D9 and D15 p.i. of Cl13. Cell number normalized to the sgCtrl group based on D2 in
vitro transduction efficiency.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (One-Way Anova analysis). Data are
representative of 2-4 independent experiments (mean±s.e.m.) with at least 3 mice/group.
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Figure S14 Fli1 inhibits TEFF-like differentiation on transcriptional and epigenetic levels. 
(A-B) Statistical analysis of Ly108-CD39+ or TCF-1-Gzmb+ TEFF-like cells and Ly108+CD39- or TCF-1+Gzmb- 
TEX precursor cell numbers from spleen for sgCtrl and the two sgFli1 groups at D8 (A) and D15 (B) p.i. with 
Cl13. Gated on Cas9(GFP)+ sgRNA (VEX)+ P14 cells. 
(C) Flow cytometry plots and statistical analysis of cell number of CD45.2+VEX+ P14 for Empty-RV and Fli1-
OE-RV groups at D8 and D16 p.i. of Cl13. At D0, CD45.2+ P14 cells were activated and CD45.1+ recipient
mice were infected with Cl13. On D1 p.i., activated P14 were transduced with either Empty-RV or Fli1-OE-
RV for 6 hours. On D2 p.i., VEX+ P14 cells were sorted from each RV transduced group and 1X105 cells
were adoptively transferred into the infected recipients.
(D-E) Flow cytometry plots and statistical analysis of Ly108-CD39+ or TCF-1-Gzmb+ TEFF-like cells and
Ly108+CD39- or TCF-1+Gzmb- TEX precursor frequencies for Empty-RV and Fli1-OE-RV groups on D8 and
D16 p.i. of Cl13. Gated on VEX+ P14 cells.
(F) Statistical analysis of CX3CR1+ and Tim-3+ frequencies for Empty-RV and Fli1-OE-RV groups on D8
and D16 p.i. of Cl13. Gated on VEX+ P14 cells.
(G) PCA plot for RNA-seq results of sgCtrl, sgFli1_290 and sgFli1_360 groups on D8 p.i. of Cl13.
(H) Overlap of all CUT&RUN Fli1 binding peaks with ATAC-seq detected peaks in sgCtrl and sgFli1 groups.
(I) Histogram of all CUT&RUN peaks co-localized with the ATAC-seq peaks. Peaks co-localized with the
ATAC-seq peaks are red; peaks not co-localized are blue.
(J) CUT&RUN IgG or Fli1 binding signals for P14 cells on D9 p.i. and open chromatin region signals
detected by ATAC-seq for sgCtrl, sgFli1_290 and sgFli1_360 groups in the Tcf7 and Id3 loci.
*P<0.05, **P<0.01, ***P<0.001 versus control (One-Way Anova analysis). Data are representative of 3
independent experiments (mean±s.e.m.) with at least 4 mice/group for A-D.
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Figure S15. Fli1 coordinates with Runx1 and antagonizes Runx3 function. 
(A) Flow cytometry plots and statistical analysis of CD45.1+mCherry+ and Ly108-CD39+/ Ly108+CD39- P14
cell numbers for Empty-RV or Runx1-OE-RV on D2 in vitro and D7 p.i. At D0, CD45.1+ P14 cells were
activated and CD45.2+ recipient mice were infected with Cl13; At D1 p.i., activated P14 cells were transduced
with Empty-RV or Runx1-OE-RV for 6 hours, and 1X105 transduced P14 cells were adoptively transferred into
infected recipient mice. Flow cytometry plots gated on the CD45.1+ P14 cells.
(B) D2 in vitro transduction efficiency of sgCtrl-VEX+Empty-mCherry, sgCtrl-VEX+Runx1-mCherry,
sgFli1_290-VEX+Empty-mCherry, and sgFli1_290-VEX+Runx1-mCherry C9P14 cells.
(C) Statistical analysis of VEX+mCherry+ C9P14 cells and Ly108-CD39+/Ly108+CD39- cell numbers from
spleen for sgCtrl-VEX+Empty-mCherry, sgCtrl-VEX+Runx1-mCherry, sgFli1_290-VEX+Empty-mCherry, and
sgFli1_290-VEX+Runx1-mCherry groups on D7 p.i. of Cl13. Gated on Cas9(GFP)+CD45.2+ P14 cells.
(D) D2 in vitro transduction efficiency of sgCtrl-mCherry+Empty-VEX, sgCtrl-mCherry+Runx3-VEX,
sgFli1_290-mCherry+Empty-VEX, and sgFli1_290-mCherry+Runx3-VEX C9P14 cells.
(E) Statistical analysis of VEX+mCherry+ C9P14 cells and Ly108-CD39+/Ly108+CD39- cell numbers from
spleen for sgCtrl-mCherry+Empty-VEX, sgCtrl-mCherry+Runx3-VEX, sgFli1_290-mCherry+Empty-VEX and
sgFli1_290-mCherry+Runx3-VEX at D8 p.i. of Cl13. Gated on Cas9+CD45.2+ P14 cells.
*P<0.05, **P<0.01 versus control (two-tailed Student’s t-test). Data are representative of 2 independent
experiments (mean±s.e.m.) with at least 5 mice/group.
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Figure S16. Fli1-deficiency results in CD8 T cell expansion during influenza virus or 
Listeria monocytogenes infection. 
(A) Flow cytometry plots showing sgRNA(VEX)+ C9P14 cells in the lungs of influenza virus (PR8-
GP33) infected mice, comparing non-transfer(NT), sgCtrl and sgFli1 groups at D8 p.i.
“Recovered” was defined by complete weight recovery at D8 p.i.
(B) Correlation of sgRNA+ C9P14 cell numbers and weight ratio (D8 p.i./D2 p.i.) during the PR8-
GP33 infection. In the “weight not recovered” group (weight ratio between 0.7 and 1.0), sgRNA+
C9P14 cell numbers were further compared.
(C) Flow cytometry plots and statistical analysis of sgRNA+ C9P14 cells in the spleens of PR8-
GP33-infected recipient mice for non-transfer (NT), sgCtrl and sgFli1 groups at D8 p.i.
(D) Flow cytometry plots and statistical analysis of sgRNA+ C9P14 cells in the spleens of Listeria
monocytogenes-infected recipients for non-transfer (NT), sgCtrl and sgFli1 groups at D7 p.i.
*P<0.05, **P<0.01 versus control (two-tailed Student’s t-test and One-Way Anova analysis). Data
are representative of 2 independent experiments (mean±s.e.m.) with at least 6 mice/group.
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Figure S17. Deleting Fli1 in CD8 T cells leads to better tumor protection in an immune 
competent setting. 
(A) Experimental design. On D0, CD45.2+Cas9+P14- mice were inoculated with 2 x 105 B16-Dbgp33
cells. On D3 post tumor inoculation (p.t.), CD8 T cells were isolated from CD45.2+ C9P14 donor
mice and activated. The next day, activated C9P14 cells were transduced with sgCtrl or sgFli1 RV
for 6 hours. On D5 p.t., sgRNA (VEX)+ P14 cells were sorted from sgCtrl or sgFli1 groups, and 3 x
106 purified VEX+ C9P14 cells were adoptively transferred into tumor-bearing mice.
(B) Tumor volume curve of tumor-bearing mice from NT, sgCtrl+ and sgFli1+ C9P14 cell transferred
groups.
(C) Tumor weight from NT, sgCtrl+ and sgFli1+ C9P14 transferred mice on D24 p.t.
(D-E) Flow cytometry plots (D) and statistical analysis (E) of sgRNA (VEX)+ C9P14 cells and Ly108-
CD39+/Ly108+CD39- populations from tumor for sgCtrl and sgFli1 groups on D24 p.t.
(F-G) Statistical analysis of sgRNA+ C9P14 cells and Ly108-CD39+/Ly108+CD39- populations from
draining lymph node (dLN, F) and spleen (G) for sgCtrl and sgFli1 groups on D24 p.t.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.001 versus control (two-tailed Student’s t-test and One-Way
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